WO2014011926A1 - Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk - Google Patents
Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk Download PDFInfo
- Publication number
- WO2014011926A1 WO2014011926A1 PCT/US2013/050142 US2013050142W WO2014011926A1 WO 2014011926 A1 WO2014011926 A1 WO 2014011926A1 US 2013050142 W US2013050142 W US 2013050142W WO 2014011926 A1 WO2014011926 A1 WO 2014011926A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- metformin
- release
- dosage form
- acid
- treatment
- Prior art date
Links
- XLNXNRITLWFSEC-UHFFFAOYSA-N CC(C)Nc1nc(Nc(cc2)ccc2Cl)nc(C)n1 Chemical compound CC(C)Nc1nc(Nc(cc2)ccc2Cl)nc(C)n1 XLNXNRITLWFSEC-UHFFFAOYSA-N 0.000 description 1
- FICAXONNIJXFPY-UHFFFAOYSA-N CCCCNc1nc(C)nc(N)n1 Chemical compound CCCCNc1nc(C)nc(N)n1 FICAXONNIJXFPY-UHFFFAOYSA-N 0.000 description 1
- DUAYDERMVQWIJD-UHFFFAOYSA-N Cc1nc(N)nc(N(C)C)n1 Chemical compound Cc1nc(N)nc(N(C)C)n1 DUAYDERMVQWIJD-UHFFFAOYSA-N 0.000 description 1
- NJYZCEFQAIUHSD-UHFFFAOYSA-N Cc1nc(N)nc(N)n1 Chemical compound Cc1nc(N)nc(N)n1 NJYZCEFQAIUHSD-UHFFFAOYSA-N 0.000 description 1
- KWSGOBTYBULKPD-UHFFFAOYSA-N Cc1nc(N)nc(NCCc(cc2)cc(O)c2O)n1 Chemical compound Cc1nc(N)nc(NCCc(cc2)cc(O)c2O)n1 KWSGOBTYBULKPD-UHFFFAOYSA-N 0.000 description 1
- MXCHKIRJTQVJDG-UHFFFAOYSA-N Cc1nc(N)nc(NCCc(cc2)cc3c2OCO3)n1 Chemical compound Cc1nc(N)nc(NCCc(cc2)cc3c2OCO3)n1 MXCHKIRJTQVJDG-UHFFFAOYSA-N 0.000 description 1
- MQGNBTAABHRQCI-UHFFFAOYSA-N Cc1nc(N)nc(NCCc2c[o]cc2)n1 Chemical compound Cc1nc(N)nc(NCCc2c[o]cc2)n1 MQGNBTAABHRQCI-UHFFFAOYSA-N 0.000 description 1
- MFHFQJXZFXMEMQ-UHFFFAOYSA-N Cc1nc(N)nc(NCCc2ccc[o]2)n1 Chemical compound Cc1nc(N)nc(NCCc2ccc[o]2)n1 MFHFQJXZFXMEMQ-UHFFFAOYSA-N 0.000 description 1
- JIUACSLHMARMKI-UHFFFAOYSA-N Cc1nc(N)nc(NCCc2ccccc2)n1 Chemical compound Cc1nc(N)nc(NCCc2ccccc2)n1 JIUACSLHMARMKI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates generally to reducing cardiometabolic risk in a comprehensive and concerted fashion in patients in need thereof, by administering a fixed dose combination therapy comprising at least one biguanide, at least one statin and at least one additional active agent in a unitary dosage form.
- Cardiovascular disease generally includes coronary artery disease, cerebrovascular disease and peripheral arterial disease, and is the major cause of morbidity and mortality in the Western world.
- CVD cardiovascular disease
- Cerbrovascular disease generally includes coronary artery disease, cerebrovascular disease and peripheral arterial disease, and is the major cause of morbidity and mortality in the Western world.
- Botzell et al. Lipoprotein Management in Patients with Cardiometabolic Risk, Diabetes Care 2008 31 : 811-822 Notwithstanding significant improvements in therapeutic options over the last few decades, the initial presentation of coronary arterial disease in particular manifests as sudden death in up to one-third of patients. Id. Accordingly, better and more effective intervention options are still needed to prevent atherosclerosis and/or reduce its rate of progression once the disease process is initiated.
- CMR cardiometabolic risk
- cardiovascular disease and type 2 diabetes often cluster, including obesity, insulin resistance, hyperglycemia, dyslipoproteinemia and hypertension.
- risk factors for cardiovascular disease and type 2 diabetes often cluster, including obesity, insulin resistance, hyperglycemia, dyslipoproteinemia and hypertension.
- Lipoprotein abnormalities including elevated triglycerides, low HDL cholesterol, and increased LDL are common findings in patients with CMR.
- administration of therapeutic agents directed at lowering LDL cholesterol such as, e.g. , statins can reduce the risk of CVD events in diabetic patients, and in non-diabetic patients having other CVD risk factors.
- statins can reduce the risk of CVD events in diabetic patients, and in non-diabetic patients having other CVD risk factors.
- statins Even with adequate cholesterol lowering, however, many patients on statin therapy still have significant CVD risk. ⁇ See Brunell, supra). Accordingly, more effective therapies are clearly still needed to better address this multivariate and complex series of disorders.
- Metformin is commonly prescribed for glycemic control in patients having type II diabetes, and has also been shown to improve serum lipids, decreasing triglycerides, free fatty acids, and LDL-cholesterol and modestly increasing HDL-cholesterol. (Bailey & Turner Metformin. N EnglJ Med. 1996 Feb 29;334(9)
- metformin also produces significant gastrointestinal complications that have restricted its use beyond diabetic patients per se, and it is further contraindicated in patients having hypoxic conditions caused by, e.g. respiratory or heart failure.
- the present invention provides more comprehensive and effective combination therapies for reducing cardiometabolic risk in patients in need thereof, and for treating and/or preventing cardiovascular disease, employing at least one biguanide, at least one statin and at least one additional active agent.
- biguanides such as metformin can be administered with significantly reduced gastrointestinal complications using delayed release (DR) formulations, thereby enabling safe and effective administration of combinations of biguanides, statins and other active agents to a much broader patient population in unitary pharmaceutical compositions.
- DR delayed release
- Suitable biguanides contemplated for use in the subject invention include, e.g.
- statins or HMG-CoA reductase inhibitors for use in the subject invention include, e.g. lovastatin, atorvastatin, fluvastatin, rosuvastatin, simvastatin, pravastatin, pitavastatin, and the like.
- Additional active agents contemplated for use in the subject compositions and methods include, e.g. anti-hypertensives and anti-platelet agents as well as diuretics, bile acid sequesterants, incretin enhancers and mimetics, oral anti-diabetic agents , anti-obesity agents, and anti- atherosclerotics.
- Suitable anti-hypertensives for use in the subject invention include, e.g., beta blockers (atenolol, betaxolol, metoprolol, nadolol, nebivolol, oxprenolol, pindolol, propranolol, timolol, etc.), alpha- 1 blockers (alfuzosin, arotinolol, doxazosin, indoramin, moxisylyte,
- alpha-2 agonists apraclonidine, brimonidine, clonidine, guanabenz, guanfacine, lofexidine, tolonidine, mixed alpha / beta blockers (bucindolol, carvedilol, labetalol, etc.), calcium channel blockers such as dihydropyridines (amlodipine, felodipine, isradipine, lercanidipine, nicardipine, nifedipine, nimodipine, nitrendipine, etc.) and non-dihydropyridines (diltiazem, verapamil, etc.), renin inhibitors (aliskiren), ACE inhibitors (captopril, enalapril, fosinopril), alpha-2 agonists (apraclonidine, brimonidine, clonidine, guanabenz, guanfacine, lofexidine, tolonidine,
- Suitable anti-platelet medications for use in the subject invention include, e.g., cyclooxygenase inhibitors (acetylsalicylic acid (aspirin), aloxiprin, carbasalate calcium, indobufen, trifusal, etc.), ADP receptor inhibitors (clopidogrel, ticlopidine, ticagrelor, etc.), phosphodiesterase inhibitors (cilostazol, etc.), adenose reuptake inhibitors (dipyridamole, etc.), thromboxane synthase or receptor inhibitors (picotamide, ramatroban, terbogrel, etc.), anagrelide, prasugrel, cloricromen, and the like.
- cyclooxygenase inhibitors acetylsalicylic acid (aspirin), aloxiprin, carbasalate calcium, indobufen, trifusal, etc.
- ADP receptor inhibitors
- Suitable diuretics for use in the subject invention include e.g., loop diuretics (bumetanide, ethacrynic acid, furosemide, torsemide, etc.), thiazide diuretics (epitizide, hydrochlorothiazide, chlorothiazide, bendroflumethiazide, etc.), thiazide-like diuretics (indapamide, chlorthalidone, metolazone, etc.), potassium-sparing diuretics (amiloride, triamterene, spironolactone, etc.), and the like.
- loop diuretics bumetanide, ethacrynic acid, furosemide, torsemide, etc.
- thiazide diuretics epipitizide, hydrochlorothiazide, chlorothiazide, bendroflumethiazide, etc.
- thiazide-like diuretics indapamide, chlorthali
- Suitable bile acid sequesterants for use in the subject invention include, e.g. , cholestyramine, colesevelam, colestipol, and the like.
- Suitable incretin mimetics and enhancers for use in the subject invention include, e.g., peptidic and non-peptidic GLP-1 mimetics (including, e.g., allosteric activators of the GLP-1 receptor), peptidic and non-peptidic PYY mimetics, peptidic and non-peptidic Ghrelin antagonists and the like.
- Suitable oral anti-diabetic agents for use in combination with metformin in the subject compositions and methods include, e.g., sulfonylureas (glyburide, glimepiride, glipizide, gliclazide, glycopyramide, gliquidone, tolbutamide, acetohexamide, tolazamide, chlorpropamide, carbutamide, etc.), nonsulfonylureas (repaglinide, nateglinide, etc.), thiazolidinediones
- dual PPAR agonists e.g., aleglitazar, farglitazar, muraglitazar, tesaglitazar, telmisartan, and the like
- dipeptidyl peptidase-4 inhibitors vildagliptin, sitagliptin, saxagliptin, linagliptin, allogliptin, septagliptin, berberine, etc.
- sodium-glucose co-transporter- 1 or 2 SGLTl or 2
- inhibitors canagliflozin, , empagliflozin, dapagliflozin, LX4211, etc.
- meglitinides nateglinide, repaglinide, etc.
- Suitable anti-obesity agents for use for use in the subject invention include, e.g., Orlistat (Zenical), Lorcaserin (Belviq), Sibutramine (Meridia, withdrawn from most markets), Rimonabant (Acomplia), Exenatide (Byetta and Bydureon), Pramlintide (Symlin), Fen-Phen, Redux, ZGN-433, Phentermine/topiramate (Qsymia), Naltrexone/buproprion (Contrave), as well as alternative medicine options including, e.g., conjugated linoleic acid, green tea extract, khat, lipoic acid, ECA Stack (Ephedrine Caffeine Stack), Raspberry ketone and the like.
- Suitable anti-artherosclerotics for use in the subject invention include compounds that can reduce atherosclerosis independent of changes in other risk factors, e.g. fish oil as well as inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) such as AMG145 (Amgen), lD05-IgG2 (Merck & Co.), and SAR236553/REGN727 (Aventis/Regeneron), peptides mimicking the LDLR that binds to PCSK9 ⁇ e.g. Shan et al. (2008) Biochem. Biophys. Res.
- PCSK9 proprotein convertase subtilisin/kexin type 9
- HDL/LDL ratio modifying compounds including, e.g., niacin, acipomox, MK-0354, other modulators of GPR81 ,
- GPR109A GPR109A, GPR109B and the like.
- fixed-dose combination dosage forms for reducing cardiometabolic risk in a patient in need thereof, comprising at least one biguanide, at least one statin, and at least one additional active agent selected from the group consisting of anti-hypertensives, anti-platelet agents, diuretics, bile acid sequesterants, oral anti-diabetic agents, incretin mimetics and enhancers, anti-obesity agents, and anti-atherosclerotics.
- the subject combination dosage forms may comprise at least one additional active agent, more preferably at least two additional active agents, more preferably at least three additional active agents, more preferably at least four or five additional active agents, wherein the metformin or other biguanide compound is formulated for delayed release.
- the statins, anti-hypertensives and additional active agents may be conventionally formulated for immediate-release, extended release and/or delayed-release in accordance with their respective established dosing protocols.
- the combination dosage form can be a multi-layer tablet, or a capsule with the three or more components encapsulated in appropriately- formulated mini-tablets.
- the fixed dose combination dosage form comprises at least one biguanide, at least one statin, at least one anti-hypertensive, and optionally at least one antiplatelet agent.
- the biguanide comprises metformin and the anti-hypertensive comprises an ACE inhibitor or an angiotensin II receptor antagonist, and the anti-platelet agent comprises aspirin.
- the subject combination dosage form comprises from about 600-800 mg of metformin, from about 20-40 mg of simvastatin or atorvastatin, from about 20-25 mg of benazepril, lisinopril or losartan, and optionally from about 75-90 mg of aspirin.
- the combination dosage form comprises less than about 950 or 900 mg of metformin or other biguanide, more preferably less than about 875 or 850 mg, and most preferably less than about 825 or 800 mg of biguanide.
- the combination dosage form comprises from about 3 or 30 or 300 to about 9 or 90 or 900 mg of metformin or other biguanide, more preferably from about 4 or 40 or 400 to about 8 or 80 or 800 mg of biguanide, most preferably from about 6 or 60 or 600 to about 8 or 80 or 800 mg of biguanide.
- Suitable biguanide compounds for use in the subject methods include, e.g., metformin, phenformin, buformin or imeglimin, including analogs, salts, solvates, polymorphs, hydrates, N-oxides, and prodrugs of such compounds.
- the fixed-dose pharmaceutical compositions according to the present teachings may be administered to a subject in need thereof to reduce their cardiometabolic risk.
- Clinical conditions presenting an increased cardiometabolic risk that may benefit from administration of the subject therapies include type II diabetes, familial combined hyperlipidemia, familial hypoalphalipoprotememia, and polycystic ovary syndrome, as well as preclinical conditions such as obesity, prediabetes and hyperglycemia in general.
- the methods and compositions disclosed herein are particularly suitable for patients having a contraindication for biguanide compounds, e.g., metformin, phenformin or buformin.
- Such contraindication may be a hypoxic condition, impaired lactate clearance, and/or impaired clearance of the biguanide compound, e.g., impaired metformin clearance.
- the at least one additional active agent selected from the group consisting of anti-hypertensives, anti-platelet agents, diuretics, bile acid sequesterants, oral anti-diabetic agents, incretin mimetics, anti-obesity agents, and anti- atherosclerotics.
- the at least one additional active agent is an antihypertensive, e.g., an ACE inhibitor or an angiotensin II receptor antagonist.
- the fixed dose combination dosage form further comprises an antiplatelet agent, e.g. , aspirin.
- the metformin or other biguanide is formulated for delayed release so as to minimize the systemic bioavailability of the biguanide compound in the patient.
- administration of the subject delayed-release formulation minimizes the mean plasma AUC, the mean plasma C max and/or the circulating plasma concentration of the biguanide compound in the patient compared to an identical protocol administering an IR or XR formulation having the same amount of the biguanide compound.
- the biguanide compound is metformin
- the IR composition is Glucophage®
- the XR composition is Glucophage® XR.
- Administration of the subject dosage forms may be twice daily (b.i.d.), in the morning and evening, or once daily (pmni in die, abbreviated as "OD").
- OD once daily
- administration may be once daily in the morning, e.g. , before 1 pm, preferably before 12 noon or 11 am, more preferably before 10 or 9 am, or with the morning meal. In other preferred embodiments, administration may be once daily in the evening, e.g., after 5 pm, more preferably after 6 pm or 7 pm, or with the evening meal. In another preferred embodiment, administration may be once daily at bedtime.
- the subject methods administer therapeutically effective amounts of the biguanide compound(s).
- the inventive methods provided herein advantageously allow for lower therapeutic doses than prior art formulations, both on a per unit basis and/or on a daily dose basis.
- the biguanide compound is administered twice daily in an oral dosage form at a per unit dose less than 1000 mg BID, e.g. 600, 700 or 800 mg BID.
- the twice daily oral dosage is less than 500 mg BID, e.g., less than 400 mg BID, e.g., less than 300 mg BID, e.g., about 150, 200 or 250 mg BID.
- the biguanide compound is administered once a day at a per unit dose of 75 mg OD, 125 mg OD, 250 mg OD, 300 mg OD, 500 mg OD, 600 mg OD, 650 mg OD, 700 mg OD, 750 mg OD, 800 mg OD. or 900 mg OD.
- the total daily dose (TDD) of the biguanide compound is less than 2000 mg/day, preferably less than 1500 mg/day, more preferably less than 1000 or 750 mg/day, most preferably less than 500, 400, 300, or 200 mg/day.
- the delayed-release formulation of the metformin or other biguanide may be enterically coated.
- the biguanide compound is targeted for delivery to the small intestine, and the formulation comprises an oral dosage form enterically coated at a pH at or above 5.0, 5.5, or 6.0, e.g., a pH 5.0 enteric coating, a pH 5.5 enteric coating, a pH 6.0 enteric coating, a pH 6.5 enteric coating, or a pH 7.0 enteric coating, or combinations thereof.
- the oral dosage form may further comprise an extended-release component for the biguanide compound.
- the biguanide compound is targeted for delivery to the distal small intestine, and the formulation comprises an oral dosage form enterically coated at a pH at or above 6.0 or 6.5.
- the biguanide compound may be or comprise metformin, a metformin salt, solvate, polymorph, hydrate, N-oxide or prodrug.
- the biguanide compound is a metformin salt selected from the group consisting of hydrochloride, phosphate, sulfate, hydrobromide, salicylate, maleate, benzoate, succinnate, ethanesulfonate, fumarate, glycolate, palmoate, oratate, acetate, isobutyrate, acetylsalicylate, nicotinic acid, adamantoate, zinc-chlorophylin, carboxylic acid, benzoic acid, dichloroacetic acid, theophylin-7-acetate, clofibrate, tartate, oxalate, tannate and hydroxyl acid.
- the biguanide compound is metformin hydroch
- FIG. 1 shows the design of the study described in Example 1.
- FIG. 2 shows the events during the treatment period of the study described in Example 1.
- FIG. 4C shows the plasma concentration of total GLP-1 (x-axis; GLP-1T pmol/L) as a function of time (y-axis; min) in subjects at baseline (p,o) or after ingestion of either
- Metformin IR ( ⁇ ) or Metformin DR ( ⁇ ) and after a meal at t 0 min.
- percent increase in Abs AUC is compared to baseline values.
- percent decrease in Abs AUC is compared to baseline values.
- FIG. 6 is a graph that shows the area under the curve of PYY (x-axis; log
- FIG. 8 shows the mean plasma metformin concentrations (x-axis; ng/mL) at Day 5 of 500 mg ( ⁇ ) and 1000 mg ( ⁇ ) Metformin DR, 1000 mg Metformin IR (o) , and 500 mg
- Metformin IR + 1000 mg Metformin DR (A ) as a function of time (y-axis; min). Dose was administered at t -1 minute.
- FIG. 9 shows the steady-state relative bioavailability in subjects with type 2 diabetes of 500 mg BID and 1000 mg BID of Metformin DR compared to 1000 mg BID of Metformin IR based on the 11 hour plasma metformin AUC on Day 5 (y-axis; % AUC ( o_n hr) ) ⁇ These levels constitute a 45% and 57% reduction in the overall plasma metformin extent of exposure for 500 mg BID and 1000 mg BID of Metformin DR compared to 1000 mg BID of Metformin IR.
- FIG. 10 shows the mean plasma PYY total concentrations (x-axis; pg/mL) as a function of time (y-axis; min) in subjects at baseline (o) or Day 5 of the designated treatment ( ⁇ ) ⁇
- FIG. 12 shows the mean plasma glucose concentration (x-axis; mg/dL) as a function of time (y-axis; min) in subjects at baseline (o) or Day 5 of the designated treatment ( ⁇ ).
- FIG. 13 shows the individual change in fasting plasma glucose concentrations (x-axis; mg/dL) as a function of time (y-axis; min) from baseline to Day 5 by scatterplot in subjects treated with 500 mg ( ⁇ ) and 1000 mg ( ⁇ ) Metformin DR, 1000 mg Metformin IR ( ⁇ ) , and 500 mg Metformin IR + 1000 mg Metformin DR ( A)(y-axis)
- the line in the panel marks the LS Mean Change in glucose (mg/dL) for each treatment.
- FIG. 14 shows the mean plasma metformin concentration (x-axis; ng/mL) of 500 mg ( ⁇ ) and 1000 mg ( ⁇ ) Metformin DR, 1000 mg Metformin IR (o) , and 2000 mg metformin extended release (Metformin XR) a function of time (y-axis; hours).
- FIG. 15 shows the C max (left panel) and AUCo-36 (right panel) of one day's dosing of 1000 mg BID metformin IR, 500 mg BID and 1000 mg BID of Metformin DR and 2000 mg QD metformin XR.
- the * signifies a statistically significant reduction in exposure compared to both metformin IR and metformin XR (all p ⁇ 0.0001)
- FIG. 16 shows the relative bioavailability of one day's dosing of 500 and 1000 mg BID Metformin DR compared to 1000 mg BID Metformin IR (left panel) and the relative bioavailability of one day's dosing of 500 and 1000 mg BID Metformin DR compared to 2000 mg QD Metformin XR (right panel)
- FIG. 17 shows the plasma AUC level (left panel) and change in fasting glucose (right panel) of 1000 mg QD AM, 1000 mg QD PM and 500 mg BID metformin DR. DETAILED DESCRIPTION
- Contemplated herein are methods and compositions for reducing cardiometabolic risk in individuals in need thereof, and for treating and/or preventing cardiovascular disease as described herein, using fixed-dose combination therapies comprising at least one biguanide, at least one statin and at least one additional active agent.
- the at least one additional active agent is advantageously selected from among anti-hypertensives, anti-platelet agents, diuretics, bile acid sequesterants, incretin mimetics and enhancers, oral anti-diabetic agents, anti-obesity agents, and anti-artherosclerotics.
- the subject compositions and methods employ at least one biguanide, e.g., metformin, at least one statin, and at least one anti-hypertensive, e.g., an ACE inhibitor or angiotensin II antagonist, and may optionally further include at least one anti-platelet agent.
- biguanide e.g., metformin
- statin e.g., statin
- anti-hypertensive e.g., an ACE inhibitor or angiotensin II antagonist
- compositions also significantly improve GI tolerability and reduce the possibility of adverse effects such as lactic acidosis, thereby enabling their safe and effective use in a much broader class of patients including those suffering or at risk of cardiovascular disease.
- compositions for reducing cardiometabolic risk and treating or preventing cardiovascular disease combining metformin or another biguanide compound formulated for DR with at least one statin and at least one additional active agent, more preferably at least two additional active agents, still more preferably at least three or four additional active agents, which can be formulated in accordance with their respective conventional dosing protocols, e.g. , IR, XR or DR.
- additional active agent e.g. IR, XR or DR.
- the fixed-dose pharmaceutical compositions further comprise at least one antihypertensive, and optionally at least one anti-platelet agent.
- the pharmaceutical composition comprises a multi-layer tablet, or a capsule with three or or more components encapsulated in appropriately- formulated mini-tablets.
- methods of treating hyperglycemic conditions in patients in need thereof comprising administering the subject compositions to said patients either once- or twice daily.
- the biguanide compound is selected from the group consisting of metformin, buformin, phenformin and imeglimin, and is administered at lower doses and/or with lower bioavailability than currently indicated while still achieving the desired metabolic improvements.
- gastrointestinal tract and "gut,” as used herein, refer to the stomach and intestine.
- the "small” or “upper” intestine includes the duodenum, jejunum and ileum and the “large” or “lower” intestine includes the caecum, colon and rectum.
- the “distal” small intestine includes the jejunum and ileum.
- Treating” or “treatment” of any condition, disease or disorder refers, in some embodiments, to ameliorating the disease, disorder, or condition (i.e., arresting or reducing the development of the disease, disorder, or condition, or at least one of the clinical symptoms thereof).
- “treating” or “treatment” refers to ameliorating at least one physical parameter, which may or may not be discernible by the subject, including physical parameters that are undesired but not clinically significant.
- “treating” or “treatment” refers to inhibiting the disease, disorder, or condition, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter) or both.
- Preventing or “prevention” of any condition, disease or disorder refers to preventing or delaying the onset of disease development if none had occurred, preventing or delaying the disease or disorder from occurring in a subject that may be predisposed to the disorder or disease but has not yet been diagnosed as having the disorder or disease, and/or preventing or delaying further disease development if already present.
- “Therapeutically effective amount” or “effective amount” means the amount of a composition, compound, therapy, or course of treatment that, when administered to a subject for treating a disease, disorder, or condition, is sufficient to effect such treatment for the disease, disorder, or condition.
- the “therapeutically effective amount” will vary depending on the composition, the compound, the therapy, the course of treatment, the disease, disorder, or condition, and its severity and the age, weight, etc., of the subject to be treated.
- the biguanide compounds described herein include one or more chiral centers, the stereochemistry of such chiral centers can independently be in the R or S configuration, or a mixture of the two.
- the chiral centers can be further designated as R or S or R,S or d,D, 1,L or d, l, D,L.
- the biguanide compounds of the invention if they can be present in optically active form, can actually be present in the form of a racemic mixture of enantiomers, or in the form of either of the separate enantiomers in substantially isolated and purified form, or as a mixture comprising any relative proportions of the enantiomers.
- diastereomers When the biguanide compounds described herein contain two or more chiral centers then diastereomers are possible. Such diastereomers may be present as pure diastereomeric enantiomers, pure racemic mixtures of diastereomeric enantiomers, mixtures of diastereomers which may be racemic or may have optical activity in their own right due to complex permutations of enantiomeric diastereomers in the balance of the mixtures.
- geometrically isomeric forms around, for example, the guanide bond then they can actually be present in the form of a mixture of geometric isomers comprising any relative proportions of the isomers, or in some cases in the form of either of the separate geometric isomers in substantially isolated and purified form.
- the geometry around such double bonds can be independently a cis/trans, E/Z mixture or an E or Z geometric isomer thereof.
- Alkyl means a straight or branched chain, saturated monovalent hydrocarbon radical.
- the hydrocarbon chain may have from one to twenty carbons, one to sixteen carbons, one to fourteen carbons, one to twelve carbons, one to ten carbons, one to eight carbons, one to six carbons, one to four carbons, etc.
- “Lower alkyl” may refer to alkyls having, e.g., one to six carbons, one to four carbons, etc.
- an straight chain alkyl may have from one to six carbon atoms and a branched alkyl three to six carbon atoms, e.
- Aryl means a monovalent monocyclic or bicyclic aromatic hydrocarbon radical, e.g., having from of 6 to 20 or 6 to 10 ring atoms e.g., phenyl or naphthyl.
- Alkylaryl means a (alkylene)-R radical where R is aryl as defined above.
- Cycloalkyl means a cyclic saturated or partially saturated monovalent hydrocarbon radical (or an alicyclic radical).
- the cycloalkyl may have from three to twenty carbon atoms, from three to sixteen carbon atoms, from three to fourteen carbon atoms, from three to twelve carbon atoms, from three to ten carbon atoms, from three to eight carbon atoms, from three to six carbon atoms, etc., wherein one or two carbon atoms may be replaced by an oxo group, e.g., admantanyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, indanyl and the like.
- Alkylcycloalkyl means a (alkylene)-R radical where R is cycloalkyl as defined above; e.g., cyclopropylmethyl, cyclobutylmethyl, cyclopentylethyl, or cyclohexylmethyl, and the like.
- Heterocyclyl or “heterocycloalkyl” means a saturated or unsaturated monovalent monocyclic group, in which one or two ring atoms are heteroatom selected from N, O, or S, the remaining ring atoms being C.
- the heterocyclyl ring is optionally fused to a (one) aryl or heteroaryl ring as defined herein.
- the heterocyclyl ring fused to monocyclic aryl or heteroaryl ring is also referred to in this Application as "bicyclic heterocyclyl” ring.
- one or two ring carbon atoms in the heterocyclyl ring can optionally be replaced by a -CO- group.
- heterocyclyl includes, but is not limited to, pyrrolidino, piperidino, homopiperidino, 2-oxopyrrolidinyl, 2-oxopiperidinyl, morpholino, piperazino,
- heterocyclyl ring When the heterocyclyl ring is unsaturated it can contain one or two ring double bonds. When the heterocyclyl group contains at least one nitrogen atom, it is also referred to herein as heterocycloamino and is a subset of the heterocyclyl group. When the heterocyclyl group is a saturated ring and is not fused to aryl or heteroaryl ring as stated above, it is also referred to herein as saturated monocyclic heterocyclyl.
- Alkylheterocycloalkyl means a -(alkylene)-R radical where R is heterocyclyl ring as defined above e.g., tetraydrofuranylmethyl, piperazinylmethyl, morpholinylethyl, and the like.
- Heteroaryl means a monovalent monocyclic or bicyclic aromatic radical, where one or more, preferably one, two, or three, ring atoms are heteroatom selected from N, O, or S, the remaining ring atoms being carbon.
- Representative examples include, but are not limited to, pyrrolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, diazolyl, pyrazolyl, triazolyl, benzothiazolyl, benzoxazolyl, quinolinyl, isoquinolinyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, tetrazolyl, and the like.
- substituted means that the referenced group is substituted with one or more additional group(s) individually and independently selected from groups described herein.
- an optional substituent is selected from oxo, halogen, -CN, -NH 2 , -OH, - NH(CH 3 ), -N(CH 3 ) 2 , alkyl (including straight chain, branched and/or unsaturated alkyl), substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl,
- fluoroalkyl substituted or unsubstituted heteroalkyl, substituted or unsubstituted alkoxy, fluoroalkoxy, -S-alkyl, -S(0) 2 -alkyl, -CONH((substituted or unsubstituted alkyl) or (substituted or unsubstituted phenyl)), -CON(H or alkyl) 2 , -OCON(substituted or unsubstituted alkyl) 2 , - NHCONH((substituted or unsubstituted alkyl) or (substituted or unsubstituted phenyl)), - NHCOalkyl, -N(substituted or unsubstituted alkyl)CO(substituted or unsubstituted alkyl), - NHCOO(substituted or unsubstituted alkyl), -C
- an optional substituent is selected from oxo, fluorine, chlorine, bromine, iodine, -CN, -NH 2 , -OH, - NH(CH 3 ), -N(CH 3 ) 2 , -CH 3 , - CH 2 CH 3 , -CH(CH 3 ) 2 , -CF 3 , -CH 2 CF 3 , -OCH 3 , -OCH 2 CH 3 , - OCH(CH 3 ) 2 , -OCF 3 , - OCH 2 CF 3 , - S(0) 2 -CH 3 , -CONH 2 , -CONHCH 3 , -NHCONHCH 3 , -COCH 3 , -COOH and the like.
- substituted groups are substituted with one, two or three of the preceding groups. In some embodiments, substituted groups are substituted with one or two of the preceding groups. In some embodiments, substituted groups are substituted with one of the preceding groups.
- a formula with chemical bonds shown only as solid lines and not as wedges or dashed lines contemplates each possible isomer, e.g., each enantiomer and diastereomer, and a mixture of isomers, such as racemic or scalemic mixtures.
- a biguanide compound of the disclosure is present in a composition as a salt.
- salts are obtained by reacting a compound of the disclosure with acids.
- pharmaceutically acceptable salts are obtained by reacting a compound of the disclosure with a base.
- the compounds are used as free-acid or free-base form in the manufacture of the compositions described herein.
- the type of salts include, but are not limited to: (1) acid addition salts, formed by reacting the free base form of the compound with a pharmaceutically acceptable: inorganic acid, such as, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, metaphosphoric acid, and the like; or with an organic acid, such as, for example, acetic acid, propionic acid, hexanoic acid, cyclop entanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, trifluoroacetic acid, tartaric acid, citric acid, benzoic acid, 3- (4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1 ,2-ethanedisulfonic acid, 2- hydroxyethanesulfonic acid, benzene
- the biguanide compound described herein are reacted with an organic base, such as, but not limited to, ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, dicyclohexylamine, tris(hydroxymethyl)methylamine.
- an organic base such as, but not limited to, ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, dicyclohexylamine, tris(hydroxymethyl)methylamine.
- the compounds described herein form salts with amino acids such as, but not limited to, arginine, lysine, and the like.
- Acceptable inorganic bases used to form salts with compounds that include an acidic proton include, but are not limited to, aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.
- amino acid includes any one of the twenty naturally-occurring amino acids or the D-form of any one of the naturally-occurring amino acids.
- amino acid also includes other non-naturally occurring amino acids besides the D-amino acids, which are functional equivalents of the naturally-occurring amino acids.
- non-naturally- occurring amino acids include, for example, norleucine ("Nle”), norvaline (“Nva”), L- or D- naphthalanine, ornithine (“Orn”), homoarginine (homoArg) and others well known in the peptide art, such as those described in M.
- Amino acids and amino acid analogs can be purchased commercially (Sigma Chemical Co.; Advanced Chemtech) or synthesized using methods known in the art.
- the biguanide compounds described herein include further forms of the compounds such as pharmaceutically acceptable salts, solvates (including hydrates), amorphous phases, partially crystalline and crystalline forms (including all
- polymorphs polymorphs
- prodrugs metabolites, N-oxides, isotopically-labeled, epimers, pure epimers, epimer mixtures, enantiomers including but not limited to single enantiomers and enantiomeric diastereomers, meso compounds, stereoisomers, racemic mixtures and diasteroisomeric mixtures.
- Biguanide compounds described herein having one or more double bonds include cis/trans isomers, E/Z isomers and geometric isomers.
- Biguanide compounds described herein can be prepared as a pharmaceutically acceptable salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, for example an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base.
- a metal ion for example an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base.
- the salt forms of the disclosed compounds can be prepared using salts of the starting materials or intermediates.
- the biguanide compounds described herein include solvent addition forms or crystal forms thereof, particularly solvates or polymorphs.
- Solvates contain either stoichiometric or non-stoichiometric amounts of a solvent, and may be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol.
- the biguanide compounds described herein possess one or more stereocenters and each center exists independently in either the R or S configuration.
- the biguanide compounds presented herein include all diastereomeric,
- sites on the biguanide compounds disclosed herein are susceptible to various metabolic reactions. Therefore incorporation of appropriate substituents at the places of metabolic reactions will reduce, minimize or eliminate the metabolic pathways.
- the appropriate substituent to decrease or eliminate the susceptibility of the aromatic ring to metabolic reactions is, by way of example only, a halogen, deuterium or an alkyl group.
- the biguanide compounds described herein are isotopically- labeled, which are identical to those recited in the various formulae and structures presented herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
- one or more hydrogen atoms are replaced with deuterium.
- metabolic sites on the compounds described herein are deuterated.
- substitution with deuterium affords certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased in vivo half-life or reduced dosage requirements.
- groups and substituents thereof can be chosen by one skilled in the field to provide stable moieties and compounds.
- Suitable HMG-CoA reductase inhibitors or statins for use in the subject invention include, e.g. lovastatin, atorvastatin, fluvastatin, rosuvastatin, simvastatin, pravastatin, pitavastatin, mevastatin, and the like.
- Alternative agents capable of decreasing triglyceride and/or LDL levels include but are not limited to ascorbic acid, asparaginase, clofibrate, colestipol, cholestyrine, fenofibrate, gemfibrozil, nicotinic acid, mevinolin, probucol and omega- 3 fatty acid. These agents are generally formulated for immediate-release, although extended- and/or delayed-release may also be utilized.
- metformin is one of the simplest structural variants of a class of compounds known as the biguanides. From a structural perspective metformin resembles a pharmacophore or fragment of a larger biologically active chemical structure.
- the biguanide compounds of the subject invention include the following:
- Ri, R 2 , R3, R4, R5, Re, and R 7 are independently selected from:
- Rx is alkyl, cycloalkyl, alkylcycloalkyl, acyl, ester, thioester;
- optionally substituted alkyl e.g., a Ci to C 12 straight chain or branched chain alkyl optionally substituted with oxygen, silicon, sulphur or optionally substituted with OH, O-alkyl, SH, S-alkyl, NH 2 , NH-alkyl
- cycloalkyl e.g., C 3 to C 7 cycloalkyl
- alkylcycloalkyl e.g., C 4 to C 12 alkylcycloalkyl
- heterocycloalkyl e.g., where the heterocycle comprises one or two hetero atoms selected from O, S, or N, including a C 2 to C 6 heterocycloalkyl
- alkylheterocycloalkyl e.g., where the heterocycle comprises one or two hetero atoms selected from O, S, or N, including a C 3 to Cn alkylheterocycloalkyl, and including wherein when N is present in the heterocyclic ring
- optionally substituted alkenyl e.g., Ci to C 12 straight chain or branched chain alkenyl optionally substituted with oxygen, silicon, sulphur or optionally substituted with OH, O-alkyl, SH, S-alkyl, NH 2 , NH-alkyl
- optionally substituted alkynyl e.g., Ci to C 12 straight chain or branched chain alkynyl optionally substituted with oxygen, silicon, sulphur or optionally substituted with OH, O-alkyl, SH, S-alkyl, NH 2 , NH-alkyl
- optionally substituted aryl e.g., phenyl, substituted phenyl, naphthyl, substituted naphthyl
- optionally substituted alkylaryl e.g., alkylphenyl, alkylsubstituted phenyl
- alkylnaphthyl, alkylsubstituted naphthyl optionally substituted heteroaryl (e.g., pyridyl, furanyl, thiophenyl, pyrrollyl, oxazolyl, isoxazolyl, thiazolyl, diazolyl, pyrazolyl, triazolyl all of which are optionally substituted); optionally substituted alkylheteroaryl; and
- R 6 and R 7 may join to form a bond, together forming a ring including the nitrogen atoms to which they are attached;
- Ri and R 2 may together form a 3 to 8 membered heterocyclic ring, including the nitrogen atoms to which they are attached; or R 4 and R 5 may together form a ring selected from the group aziridine, pyrrolyl, imidazolyl, pyrazolyl, indolyl, indolinyl, pyrrolidinyl, piperazinyl and piperidyl, including the nitrogen atoms to which they are attached.
- O-Rx may be selected from: O-Ci to Cs straight chain or branched chain alkyl; O-C3 to C 7 cycloalkyl; 0-C 4 to Cs alkylcycloalkyl; O-acyl; O-esters; and O-thioesters.
- optional substitutions may include, e.g., OH, O-alkyl, SH, S- alkyl, NH 2 , NH-alkyl.
- an alkyl, alkenyl, alkynyl, etc. may be substituted with an oxygen, silicon, sulphur, etc. to form a heteroalkyl, heteroalkenyl, heteroalkynyl, etc.
- each of: R3, R 6 , and R 7 , or R3, R4, R 5 , and R 7 ,or R3, R 4 , R 5 , and R 7 , or R 3 , R4, R 5 , R ⁇ and R 7 , or R 2 , R3, R4, R 5 , Re and R 7 are independently selected from:
- Ri, R 2 , R4, and R 5 , or R ls R 2 , and R 6 , or R ls R 2 , and R 6 , or Ri and R 2 , or R ls respectively, are independently selected from:
- optionally substituted alkyl e.g., Ci to C 12 straight chain or branched chain alkyl optionally hetero substituted with oxygen, silicon, sulphur or optionally substituted with OH, O- alkyl, SH, S-alkyl, NH 2 , NH-alkyl
- optionally substituted alkenyl e.g., Ci to C 12 straight chain or branched chain alkenyl optionally hetero substituted with oxygen, silicon, sulphur or optionally substituted with OH, O-alkyl, SH, S-alkyl, NH 2 , NH-alkyl
- optionally substituted alkynyl e.g., Ci to C 12 straight chain or branched chain alkynyl optionally hetero substituted with oxygen, silicon, sulphur or optionally substituted with OH, O-alkyl, SH, S-alkyl, NH 2 , NH- alkyl
- optionally substituted alkynyl e.g., Ci to
- Ri and R 2 may together form a 3 to 8 membered heterocyclic ring, including the nitrogen atoms to which they are attached;
- R 4 and R 5 may together form a ring selected from the group aziridine, pyrrolyl, imidazolyl, pyrazolyl, indolyl, indolinyl, pyrrolidinyl, piperazinyl and piperidyl, including the nitrogen atoms to which they are attached.
- R ls R 2 , R 3 , R 4 , R 5 , Re, and R 7 of Formula I are shown below. Additional combinations of selections of substituents of Ri, R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are envisioned and disclosed in co-pending U.S. Patent Application Serial No. 13/547,022, the disclosure of which is expressly incorporated by reference herein.
- the biguanide compounds of Formula I may include an asymmetric center or centers, and may be in the form of a composition of a racemic mixture, a diastereoisomeric mixture, a single enantiomer, an enantiomeric diastereomer, a meso compound, a pure epimer, or a mixture of epimers thereof, etc. Further, the biguanide compounds may have one or more double bonds, and may be in a form of a cis/trans, E/Z mixture or an E or Z geometric isomer thereof.
- the biguanide compounds of Formula I may also be prepared as a salt form, e.g., pharmaceutically acceptable salts, including suitable acid forms, e.g., salt forms selected from hydrochloride, hydrobromide, acetate, propionate, butyrate, sulphate, hydrogen sulphate, sulphite, carbonate, hydrogen carbonate, phosphate, phosphinate, oxalate, hemi-oxalate, malonate, hemi-malonate, fumarate, hemi-fumarate, maleate, hemi-maleate, citrate, hemi-citrate, tartrate, hemi-tartrate, aspartate, glutamate, etc.
- suitable acid forms e.g., salt forms selected from hydrochloride, hydrobromide, acetate, propionate, butyrate, sulphate, hydrogen sulphate, sulphite, carbonate, hydrogen carbonate, phosphate, phosphinate
- biguanide compounds specifically contemplated for use in the subject invention include the related heterocyclic compounds described in co-pending U.S. Patent Application Serial No. 13/547,022, the disclosure of which is expressly incorporated herein by reference.
- the phrase "biguanide compound" as used herein includes these related heterocyclic compounds, exemplary embodiments of which include the following:
- the compounds of the disclosure may be prepared as a three component salt form including the components A, B, and C wherein:
- A is the protonated form of a natural or unnatural amino acid
- A is the protonated form of a natural amino acid selected from alanine, aspartic acid, asparagine, arginine, glycine, glutamine, glutamic acid lysine, phenylalanine, tyrosine, serine, threonine, tryptophan, leucine, isoleucine, histidine, methionine, proline, cysteine, or cystine;
- B is the dianion of an acid selected from oxalic, malonic, citric, maleic, fumaric, tartaric, aspartic, glutamic acids and the like;
- C is the protonated form of a compound of Formula I.
- the therapeutic efficacy of metformin and other biguanide compounds does not actually require the systemic exposure of metformin that presents an increased risk of lactic acidosis.
- the occurrence of GI side effects can also be significantly reduced by employing delayed-release formulations, and accordingly the methods and compositions provided herein can be safely and effectively used for a wider range of cardiometabolic conditions in a much broader population of patients in need thereof, including reducing cardiometabolic risk in general, and treating or preventing cardiovascular disease in particular.
- cardiovascular disease refers to any disease or disorder of the heart or blood vessels (i.e. arteries and veins) or any symptom thereof, or any disease or condition that causes or contributes to a cardiovascular disease.”
- cardiovascular diseases include acute cardiac ischemic events, acute myocardial infarction, angina, angina pectoris, arrhythmia, atrial fibrulation, atherosclerosis, arterial fibrillation, cardiac insufficiency, cardiovascular disease, chronic heart failure, chronic stable angina, congestive heart failure, coronary artery disease, coronary heart disease, deep vein thrombosis, diabetes, diabetes mellitus, diabetic neuropathy, diastolic dysfunction in subjects with diabetes mellitus, edema, essential hypertension, eventual pulmonary embolism, fatty liver disease, heart disease, heart failure, homozygous familial hypercholesterolemia (HoFH), homozygous familial sitosterolemia, hypercholesterolemia, hyperlipidemia, hyperlipidemia in
- compositions and methods of the present invention also find advantageous use in the treatment and/or prophylaxis of metabolic disorders, including being overweight, obesity, prediabetes, Polycystic Ovary Syndrome, dislipidemia or disorders of lipid metabolism, as well as hyperglycemic conditions, such as insulin-dependent (type 1) or -independent (type 2) diabetes, as well as physiological conditions or disorders associated with or that result from the hyperglycemic condition.
- hyperglycemic conditions treatable by a method of the invention also include a histopathological change associated with chronic or acute hyperglycemia (e.g., diabetes).
- Particular examples include degeneration of pancreas ( ⁇ -cell destruction), kidney tubule calcification, degeneration of liver, eye damage (diabetic retinopathy), diabetic foot, ulcerations in mucosa such as mouth and gums, excess bleeding, delayed blood coagulation or wound healing and increased risk of coronary heart disease, stroke, peripheral vascular disease, dyslipidemia, hypertension and obesity.
- hypoglycemic or “hyperglycemia,” when used in reference to a condition of a patient, means a transient or chronic abnormally high level of glucose present in the blood of a patient.
- the condition can be caused by a delay in glucose metabolism or absorption such that the patient exhibits glucose intolerance or a state of elevated glucose not typically found in normal patients (e.g., in glucose-intolerant subdiabetic patients at risk of developing diabetes, or in diabetic patients).
- Fasting plasma glucose (FPG) levels for normoglycemia are less than about 110 mg/dl, for impaired glucose metabolism, between about 110 and 126 mg/dl, and for diabetics greater than about 126 mg/dl.
- Metabolic disorders also include obesity or an undesirable body mass.
- Leptin, cholecystokinin, PYY and GLP-1 decrease hunger, increase energy expenditure, induce weight loss or provide normal glucose homeostasis.
- a method of the invention for treating obesity or an undesirable body mass, or hyperglycemia involves the local administration of metformin to activate enteroendocrine cell production of cholecystokinin, oxyntomodulin, GIP, GLP-2, PYY or GLP-1.
- Disorders treatable also include those typically associated with obesity, for example, abnormally elevated serum/plasma LDL, VLDL, triglycerides, cholesterol, plaque formation leading to narrowing or blockage of blood vessels, increased risk of hypertension/stroke, coronary heart disease, etc.
- the starting material used for the synthesis of compounds described herein can be obtained from commercial sources, such as Aldrich Chemical Co. (Milwaukee, Wis.), Sigma Chemical Co. (St. Louis, Mo.), or the starting materials can be synthesized.
- the compounds described herein, and other related compounds having different substituents can be synthesized using techniques and materials known to those of skill in the art, such as described, for example, in March, ADVANCED ORGANIC CHEMISTRY 4th Ed., (Wiley 1992); Carey and Sundberg, ADVANCED ORGANIC CHEMISTRY 4th Ed., Vols.
- the biguanide compounds of the disclosure may be administered to a subject in need thereof to reduce cardiometabolic risk in general, and to treat and/or prevent cardiovascular disease in particular.
- a subject in need thereof to reduce cardiometabolic risk in general, and to treat and/or prevent cardiovascular disease in particular.
- the effective use of such compounds in the broader patient population exhibiting one or more cardiometabolic risk factors, and/or suffering from or at risk of cardiovascular disease can now be successfully and safely achieved.
- the compound is metformin.
- metformin Prior formulations of metformin are reported to have an average bioavailability of 30% to 60% while many comparable small molecules have bioavailability of greater than 60%. See, e.g., Tucker et al., "Metformin kinetics in healthy subjects and in patients with diabetes mellitus" Br. J. Clin. Pharmacol. 1981, 12(2) 235-246.
- metformin administration increases plasma concentrations of GLP-1 in normal, diabetic and DPP-IV-deficient rodents, as well as in humans with and without type II diabetes, but has been reported to do so indirectly and independent of a direct impact on intestinal L cells. Mulherin et al., supra.
- enteroendocrine activation by metformin may be triggered by luminal signals on the epithelial aspect of the gut, and therefore systemic bioavailability of metformin is actually unnecessary after oral ingestion in order to stimulate the release of gastrointestinal hormones such as GLP-1.
- compositions comprising biguanide compounds (including analogs, salts, solvates, polymorphs, hydrates, N-oxides, and prodrugs thereof) adapted to minimize the systemic bioavailability of the compound.
- the subject compositions and methods are formulated so as to minimize and preferably avoid an initial release in the stomach and/or proximal small intestine (areas with the greatest absorption) in order to reduce systemic bioavailability upon oral administration.
- the embodiments described herein provide a treatment method comprising administering a delayed-release composition comprising a biguanide compound (including any analogs, salts, solvates, polymorphs, hydrates, N-oxides, or prodrugs thereof) formulated to be delivered to one or more locations of the small intestine and/or lower intestine, and preferably distal small intestine, in order to minimize systemic bioavailability by avoiding absorption in the stomach and proximal small intestine and corresponding rapid increase in C max .
- the biguanide compounds are targeted beyond the stomach to one or more regions of the small intestine, and are preferably targeted downstream or distal of the duodenum.
- the compounds are delivered to the jejunum, ileum, caecum and colon, or a combination thereof. In preferred embodiments, the compounds are delivered to the jejunum, ileum and caecum, or a combination thereof. In preferred embodiments, the compounds are preferentially targeted to the ileum. In additional embodiments, the compound is delivered downstream or distal of the jejunum, or solely to the lower intestine.
- the biguanide compound (including an analog, salt, solvate, polymorph, hydrate, N-oxide, or prodrug thereof) is delivered to one or more regions of the upper intestine and one or more regions of the lower intestine.
- the compound can be delivered to the duodenum and the colon.
- the compound can be delivered to the duodenum, jejunum, ileum and colon.
- the administration of biguanides such as metformin to the preferred regions or locations of the intestine may be achieved by any known method.
- the biguanide compound is formulated in a delayed-release composition for oral delivery that delivers the compound to the targeted regions or locations of the intestine.
- the compound may be delivered in any proportion and manner.
- the methods disclosed herein minimize the systemic bioavailability of the biguanide compound.
- the biguanide compounds have reduced average systemic bioavailability.
- Reduced average systemic bioavailabity in some embodiments, is lower average systemic bioavailability as compared to an immediate-release or extended-release formulation having an equivalent amount of the biguanide compound.
- reduced average systemic bioavailability is when the average systemic bioavailability is more than a 50% reduction, more than a 40% or 45% reduction, more than a 30% or 35% reduction, more than a 20% or 25% reduction , and more than a 10% or 15% reduction in average systemic bioavailability in comparison with an immediate- or extended- release formulation having an equivalent amount of the biguanide compound.
- the subject methods minimize the mean plasma C max and/or mean AUC levels of the biguanide compound in contraindicated patients.
- the administration methods result in minimal plasma absorption, mean C max and/or mean AUC levels of the biguanide compounds in the patient.
- the mean plasma C max , and/or mean AUC levels of the biguanide compound are considered sub-therapeutic for the described compositions as compared to the reported C max and/or AUC levels of conventional immediate-release and extended-release formulations having identical amounts of metformin.
- negligible or sub-therapeutic metformin plasma C max and/or AUC levels include 75%, 60%, 50%, 40% and 30% of reported C max and/or AUC levels of known metformin formulations (e.g., GLUMETZA®, GLUCOPHAGE®, GLUCOPHAGE® XR, RIOMET®, FORTAMET®, OBIMET®, GLUFORMIN®, DIANBEN®, DIABEX®, DIAFORMIN®, Metformin IR®, Metformin SR®, and the like).
- known metformin formulations e.g., GLUMETZA®, GLUCOPHAGE®, GLUCOPHAGE® XR, RIOMET®, FORTAMET®, OBIMET®, GLUFORMIN®, DIANBEN®, DIABEX®, DIAFORMIN®, Metformin IR®, Metformin SR®, and the like).
- the inventive compositions and methods directed to metformin produce a C max that is no more than 75% or 85%, preferably no more than 50% or 60%, more preferably no more than 25% or 30% or 40% of the same dose of an immediate release metformin formulation (e.g. GLUCOPHAGE®) following oral ingestion.
- an immediate release metformin formulation e.g. GLUCOPHAGE®
- the inventive methods provide a C max that is no more than 3x, more preferably no more than 2.5x or 2x, still more preferably no more than 1.8x or 1.5x the initial trough plasma concentration 10-12 hours after the last oral ingestion of metformin.
- the inventive compositions and methods provide a mean plasma AUC over the dosing interval that is no more than 75% or 80%, preferably no more than 50% or 60%, more preferably no more than 25%, 30% or 40% of the same dose of an immediate release formulation (e.g. GLUCOPHAGE®) following oral ingestion.
- an immediate release formulation e.g. GLUCOPHAGE®
- administration of the subject delayed-release formulation minimizes the mean plasma AUC, the mean plasma C max and/or the circulating plasma concentration of the biguanide compound in contraindicated patients compared to an identical protocol administering an IR or XR formulation having the same amount of the biguanide compound.
- the mean plasma AUCo- ⁇ of the biguanide compound resulting from administration is less than about 15,000 ng*h/mL or 14,000 ng*h/mL, preferably less than about 12,000 ng*h/mL, 1 1 ,000 ng*h/mL or 10,000 ng*h/mL, more preferably less than about 9,000 ng*h/mL, 8,000 ng*h/mL or 7,000 ng*h/mL.
- the resulting mean plasma C max of the biguanide compound is less than about 1000 ng/mL, preferably less than about 900 ng/mL or 800 ng/mL, more preferably less than about 700 ng/mL, 600 ng/mL or 500 ng/mL.
- the resulting circulating plasma concentration of the biguanide compound is below about 5 ⁇ g/ml or 4 ⁇ g/ml, preferably below about 3 ⁇ g/ml or 2.5 ⁇ g/ml, more preferably below about 2 ⁇ g/ml, 1 ⁇ g/ml, 0.5 ⁇ g/ml, or 0.25 ⁇ g/ml in the patient.
- the biguanide compound is metformin
- the IR composition is Glucophage®
- the XR composition is Glucophage® XR.
- the present invention contemplates fixed-dose oral dosage forms combining a delayed-release formulation of metformin or other biguanide compounds with appropriate conventional formulations of at least one statin and at least one additional active agent, more preferably at least two additional active agents, still more preferably at least three or four additional active agents, including, e.g. anti-hypertensives, anti-platelet agents, diuretics, bile acid sequesterants, incretin mimetics, oral anti-diabetic agents, anti-obesity agents, and anti- atherosclerotics.
- These combination dosage forms provide for additive and/or synergistic effects, resulting in the need for lower dosages of a known therapy, the compositions described herein, or both. Additional benefits of combination therapies include the reduction in toxicities associated with any of the known therapies.
- Suitable anti-hypertensives for use in the subject invention include, e.g., beta blockers (atenolol, betaxolol, metoprolol, nadolol, nebivolol, oxprenolol, pindolol, propranolol, timolol, etc.), alpha- 1 blockers (alfuzosin, arotinolol, doxazosin, indoramin, moxisylyte,
- alpha-2 agonists apraclonidine, brimonidine, clonidine, guanabenz, guanfacine, lofexidine, tolonidine, mixed alpha / beta blockers (bucindolol, carvedilol, labetalol, etc.), calcium channel blockers such as dihydropyridines (amlodipine, felodipine, isradipine, lercanidipine, nicardipine, nifedipine, nimodipine, nitrendipine, etc.) and non-dihydropyridines (diltiazem, verapamil, etc.), renin inhibitors (aliskiren), ACE inhibitors (captopril, enalapril, fosinopril), alpha-2 agonists (apraclonidine, brimonidine, clonidine, guanabenz, guanfacine, lofexidine, tolonidine,
- Suitable anti-platelet medications for use in the subject invention include, e.g. , cyclooxygenase inhibitors (acetylsalicylic acid (aspirin), aloxiprin, carbasalate calcium, indobufen, trifusal, etc.), ADP receptor inhibitors (clopidogrel, ticlopidine, ticagrelor, etc.), phosphodiesterase inhibitors (cilostazol, etc.), adenose reuptake inhibitors (dipyridamole, etc.), thromboxane synthase or receptor inhibitors (picotamide, ramatroban, terbogrel, etc.), anagrelide, prasugrel, cloricromen, and the like.
- cyclooxygenase inhibitors acetylsalicylic acid (aspirin), aloxiprin, carbasalate calcium, indobufen, trifusal, etc.
- Suitable diuretics for use in the subject invention include e.g., loop diuretics (bumetanide, ethacrynic acid, furosemide, torsemide, etc.), thiazide diuretics (epitizide, hydrochlorothiazide, chlorothiazide, bendroflumethiazide, etc.), thiazide-like diuretics (indapamide, chlorthalidone, metolazone, etc.), potassium-sparing diuretics (amiloride, triamterene, spironolactone, etc.), and the like. These agents are generally formulated for immediate-release, although extended- and/or delayed-release may also be utilized.
- Suitable bile acid sequesterants for use in the subject invention include, e.g. , cholestyramine, colesevelam, colestipol, and the like. These agents are generally formulated for immediate-release, although extended- and/or delayed-release may also be utilized.
- Suitable incretin mimetics and enhancers for use in the subject invention include, e.g., peptidic and non-peptidic GLP-1 mimetics (including, e.g., allosteric activators of the GLP-1 receptor), peptidic and non-peptidic PYY mimetics, peptidic and non-peptidic Ghrelin antagonists and the like. These agents are generally formulated for immediate-release, although extended- and/or delayed-release may also be utilized.
- Suitable oral anti-diabetic agents for use in combination with metformin in the subject compositions and methods include, e.g., sulfonylureas (glyburide, glimepiride, glipizide, gliclazide, glycopyramide, gliquidone, tolbutamide, acetohexamide, tolazamide, chlorpropamide, carbutamide, etc.), nonsulfonylureas (repaglinide, nateglinide, etc.), thiazolidinediones (rosiglitazone, pioglitazone, rivoglitazone, troglitazone, ciglitazone, darglitazone, netoglitazone, englitazone, etc.), dual PPAR agonists (e.g., aleglitazar, farglitazar, muraglitazar, tesaglitazar, telmisartan, and the like), dipeptide-(
- Suitable GPR40, GPR41 and GPR43 agonists are also described in the following publications and patent applications: Stoddart LA, Smith NJ, Milligan G. International Union of Pharmacology. LXXI Free fatty acid receptors FFAI, -2, and -3: pharmacology and pathophysiological functions Pharmacol Rev. (2008) Dec;60(4):405-417; Trond Ulven.
- Short- chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets Front Endocrinol (Lausanne) (2012); 3: 111; WO/2012/147516 - Cyclic amide derivative; WO/2012/147518 -Novel 3-hydroxyisothiazole 1-oxide derivative; WO/2012/136221
- Suitable GPR119 agonists are described in the following patent applications: WO/2013/055910 - Modulators of the GPR119 receptor and the treatment of disorders related thereto; WO/2013/011402 - GPR 119 modulators; WO/2012/173174 - Azaspiroalkane compound; WO/2012/173174 - Azaspiroalkane compound; WO/2012/168315 - Substituted piperidines as GPR119 modulators for the treatment of metabolic disorders; WO/2012/170702 - Modulators of the GPR119 receptor and the treatment of disorders related thereto; WO/2012/154009 - Thienopyrimidine derivatives; pharmaceutically acceptable salts thereof; method for preparing thienopyrimidine derivatives; and pharmaceutical composition containing thienopyrimidine derivatives as active ingredients for preventing or treating diabetes-related diseases; WO/2012/145603 - Modulators of the GPR119 receptor and the treatment of disorders related thereto;
- WO/2012/058649 Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(-3-methylbutyl)-4-(4- methylpentanoyl)cyclopent-2-en-l-one derivatives, substantially enantiomerically pure compositions and methods; WO/2011/159297 - GPRl 20 receptor agonists and uses thereof; WO/2011/072132 - Methods of treating inflammatory conditions; WO/2010/080537 - GPR120 receptor agonists and uses thereof; WO/2010/048207 - Aryl GPR120 receptor agonists and uses thereof; WO/2009/147990 - Novel isoxazole derivative; WO/2009/125804 - Screening method; WO/2009/038204 - Novel long-chain fatty acid derivative compound and G-protein-coupled receptor agonist containing the compound as active ingredient; WO/2008/139987 - G-protein- conjugated receptor agonist; WO/2008/103
- WO/2007/134613 Modulation of GPR120 activity in adipocytes/fat tissue
- WO/2007/026874 Method for screening of substance effective on disease using GPR120 and phospho lipase
- WO/2007/014824 - Fat taste receptors and their methods of use; each of which are incorporated by reference in their entirety. These agents are generally formulated for immediate-release, although extended- and/or delayed-release may also be utilized.
- Suitable anti-obesity agents for use for use in subject invention include, e.g., Orlistat (Zenical), Lorcaserin (Belviq), Sibutramine (Meridia), Rimonabant (Acomplia), Exenatide (Byetta and Bydureon), Pramlintide (Symlin), Fen-Phen, Redux, ZGN-433,
- Phentermine/topiramate Qsymia
- Naltrexone/buproprion Contrave
- alternative medicine options including, e.g., conjugated linoleic acid, green tea extract, khat, lipoic acid, ECA Stack (Ephedrine Caffeine Stack), Raspberry ketone and the like.
- conjugated linoleic acid green tea extract, khat, lipoic acid
- ECA Stack Ephedrine Caffeine Stack
- Raspberry ketone Raspberry ketone and the like.
- These agents are generally formulated for immediate-release, although extended-release or delayed-release may also be utilized.
- Suitable anti-artherosclerotics for use in the subject invention include compounds that can reduce atherosclerosis independent of changes in other risk factors, e.g. fish oil as well as inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) such as AMG145 (Amgen), lD05-IgG2 (Merck & Co.), and SAR236553/REGN727 (Aventis/Regeneron), peptides mimicking the LDLR that binds to PCSK9 ⁇ e.g. Shan et al. (2008) Biochem. Biophys. Res.
- PCSK9 proprotein convertase subtilisin/kexin type 9
- HDL/LDL ratio modifying compounds including, e.g., niacin, acipomox, MK-0354, other modulators of GPR81 ,
- GPR109A, GPR109B and the like are described in the following paper and patent applications: Offermanns S, Colletti SL, Lovenberg TW, Semple G, Wise A, Uzerman AP. International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and Classification of Hydroxy-carboxylic Acid Receptors (GPR81, GPR109A, and GPR109B) Pharmacol Rev. (2011) Jun;63(2):269-90. doi:
- WO/2009/151542 - Nicotinic acid receptor ligands WO/2006/127595 - 5-aminopyrazole carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof; WO/2006/069242 - Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related disorders; WO/2005/051937 - 4-oxo-4;5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof; WO/2005/044816 - Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof;
- WO/2005/028488 Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and LDL/HDL levels
- WO/2005/011677 5-substituted 2h-pyrazole-3- carboxylic acid derivatives as agonists for the nicotinic acid receptor RUP25 for the treatment of dyslipidemia and related diseases
- WO/2004/033431 Hydroxypyrazoles for use against metabolic-related disorders
- WO/2004/032928 5-substituted 2H-pyrazone-3 -carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia; each of which are incorporated by reference in their entirety.
- These agents are generally formulated for immediate-release, although extended- and/or delayed-release may also be utilized.
- the subject compositions and methods are administered in conjunction with anti-psychotics or anti-depressants which have a propensity to induce weight gain, and/or pre-diabetes and diabetes.
- Suitable anti-psychotics for use for use in conjunction with the subject compositions and methods include, e.g., Haloperidol (Haldol, Serenace) Droperidol (Droleptan, Inapsine), Chlorpromazine (Thorazine, Largactil), Fluphenazine (Prolixin), Perphenazine (Trilafon), Prochlorperazine (Compazine), Thioridazine (Mellaril), Trifluoperazine (Stelazine), Mesoridazine (Serentil), Periciazine, Promazine.
- Trifiupromazine (Vesprin), Levomepromazine (Nozinan), Promethazine (Phenergan), Pimozide (Orap), Cyamemazine (Tercian), Chlorprothixene (Cloxan, Taractan, Truxal), Clopenthixol (Sordinol), Flupenthixol (Depixol, Fluanxol), Thiothixene (Navane), Zuclopenthixol (Cisordinol, Clopixol, Acuphase), Clozapine (Clozaril), Olanzapine (Zyprexa), Risperidone (Risperdal), Quetiapine (Seroquel), Ziprasidone (Geodon), Amisulpride (Solian), Asenapine (Saphris), Paliperidone (Invega), Iloperidone (Fanapt, Fanapta, and previously known as Zomaril), Zo
- Suitable anti-depressants which have a propensity to induce weight gain, and/or prediabetes and diabetes for use for use in conjunction with the subject compositions and methods include, e.g., Citalopram (Celexa), Escitalopram (Lexapro, Cipralex), Paroxetine (Paxil,
- Nefadar Nefadar
- Trazodone Desyrel
- Norepinephrine-dopamine reuptake inhibitors Bupropion (Wellbutrin, Zyban)
- Tianeptine Stablon, Coaxil, Tatinol
- Amineptine Agomelatine
- Valdoxan Valdoxan
- Melitor Thymanax
- Amitriptyline Elavil, Endep
- Clomipramine Anafranil
- Doxepin Doxepin
- compositions provided herein may be used with other commercially available diet aids or other weight loss and/or anti-obesity agents, such as, by way of example, PYY and PYY agonists, GLP-1 and GLP-1 agonists, CCK and CCK agonists, exendin and exendin agonists, GIP and GIP agonists, amylin and amylin agonists, ghrelin modulators (e.g., inhibitors) and leptin and leptin agonists.
- compositions comprising the biguanide compound provided herein are used in combination with amylin, amylin agonists or mimetics.
- Exemplary amylin agonists or mimetics include pramlintide and related compounds.
- the compounds and compositions provided herein are used in combination with leptin, leptin agonists or mimetics. Additional leptin agonists or mimetics can be identified using the methods described by U.S. Pat. No. 7,247,427 which is incorporated by reference herein.
- the compounds and compositions provided herein increase leptin sensitivity and increase effectiveness of leptin, leptin agonists or mimetics.
- Additional anti-obesity agents suitable for use in the subject methods include those that are in current development.
- Other anti-obesity agents include phentermine, fenfluramine, sibutramine, rimonabant, topiramate, zonisamide, bupropion, naltrexone, lorcaserin, or related sympathomimetics and orlistat or other intestinal lipase inhibitors, alone or in combination.
- Therapies, drugs and compounds useful for the treatment of weight loss, binge eating, food addictions and cravings may be administered with the compositions described herein.
- the patient may further be administered at least one other drug which is known to suppress hunger or control appetite.
- Such therapies drugs and compounds include but are not limited to phenteramines such as Meridia® and Xenical®. Additional therapies, drugs and compounds are known in the art and contemplated herein.
- compositions and methods may be used as part of a combination therapy for the control, prevention or treatment of obesity or eating disorders or conditions.
- Compounds used as part of a combination therapy to treat obesity or reduce weight include, but are not limited to, central nervous system agents that affect neurotransmitters or neural ion channels, including antidepressants (bupropion), noradrenalin reuptake inhibitors (GW320659), selective 5HT 2c receptor agonists, antiseizure agents (topiramate, zonisamide), some dopamine antagonists, and cannabinoid-1 receptor antagonists (CB-1 receptor antagonists) (rimonabant); leptin/insulin/central nervous system pathway agents, including leptin analogues, leptin transport and/or leptin receptor promoters, ciliary neurotrophic factor (Axokine), neuropeptide Y and agouti-related peptide antagonists, pro-opiomelanocortin and cocaine and
- central nervous system agents that affect neurotrans
- indanone/indanols amino sterols (trodusquemine/trodulamine), and other gastrointestinal lipase inhibitors (ATL962); amphetamines, such as dextroamphetamine; other sympathomimetic adrenergic agents, including phentermine, benzphetamine, phendimetrazine, mazindol, and diethylpropion.
- amphetamines such as dextroamphetamine
- other sympathomimetic adrenergic agents including phentermine, benzphetamine, phendimetrazine, mazindol, and diethylpropion.
- active agents of interest include ecopipam; oxyntomodulin (OM); inhibitors of glucose-dependent insulinotropic polypeptide (GIP); gastrin-releasing peptide; neuromedin B; enterostatin; amfebutamone, SR-58611; CP-045598; AOD-0604; QC-BT16; rGLP-1; 1426 (HMPv-1426); N-5984; ISIS-113715; solabegron; SR-147778; Org-34517; melanotan-II;
- cetilistat c-2735; c-5093; c-2624; APD-356; radafaxine; fiuasterone; GP-389255; 856464; S- 2367; AVE-1625; T-71; oleoyl-estrone; peptide YY [3-36] intranasal; androgen receptor agonists; PYY 3-36; DOV-102677; tagatose; SLV-319; 1954 (Aventis Pharma AG);
- oxyntomodulin Thiakis; bromocriptine, PLIVA; diabetes/hyperlipidemia therapy, Yissum; CKD-502; thyroid receptor beta agonists; beta-3 adrenoceptor agonist; CDK-A agonists; galanin antagonist; dopamine D1/D2 agonists; melanocortin modulators; verongamine; neuropeptide Y antagonists; melanin-concentrating hormone receptor antagonists; dual PPAR alpha/gamma agonists; CGEN-P-4; kinase inhibitors; human MCH receptor antagonists; GHS-R antagonists; ghrelin receptor agonists; DG70 inhibitors; cotinine; CRF-BP inhibitors; urocortin agonists; UCL-2000; impentamine; .beta.-3 adrenergic receptor; pentapeptide MC4 agonists; trodusquemine; GT-2016; C-75; CPOP; MCH-1 receptor antagonists; RED
- HSD 1 lbeta-hydroxysteroid dehydrogenase
- QRX-431 E-6776; RI-450; melanocortin-4 antagonists; melanocortin 4 receptor agonists; obesity therapeutics (CuraGen); leptin mimetics; A-74498; second-generation leptin; NBI-103; CL-314698; CP-114271; beta-3 adrenoceptor agonists; NMI 8739; UCL-1283; BMS-192548; CP-94253; PD-160170; nicotinic agonist; LG-100754; SB-226552; LY-355124; CKD-711; L-751250; PPAR inhibitors; G-protein therapeutics; obesity therapy (Amylin Pharmaceuticals Inc.); BW-1229; monoclonal antibody (ObeSys/CAT); L-742791; (S)sibutramine; MBU-23; YM-268;
- HSD 1
- GHRH mimetics GHRH mimetics; obesity therapy (Yamanouchi Pharmaceutical Co. Ltd.); SB-251023; CP- 331684; BIBO-3304; cholesten-3-ones; LY-362884; BRL-48962; NPY-1 antagonists; A-71378; .RTM.-didesmethylsibutramine; amide derivatives; obesity therapeutics (Bristol-Myers Squibb Co.); obesity therapeutics (Ligand Pharmaceuticals Inc.); LY-226936; NPY antagonists; CCK-A agonists; FPL-14294; PD-145942; ZA-7114; CL-316243; SR-58878; R-1065; BIBP-3226; HP- 228; talibegron; FR-165914; AZM-008; AZM-016; AZM-120; AZM-090; vomeropherin; BMS- 187257; D-3800; AZM-131; gene
- diethylpropion diethylpropion; phendimetrazine; benzphetamine; amfebutmone; sertraline; AOD-9604; ATL- 062; BVT-933; GT389-255; SLV319; HE-2500; PEG-axokine; L-796568; and ABT-239.
- compounds for use in combination with a composition comprising the biguanido compound provided heroin include rimonabant, sibutramino, orlistat, PYY or an analog thereof, CB 1 antagonist, leptin, phentermine, and exendin analogs.
- Exemplary dosing ranges include phentermine resin (30 mg in the morning), fenfluramine hydrochloride (20 mg throe times a day), and a combination of phentermine rosin (15 mg in the morning) and Lorcasorin(30 mg boforo tho ovoning moal), and sibutramino (10 20 mg).
- the metformin component of the combination dosage form is adapted for delayed release so as to minimize plasma absorption. Delivery may be by any known method including, e.g., oral, rectal, nasogastric tube, parenteral injection such as intraluminal intestinal injection. In preferred embodiments, the subject combination dosage forms are orally administered. Oral delivery of biguanide compounds is described in the delayed release formulations section and includes timed release systems, enteric coatings and pH dependent systems, and the like.
- the biguanide compound is delivered to several places in the gastrointestinal tract such as the duodenum, jejunum, ileum, lower intestine or combinations thereof following administration, while the two or more additional active agents are formulated for immediate- and/or extended release.
- a combination dosage form comprising the biguanide compound can deliver to the lower intestine by means of a timed or delayed (enteric) release component, while the additional active agents are released either immediately upon ingestion.
- the combination dosage forms of the present invention are fixed-dose unitary dosage forms such as bi- or tri- or multiple-layer tablets, or multi-particulate forms such as encapsulated micro-tablets or granules.
- the delayed-release component releases the biguanide compound after onset of a desired pH, due to the enteric coating.
- pHs contemplated include about pH 5.0 or about pH 5.5, more preferably about pH 6.0, about pH 6.5 and about pH 7.0. After onset of a desired pH, the compound begins release.
- Such compositions may release the biguanide compound in about 15 minutes, about 20 minutes, about 25 minutes or about 30 minutes after the onset of the desired pH, and/or may have timed, extended or slow release aspects that release the biguanide compound over the course of a longer time period such as about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours or about 8 hours.
- Exemplary two component delivery system can be, in some embodiments, a bilayer or trilayer tablet. Three, four and additional components are contemplated within the embodiments.
- dosages of the compound can range from about 1 mg to about 1000 mg, about 10 mg to about 950 mg, about 50 mg to about 900 mg or about 100 mg or about 800 mg per day.
- the dosage of the compound is about 800 mg, about 700, about 600 mg, about 500 mg, about 400 mg, about 300 mg, about 250 mg, about 200 mg, about 150 mg, about 100 mg, about 75 mg, about 50 mg, about 25 mg, about 10 mg or about 1 mg per day.
- the dosage of the compound is less than 400 mg.
- the dosage of the compound is 250 mg.
- Salts of biguanide compound include, but are not limited to, hydrochloride, phosphate, sulfate, hydrobromide, salicylate, maleate, benzoate, succinnate, ethanesulfonate, fumarate, glycolate, pamoate, oratate, acetate, isobutyrate, acetylsalicylate, nicotinic acid, adamantoate, zinc chlorophylin, carboxylic acid, benzoic acid, dichloroacetic acid, theophylin-7- acetate, clofibrate, tartate, oxalate, tannate and hydroxyl acid salts.
- the salt is metformin hydrochloride.
- compositions provided herein include those suitable for oral or rectal administration, although the most suitable route can depend upon for example the condition and disorder of the recipient.
- the compositions are preferably presented in unitary fixed-dosage form and can be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients.
- Formulations suitable for oral administration can be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in- water liquid emulsion or a water-in-oil liquid emulsion.
- composition preparations which can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets can be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders (e.g., povidone, gelatin, hydroxypropylmethyl cellulose), inert diluents, preservative, disintegrant (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) or lubricating, surface active or dispersing agents.
- binders e.g., povidone, gelatin, hydroxypropylmethyl cellulose
- inert diluents preservative
- disintegrant e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose
- Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets can optionally be coated or scored and can be formulated so as to provide slow or controlled release of the active ingredient therein. Tablets can optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach. All formulations for oral administration should be in dosages suitable for such administration.
- the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers can be added. Dragee cores are provided with suitable coatings.
- concentrated sugar solutions can be used, which can optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments can be added to the tablets or Dragee coatings for identification or to characterize different combinations of active compound doses.
- compositions described herein can include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration can include flavoring agents.
- compositions described herein can also contain the biguanide compound in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
- Compositions intended for oral use can be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions can contain one or more agents selected from, by way of non-limiting example, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
- delayed release in which the location of the release is controlled so as to minimize systemic absorption.
- delayed release can be obtained by the appropriate selection of formulation parameters and ingredients (e.g., appropriate controlled release compositions and coatings). Examples include single or multiple unit tablet or capsule compositions, oil solutions, suspensions, emulsions, microcapsules, microspheres, nanoparticles and liposomes.
- the release mechanism can be controlled such that the biguanide compounds are released at period intervals or the location of the release is controlled, the release of combined agents can be simultaneous, or a delayed release of the biguanide compound in a combination can be affected when the early release of another combined therapeutic one is preferred over the other.
- Different delivery systems described herein can also be combined to release at an onset of multiple period intervals (e.g., about 30 minutes, about 120 minutes, about 180 minutes and about 240 minutes after oral administration) or at different locations (e.g., release in the lower intestine, upper intestine, the jejunum, ileum, caecum, colon, and/or rectum) or a combination thereof.
- a pH dependent system can be combined with a timed release system or any other system described herein to achieve a desired release profile.
- the biguanide compounds are formulated as a delayed release component coupled with an immediate- and/or extended release component of two or more additional active agents in a unitary dosage form.
- the immediate release component can be formulated by any known method such as a layer that envelops a portion of the delayed release component or the like.
- Exemplary ratios of immediate release of an additional therapeutic agent to delayed release of a biguanide compound are about 10% IR to about 90% DR, about 15% IR to about 85% DR, about 20% IR to about 80% DR, about 25% IR to about 75% DR, about 30% IR to about 70% DR, about 35% IR to about 65% DR, about 40% IR to about 60% DR, about 45% IR to about 55% DR, or about 50% IR to about 50% DR.
- the immediate release of an active agent to delayed release of an active agent is about 25% IR to about 75% DR.
- the immediate release of an active agent to delayed release of an active agent is about 20% IR to about 80% DR.
- Unitary dosage forms with an IR and DR component include any known formulation including bilayer tablets, coated pellets, and the like.
- the delayed-release mechanism is a "timed” or temporal release (“TR") system that releases an active agent, for example a biguanide compound, at certain timepoints subsequent to administration.
- TR temporal release
- Timed release systems are well known in the art and suitable timed release systems can include any known excipient and/or coating.
- excipients in a matrix, layer or coating can delay release of an active agent by slowing diffusion of the active agent into an environment.
- Suitable timed release excipients include but are not limited to, acacia (gum arabic), agar, aluminum magnesium silicate, alginates (sodium alginate), sodium stearate, bladderwrack, bentonite, carbomer, carrageenan, Carbopol, cellulose, microcrystalline cellulose, ceratonia, chondrus, dextrose, furcellaran, gelatin, Ghatti gum, guar gum, galactomannan, hectorite, lactose, sucrose, maltodextrin, mannitol, sorbitol, honey, maize starch, wheat starch, rice starch, potato starch, gelatin, sterculia gum, xanthum gum, Glyceryl behenate (e.g., Compritol 888 ato), Gylceryl distearate (e.g.
- Precirol ato 5 polyethylene glycol (e.g., PEG 200-4500), polyethylene oxide, adipic acid, gum tragacanth, ethyl cellulose (e.g., ethyl cellulose 100), ethylhydroxyethyl cellulose, ethylmethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxyethylmethyl cellulose (e.g., KIOOLV, K4M, K15M), hydroxypropyl cellulose, poly(hydroxyethyl methacrylate), cellulose acetate (e.g.
- cellulose acetate CA-398-10 NF cellulose acetate CA-398-10 NF
- cellulose acetate phthalate cellulose acetate propionate
- cellulose acetate butyrate hydroxypropyl methyl cellulose acetate succinate
- hydroxypropyl methyl cellulose phthalate cellulose butyrate
- cellulose nitrate oxypolygelatin, pectin, polygeline, povidone, propylene carbonate, polyandrides, methyl vinyl ether/maleic anhydride copolymer (PVM/MA), poly(methoxyethyl methacrylate), poly(methoxyethoxyethyl methacrylate), hydroxypropyl cellulose, hydroxypropylmethyl cellulose, sodium carboxymethyl-cellulose (CMC), silicon dioxide, vinyl polymers, e.g.
- polyvinyl pyrrolidones PVP: povidone
- polyvinyl acetates polyvinyl acetate phthalates and mixtures
- Kollidon SR acryl derivatives (e.g. polyacrylates, e.g. cross-linked polyacrylates, methycrylic acid copolymers), Splenda® (dextrose, maltodextrin and sucralose) or combinations thereof.
- the timed release excipient may be in a matrix with active agent, in another compartment or layer of the formulation, as part of the coating, or any combination thereof. Varying amounts of one or more timed release excipients may be used to achieve a designated release time.
- One non-limiting example includes formulations of the TIMERx® system.
- This controlled release formulation system provides for altered temporal release (SyncroDoseTM) as well as biphasic release (Geminex®).
- SynchronizationTM altered temporal release
- Gaminex® biphasic release
- compositions can be created which target the upper gastrointestinal tract, the lower gastrointestinal tract, or both, in addition to temporally controlling the release of such compounds in any of these locations.
- the timed release systems are formulated to release the compound at an onset of about 5 minutes, about 10 minutes, about 20 minutes, about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 100 minutes, about 110 minutes, about 120 minutes, about 130 minutes, about 140 minutes, about 150 minutes, about 160 minutes, about 170 minutes, about 180 minutes, about 190 minutes, about 200 minutes, about 210 minutes, about 220 minutes, about 230 minutes, about 240 minutes, about 250 minutes, about 260 minutes, about 270 minutes, about 280 minutes, about 290 minutes, about 300 minutes, about 310 minutes, about 320 minutes, about 330 minutes, about 340 minutes, about 350 minutes, about 360 minutes, about 370 minutes, about 380 minutes, about 390 minutes, about 400, about 400, about 410, or about 420 minutes subsequent to administration.
- timed release systems are formulated to release at more than one time point.
- the timed release systems are formulated to release at an onset of about 10 minutes, about 30 minutes, about 120 minutes, about 180 minutes and about 240 minutes after administration.
- the timed release systems are formulated to release at an onset of about 5 to about 45 minutes, about 105 to about 135 minutes, about 165 to about 195 minutes, about 225 to about 255 minutes or a combination of times thereof following administration to a patient.
- the formulation may also be coated with an enteric coating, which protects an active agent, for example a biguanide compound, from degradation in an acidic environment, such as the stomach, and allows a delayed release into a target area, for example the ileum, for uptake.
- an active agent for example a biguanide compound
- the enteric coating may be, as a non- limiting example, wax or wax like substance, such as carnauba wax, fatty alcohols, hydrogenated vegetable oils, zein, shellac, sucrose, Arabic gum, gelatin, dextrin, psyllium husk powder, polymethacrylates, anionic polymethacrylates, mixtures of poly(methacrylic acid, methyl methacrylate), polymers or copolymers derived from acrylic and/or methacrylic acid esters, cellulose acetate phthalate, cellulose acetate trimelliate, hydroxypropyl methylcellulose phthalate (HPMCP), cellulose propionate phthalate, cellulose acetate maleate, polyvinyl alcohol phthalate, hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose hexahydrophthalate, polyvinyl acetate phthalate, mixtures of poly(methacrylic acid, ethyl acrylate),
- silicone microspheres for pH-controlled gastrointestinal drug delivery have been described by Carelli et al, Int. J. Pharmaceutics 179: 73-83, 1999.
- the microspheres are pH-sensitive semi-interpenetrating polymer hydrogels made of varying proportions of poly(methacrylic acid-co-methylmethacrylate) (EUDRAGIT® LI 00 or EUDPvAGIT® SI 00) and crosslinked polyethylene glycol 8000 that are encapsulated into silicone microspheres.
- EUDRAGIT® series of methacrylic acid copolymers are commercially available from Evonik Industries in Darmstadt, Germany.
- the enteric coatings can be formulated to release a biguanide compound at a desired pH using combinations of enteric polymers. It is well-known that different locations of the gastrointestinal system have specific pHs. For example, the duodenum may correspond to a pH 5.5 environment and the jejunum may correspond to pH 6.0 environment. In preferred embodiments, the enteric coatings are formulated to release the compound at an onset of a desired pH, e.g., in the distal small intestine and lower intestine, i.e., at about pH 6, about pH 6.5, or about pH 7. In embodiments with multiple releases, the enteric coatings are formulated to release at an onset of two or more pH values.
- the enteric coatings are formulated to release at an onset of pH 6.0, 6.5 and 7.0. In certain embodiments, the enteric coatings are formulated to release at an onset of pH 6.5 and 7.0. In certain embodiments, the enteric coatings are formulated to release at the jejunum, ileum, and lower intestine. In yet other embodiments, the enteric coatings are used in combination with other release systems such as a timed release system.
- the enteric coatings are used in combination with an immediate release/ extended release unitary dosage form.
- a unitary dosage form such as a bilayer tablet with a 20% IR/80% MR component of the biguanide compound can be coated with an enteric coating that releases at pH, e.g., 5.5, 6.0, 6.5, 7.0 so that the release is delayed until the dosage form reaches a pH of e.g., 5.5, 6.0, 6.5, 7.0 thereby releasing the IR component immediately and the MR component according to its MR release properties.
- the enteric coatings are used in combination with an immediate release/timed release unitary dosage forms.
- microcapsules gastroretentive systems described in U.S. Pat. Nos. 6,022,562, 5,846,566 and 5,603,957 can be used in the delayed release delivery methods described herein.
- Microparticles of an active agent or drug are coated by spraying with a material consisting of a mixture of a film-forming polymer derivative, a hydrophobic plasticizer, a functional agent and a nitrogen-containing polymer.
- the resulting microcapsules are less than or equal to 1000 microns (gm) in size, and in certain cases such microcapsules are between 100 and 500 microns. These microcapsules remain in the small intestine for at least 5 hours.
- Film- forming polymer derivatives used in such microcapsules include, but are not limited to, ethylcellulose, cellulose acetate, and non-hydrosoluble cellulose derivates.
- the nitrogen-containing polymers include, but are not limited to, polyacrylamide, poly-N- vinylamide, poly-N-vinyl-lactam and polyvinylpyrrolidone.
- the plasticizer used in such microcapsule include, but are not limited to, glycerol esters, phthalates, citrates, sebacates, cetylalcohol esters, castor oil and cutin.
- the surface-active and/or lubricating agent used in such microcapsule include, but are not limited to, anionic surfactants, such as by way of example the alkali metal or alkaline-earth metal salts of fatty acids, stearic acid and/or oleic acid, nonionic surfactants, such as by way of example, polyoxyethylenated esters of sorbitan and/or polyoxyethylenated esters of sorbitan and/or polyoxyethylenated derivatives of castor oil; and/or lubricants such as stearates, such as by way of example, calcium, magnesium, aluminum stearate, zinc stearate, stearylfumarate, sodium stearylfimarate, and glyceryl behenate.
- anionic surfactants such as by way of example the alkali metal or alkaline-earth metal salts of fatty acids, stearic acid and/or oleic acid
- a lower GI delivery formulation comprises a tablet for lower GI delivery.
- the inner composition of the tablet comprises about 0.01% weight to about 10.0%) by weight of a suitable active ingredient; about 50%> by weight to about 98%> by weight of a hydrocolloid gum obtainable from higher plants; and about 2% by weight to about 50% by weight of a pharmaceutically acceptable excipient such as a binder.
- a pharmaceutically acceptable excipient such as a binder.
- Other optional materials may be present that will assist in establishing the desired characteristics of the pharmaceutical composition. These include materials that may enhance absorption of the active ingredient in the lower GI, may protect the active ingredient against degradation, may prevent dissolution, and the like.
- a coating that is preferably of enteric polymeric material.
- the inner composition of the tablet may be one of several designs: (a) it may be a matrix of a therapeutically effective amount of the active ingredient uniformly dispersed throughout in combination with a high percentage of the hydrocolloid and a generally lesser amount of other excipients; (b) it may have a core, in which the active ingredient is concentrated, surrounded by a layer of material that is free of the active ingredient and that has a high percentage of the hydrocolloid and a generally lesser amount of other excipients; (c) it may have a concentration gradient of the active ingredient such that there is a greater amount in the core of the tablet with lesser amounts in multiple layers surrounding the core and very little or no active ingredient in the outer layer.
- the design of the tablet is that of (a), (b) or (c) above, the specificity for regional delivery to the lower GI
- Suitable hydrocolloids are well known in the art. See for example "The Chemistry of Plant Gums and Mucilages" by Smith and Montgomery from the A.C.S. Monograph series, #141, 1959, Reinhold Publishing Co. and the Eighteenth Edition of The Merck Index.
- the amount of the hydrocolloid that will be used is an amount that allows the composition to traverse the upper GI tract without significant disintegration and without releasing significant amounts of active ingredient in the upper GI tract, i.e. to provide a delayed-release profile. Generally, that amount of hydrocolloid will be more than about 50% but less than about 98%.
- a tablet will traverse the stomach and upper intestinal tract in about 3 to 6 hours. During this time, little active ingredient (less than 20%, preferably less than 10%) is released from the tablet of this invention. Once the tablet reaches the lower GI, the release of the active ingredient is triggered by enzymatic degradation of the galactomannan gum.
- compositions directed to biguanide compound delivery may further employ controlled, sustained, or extended release formulations known collectively as "modified release” formulations.
- Compositions can be administered by modified release systems or by delivery devices that are well known to those of ordinary skill in the art. Examples include, but are not limited to, those described in U.S. Pat. Nos. 3,845,770; 3,916,899; 3,536,809; 3,598,123; 4,008,719; 5,674,533; 5,059,595; 5,591,767; 5,120,548; 5,073,543; 5,639,476; 5,354,556; and 5,733,566.
- Such dosage forms can be used to provide modified release of one or more active ingredients using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a combination thereof to provide the desired release profile in varying proportions.
- Suitable modified release formulations known to those of ordinary skill in the art, including those described herein, can be readily selected for use with the active ingredients of the invention.
- the invention thus encompasses single unit dosage forms suitable for oral administration such as, but not limited to, tablets, capsules, gelcaps, and caplets that are further adapted for modified release.
- the modified release systems are formulated to release the compound at a duration of about 30 minutes, about 40 minutes, about 50 minutes, about 60 minutes, about 70 minutes, about 80 minutes, about 90 minutes, about 100 minutes, about 110 minutes, about 120 minutes, about 130 minutes, about 140 minutes, about 150 minutes, about 160 minutes, about 170 minutes, about 180 minutes, about 190 minutes, about 200 minutes, about 210 minutes, about 220 minutes, about 230 minutes, about 240 minutes, about 250 minutes, about 260 minutes, about 270 minutes, about 280 minutes, about 290 minutes, about 300 minutes, about 310 minutes, about 320 minutes, about 330 minutes, about 340 minutes, about 350 minutes, about 360 minutes, about 370 minutes, about 380 minutes, about 390 minutes, about 400, about 400, about 410, or about 420 minutes subsequent to onset of the release.
- modified release systems are formulated to release at more than one durations of time at different time points.
- chitosan and mixtures of chitosan with carboxymethylcellulose sodium have been used as vehicles for the sustained release of active ingredients, as described by Inouye et al, Drug Design and Delivery 1 : 297-305, 1987.
- Mixtures of these compounds and agents of the combinations of the invention when compressed under 200 kg/cm2, form a tablet from which the active agent is slowly released upon administration to a patient.
- the release profile can be changed by varying the ratios of chitosan, CMC-Na, and active agent(s).
- the tablets can also contain other additives, including lactose, CaHP04 dihydrate, sucrose, crystalline cellulose, or croscarmellose sodium.
- Baichwal in U.S. Pat. No. 6,245,356, describes sustained release oral, solid dosage forms that include agglomerated particles of a therapeutically active medicament in amorphous form, a gelling agent, an ionizable gel strength enhancing agent and an inert diluent.
- the gelling agent can be a mixture of a xanthan gum and a locust bean gum capable of cross-linking with the xanthan gum when the gums are exposed to an environmental fluid.
- the ionizable gel enhancing agent acts to enhance the strength of cross-linking between the xanthan gum and the locust bean gum and thereby prolonging the release of the medicament component of the formulation.
- acceptable gelling agents include those gelling agents well known in the art. Examples include naturally occurring or modified naturally occurring gums such as alginates, carrageenan, pectin, guar gum, modified starch, hydroxypropylmethylcellulose, methylcellulose, and other cellulosic materials or polymers, such as, for example, sodium carboxymethylcellulose and hydroxypropyl cellulose, and mixtures of the foregoing.
- Baichwal and Staniforth in U.S. Pat. No. 5,135,757 describe a free-flowing slow release granulation for use as a pharmaceutical excipient that includes from about 20 to about 70 percent or more by weight of a hydrophilic material that includes a heteropolysaccharide (such as, for example, xanthan gum or a derivative thereof) and a polysaccharide material capable of cross- linking the heteropolysaccharide (such as, for example, galactomannans, and most preferably locust bean gum) in the presence of aqueous solutions, and from about 30 to about 80 percent by weight of an inert pharmaceutical-filler (such as, for example, lactose, dextrose, sucrose, sorbitol, xylitol, fructose or mixtures thereof).
- an inert pharmaceutical-filler such as, for example, lactose, dextrose, sucrose, sorbitol, xylitol, fructose
- the mixture After mixing the excipient with a tricyclic compound/corticosteroid combination, or combination agent, of the invention, the mixture is directly compressed into solid dosage forms such as tablets.
- the tablets thus formed slowly release the medicament when ingested and exposed to gastric fluids.
- a slow release profile can be attained.
- Slow-release formulations can also include a coating which is not readily water- soluble but which is slowly attacked and removed by water, or through which water can slowly permeate.
- the combinations of the invention can be spray-coated with a solution of a binder under continuously fluidizing conditions, such as describe by Kitamori et al, U.S. Pat. No. 4,036,948.
- water-soluble binders include pregelatinized starch (e.g., pregelatinized corn starch, pregelatinized white potato starch), pregelatinized modified starch, water-soluble celluloses (e.g.
- hydroxypropyl-cellulose hydroxymethyl-cellulose, hydroxypropylmethyl-cellulose, carboxymethyl-cellulose
- polyvinylpyrrolidone polyvinyl alcohol
- dextrin gum arabicum and gelatin
- organic solvent-soluble binders such as cellulose derivatives (e.g., cellulose acetate phthalate, hydroxypropylmethyl-cellulose phthalate, ethylcellulose).
- Villa et al in U.S. Pat. No. 6,773,720, describes a modified-release system containing an inner lipophilic matrix where an active ingredient is inglobated and an outer hydrophilic matrix in which the lipophilic matrix is dispersed.
- An active ingredient such as a biguanide or related heterocyclic compound, is first inglobated in a low melting lipophlilic excipient or mixture of excipients while heating to soften and/or melt the excipient itself, which thereby incorporates the active ingredient by simple dispersion. After cooling at room temperature, an inert matrix forms, which can be reduced in size to obtain matrix granules containing the active ingredient particles.
- the inert matrix granules are subsequently mixed together with one or more hydrophilic water-swellable excipients.
- a high viscosity swollen layer is formed, which coordinates the solvent molecules and acts as a barrier to penetration of the aqueous fluid itself inside the new structure.
- Said barrier antagonizes the staring "burst effect" caused by dissolution of the active ingredient inglobated inside the inert matrix, which is in its turn inside the hydrophilic matrix.
- One commercially available system of this type is from Cosmo Technologies Limited (Italy) under the trade name MMX® technology.
- the lipophilic/hydrophilic matrices can be further enterically coated for pH specific delivery.
- Formulations for upper intestinal delivery, lower intestinal delivery or both are known in the art. Targeting of active ingredients to various regions of the gut is described, e.g., in The Encyclopedia of Pharmaceutical Technology, by James Swarbrick and James Boylan, Informa Health Care, 1999, at pp. 287-308. Any suitable formulation for gastrointestinal delivery for site- specific delivery and/or specific temporal delivery (i.e. delayed, controlled, extended, or sustained release) can be used with the invention and is contemplated herein. [00175] Any of the delivery systems described herein may be used in combination with others to achieve multiple releases and/or specific release profiles. In some embodiments, the biguanide compound is in a formulation that achieves multiple releases in gastrointestinal locations following administration.
- the biguanide compound is in a multiple release formulation that releases at an onset of about 10 minutes, about 30 minutes, about 120 minutes, about 180 minutes, about 240 minutes, or combinations thereof following administration. In certain embodiments, the biguanide compound is in a multiple release formulation that releases at an onset of about 5 to about 45 minutes, about 105 to about 135 minutes, about 165 to about 195 minutes, about 225 to about 255 minutes, or combinations thereof following administration.
- the biguanide compound is in a multiple release formulation that releases in the duodenum, jejunum, ileum, lower intestine or combinations thereof following administration.
- the biguanide compound is in a multiple release formulation that releases at an onset of about pH 5.5, about pH 6.0, at about pH 6.5, about pH 7.0, or combinations thereof following administration.
- the biguanide compound is in a multiple release formulation that releases in ranges at about pH 5.0 to about pH 6.0, about pH 6.0 to about pH 7.0, about pH 7.0 to about pH 8.0, or combinations thereof following administration.
- the biguanide compound is in a multiple release formulation that releases a fraction or portion of the biguanide as an immediate release with the rest of the compound released in a delayed manner as described herein.
- Oral dosage forms suitable for use in the subject compositions and methods include tablets, hard capsules, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol, as well as troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, syrups or elixirs.
- Suitable oral dosage forms can be prepared according to any method known to the art for the manufacture of pharmaceutical compositions, and such compositions can contain one or more agents selected from, by way of non-limiting example, sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations.
- Tablets contain the active ingredient in admixture with pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
- excipients can be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as microcrystalline cellulose, sodium crosscarmellose, corn starch, or alginic acid; binding agents, for example starch, gelatin, polyvinyl-pyrrolidone or acacia, and lubricating agents, for example, magnesium stearate, stearic acid or talc. Tablets can be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets can be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders (e.g., povidone, gelatin, hydroxypropylmethylcellulose), inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) or lubricating, surface active or dispersing agents.
- Molded tablets can be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets are coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby minimize systemic bioavailability as described more fully herein.
- Formulations for oral use can also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
- an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin
- water soluble carrier such as polyethyleneglycol or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
- push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- suitable liquids such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers can be added.
- Dragee cores are provided with suitable coatings.
- suitable coatings can be used, which can optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments can be added to the tablets or Dragee coatings for identification or to characterize different combinations of active compound doses.
- the compounds and compositions described herein can include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration can include flavoring agents.
- the compositions provided herein are in liquid form.
- Liquid forms include, by way of non-limiting example, neat liquids, solutions, suspensions, dispersions, colloids, foams and the like.
- liquid forms contain also a nutritional component or base (e.g., derived from milk, yogurt, shake, or juice).
- the compound are micronized or as nanoparticles in the liquid form.
- the compounds may be coated to mask the tastant properties. In other instances, the compounds are coated to modify delivery to the intestine and colon.
- Aqueous solutions or suspensions contain the active ingredient(s) in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethyHcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents can be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene-oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides,
- the aqueous solutions or suspensions can also contain one or more preservatives, for example ethyl, or n- propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
- the flavoring agents are the compounds.
- Oily suspensions can be formulated by suspending the active ingredient(s) in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such as liquid paraffin.
- the oily suspensions can contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol.
- Sweetening agents such as those set forth above, and flavoring agents can be added to provide a palatable oral preparation.
- These compositions can be preserved by the addition of an antioxidant such as butylated hydroxyanisol or alpha-tocopherol.
- Dispersible powders and granules suitable for preparation of an aqueous solutions or suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives.
- Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, can also be present.
- These compositions can be preserved by the addition of an antioxidant such as ascorbic acid.
- Compositions can also be in the form of an oil-in- water emulsion.
- the oily phase can be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
- Suitable emulsifying agents can be naturally-occurring phosphatides, for example soy bean lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate.
- the emulsions can also contain sweetening agents, flavoring agents, preservatives and antioxidants.
- Syrups and elixirs can be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations can also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant.
- sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
- Such formulations can also contain a demulcent, a preservative, flavoring and coloring agents and antioxidant.
- compositions can also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
- rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
- suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
- Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.
- compositions comprising the biguanide compound in a delayed-release formulation suitable for oral administration such as a tablet, capsule, cachet, pill, lozenge, powder or granule, solution, liquid, or suspension.
- the pharmaceutical composition is preferably in a unit dosage form suitable for single administration of precise dosages, e.g., 100 mg, 200 mg, 250, mg, 300 mg, 400 mg, 500 mg, 600 mg, 750 mg, 800 mg, or 1000 mg of the desired biguanide compound, particularly metformin, phenformin, buformin or imeglimin or a salt thereof.
- the pharmaceutical composition may comprise conventional pharmaceutical carriers or excipients and the biguanide compound according to the invention as an active ingredient. They may further comprise other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
- Suitable carriers include inert diluents or fillers, water and various organic solvents.
- the compositions can, if desired, contain additional ingredients such as flavorings, binders, excipients and the like.
- excipients such as citric acid
- disintegrants such as starch or other cellulosic material, alginic acid and certain complex silicates and with binding agents such as sucrose, gelatin and acacia.
- lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes.
- compositions of a similar type can also be employed in soft and hard filled gelatin capsules.
- Materials include lactose or milk sugar and high molecular weight polyethylene glycols.
- the active compound therein can be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof.
- compositions or formulations described herein include any commonly used excipients in pharmaceutics and are selected on the basis of compatibility with the active agent(s) and release profile properties of the desired dosage form.
- Excipients include, but are not limited to, binders, fillers, flow aids/glidents, disintegrants, lubricants, stabilizers, surfactants, and the like.
- a summary of excipients described herein, may be found, for example in Remington: The Science and Practice of Pharmacy, Nineteeth Ed (Easton, PA: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, (Easton, PA: Mack Publishing Co 1975); Liberman, H.A.
- Binders impart cohesive qualities and include, e.g., alginic acid and salts thereof; cellulose derivatives such as carboxymethylcellulose, methylcellulose (e.g., Methocel®), hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose (e.g., Klucel®), ethylcellulose (e.g., Ethocel®), and microcrystalline cellulose (e.g., Avicel®); microcrystalline dextrose; amylose; magnesium aluminum silicate; polysaccharide acids; bentonites; gelatin; polyvinylpyrrolidone/vinyl acetate copolymer; crospovidone; povidone; starch; pregelatinized starch; tragacanth, dextrin, a sugar, such as sucrose (e.g., Dipac®), glucose, dextrose, molasses, mannitol, sorbitol, xylitol (e.g.
- Disintegrants facilitate breakup or disintegration of oral solid dosage forms after administration.
- examples of disintegrants include a starch, e.g., a natural starch such as corn starch or potato starch, a pregelatinized starch such as National 1551 or Amijel®, or sodium starch glycolate such as Promogel® or Explotab®; a cellulose such as a wood product, methylcrystalline cellulose, e.g., AvicelO, Avicel® PH101, Avicel® PH102, Avicel® PH105, Elcema® PI 00, Emcocel®, Vivacel®, Ming Tia®, and Solka-Floc®, methylcellulose, croscarmellose, or a cross-linked cellulose, such as cross-linked sodium carboxymethylcellulose (Ac-Di-Solt), cross-linked carboxymethylcellulose, or cross-linked croscarmellose; a cross- linked starch such as sodium starch glycolate; a cross-linked polymer
- Lubricants are compounds which prevent, reduce or inhibit adhesion or friction of materials.
- Exemplary lubricants include, e.g., stearic acid; calcium hydroxide; talc; sodium stearyl fumerate; a hydrocarbon such as mineral oil, hydrogenated castor oil or hydrogenated vegetable oil such as hydrogenated soybean oil (Sterotex®); higher fatty acids and their alkali- metal and alkaline earth metal salts, such as aluminum, calcium, magnesium, zinc; stearic acid, sodium stearates, magnesium stearates, glycerol, talc, waxes, Stearowet® boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, a polyethylene glycol or a methoxypolyethylene glycol such as CarbowaxTM, ethylene oxide polymers, sodium oleate, glyceryl behenate (E.g.
- Compritol 888 Ato glyceryl disterate (Precirol Ato 5), polyethylene glycol, magnesium or sodium lauryl sulfate, colloidal silica such as SyloidTM, Carb-O-SilO, DL-leucine, a starch such as corn starch, silicone oil, a surfactant, and the like.
- Flow-aids or glidants improve the flow characteristics of powder mixtures.
- Such compounds include, e.g., colloidal silicon dioxide such as Cab-o-sil®; tribasic calcium phosphate, talc, corn starch, DL-leucine, sodium lauryl sulfate, magnesium stearate, calcium stearate, sodium stearate, kaolin, and micronized amorphous silicon dioxide (Syloid®)and the like.
- Plasticizers aid in coating of oral solid dosage forms.
- Exemplary plasticizers include, but are not limited to, triethyl citrate, triacetin (glyceryl triacetate), acetyl triethyl citrate, polyethylene glycols (PEG 4000, PEG 6000, PEG 8000), Carbowax 400 (polyethylene glycol 400), diethyl phthalate, diethyl sebacate, acetyltriethylcitrate, oleic acid, glyceralmonosterate, tributyl citrate, acetylated monoglycerides, glycerol, fatty acid esters, propylene glycol, and dibutyl phthalate and the like.
- excipients are given as examples only and are not meant to include all possible choices.
- suitable excipient classes include coloring agents, granulating agents, preservatives, anti-foaming agents, solubulizers and the like. Additionally, many excipients can have more than one role or function, or can be classified in more than one group; the classifications are descriptive only, and are not intended to limit any use of a particular excipient.
- Efficacy of treatment of diabetes/metabolic syndrome and diabetes-associated conditions with the compositions and methods described herein can be assessed using assays and methodologies known in the art.
- quantitative assessment of renal function and parameters of renal dysfunction are well known in the art.
- assays for the determination of renal function/dys function include serum creatinine level; creatinine clearance rate; cystatin C clearance rate, 24-hour urinary creatinine clearance, 24-hour urinary protein secretion; Glomerular filtration rate (GFR); urinary albumin creatinine ratio (ACR); albumin excretion rate (AER); and renal biopsy.
- pancreatic function and parameters of pancreatic dysfunction or insufficiency are also well known in the art.
- assays for the determination of pancreas function/dys function include evaluating pancreatic functions using biological and/or physiological parameters such as assessment of islets of Langerhans size, growth and/or secreting activity, beta-cells size, growth and/or secreting activity, insulin secretion and circulating blood levels, glucose blood levels, imaging of the pancreas, and pancreas biopsy, glucose uptake studies by oral glucose challenge, assessment of cytokine profiles, blood-gas analysis, extent of blood-perfusion of tissues, and angiogenesis within tissues.
- reducing weight it is meant that the patient loses a portion of his/her total body weight over the course of treatment (whether the course of treatment be days, weeks, months or years).
- reducing weight can be defined as a decrease in proportion of fat mass to lean mass (in other words, the patient has lost fat mass, but maintained or gained lean mass, without necessarily a corresponding loss in total body weight).
- An effective amount of a the biguanide compound treatment administered in this embodiment is an amount effective to reduce a patient's body weight over the course of the treatment, or alternatively an amount effective to reduce the patient's percentage of fat mass over the course of the treatment.
- the patient's body weight is reduced, over the course of treatment, by at least about 1%, by at least about 5%, by at least about 10%, by at least about 15%, or by at least about 20%.
- the patient's percentage of fat mass is reduced, over the course of treatment, by at least 1%, at least 5%, at least 10%, at least 15%, at least 20%, or at least 25%.
- Total body weight and fat content can be measured at the end of the dietary period.
- a frequently used method to determine total body fat is to surgically remove and weigh the retroperitoneal fat pad, a body of fat located in the retroperitoneum, the area between the posterior abdominal wall and the posterior parietal peritoneum.
- the pad weight is considered to be directly related to percent body fat of the animal. Since the relationship between body weight and body fat in rats is linear, obese animals have a correspondingly higher percent of body fat and retroperitoneal fat pad weight.
- food cravings can be measured by using a questionnaire, whether known in the art or created by the person studying the food cravings.
- a questionnaire would preferably rank the level of food cravings on a numerical scale, with the patient marking 0 if they have no food cravings, and marking (if on a scale of 1-10) 10 if the patient has severe food cravings.
- the questionnaire would preferably also include questions as to what types of food the patient is craving.
- Binge eating can be determined or measured using a questionnaire and a Binge Eating Scale (BES).
- Binge eating severity can be divided into three categories (mild, moderate, and severe) based on the total BES score (calculated by summing the scores for each individual item). Accordingly, methods are provided for reducing the BES score of a patient comprising administering to a patient in need thereof a compound treatment in an amount effective to reduce the BES score of the patient. In some embodiments, administration of a compound treatment changes the BES category of the patient, for example, from severe to moderate, from severe to mild, or from moderate to mild.
- patients are pre-evaluated for expression of metabolic hormones using methods described herein.
- the therapy provided to the individual can thus be targeted to his or her specific needs.
- a patient's hormonal profile is pre- evaluated and depending on the changes that the physician desires to affect, a certain determined amount of the compound/metabolite combination is administered. The evaluation process can be repeated and the treatment adjusted accordingly at any time during or following treatment.
- the levels of hormones assayed in association with the methods of the invention including, but not limited to, GLP-1, GLP-2, GIP, oxyntomodulin, PYY, CCK, glycentin, insulin, glucagon, ghrelin, amylin, uroguanylin, C-peptide and/or combinations thereof are detected according to standard methods described in the literature.
- proteins can be measured by immunological assays, and transcription products by nucleic acid amplification techniques.
- Functional assays described in the art can also be used as appropriate.
- samples assayed comprise cultured cells, patient cell or tissue samples, patient body fluids, e.g., blood or plasma, etc.
- the levels of analytes e.g., glucose, triglycerides, HDL, LDL, apoB and the like
- analytes assayed in association with the methods of the invention are detected according to any known method.
- immunofluorescence can be used to assay for GLP-1.
- Cells can be grown on matrigel-coated cover slips to confluent monolayers in 12-well plates at 37°C, fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) and incubated with primary antiserum (e.g., rabbit anti-alpha gustducin, 1 : 150; Santa Cruz Biotechnology, and rabbit anti-GLP-1, Phoenix) overnight at 4°C following permeabilization with 0.4% Triton-X in PBS for 10 minutes and blocking for 1 hour at room temperature.
- primary antiserum e.g., rabbit anti-alpha gustducin, 1 : 150; Santa Cruz Biotechnology, and rabbit anti-GLP-1, Phoenix
- the appropriate secondary antibody is applied (AlexaFluor 488 anti-rabbit immunoglobulin, 1 : 1000; Molecular Probes) for 1 hour at room temperature. After three washing steps, the cells can be fixed in Vectashield medium and the immunofluorescence visualized.
- GLP-1 R A isolated from cells can be assayed using RT-PCR.
- RT-PCR RNA isolation from cells can be performed using standard methodology.
- the RT-PCR reaction can be performed in a volume of 50 pi in a Peltier thermal cycler (PTC-225 DNA Engine Tetrad Cycler; MJ Research), using published primer sequences (Integrated DNA Technologies).
- Reverse transcription can be performed at 50°C for 30 minutes; after an initial activation step at 95°C for 15 minutes.
- PCR can be performed by denaturing at 94°C for 1 minute, annealing at 55°C for 1 minute and extension at 72°C for 1 minute for 40 cycles, followed by a final extension step at 72°C for 10 minutes.
- Negative controls can be included as appropriate, for example, by substituting water for the omitted reverse transcriptase or template.
- the control can be RNA isolated from, e.g., rat lingual epithelium. PCR products can be separated in 2% agarose gel with ethidium bromide, and visualized under UV light.
- Radioimmunoassay (RIA) for total GLP-1 in patient blood samples can be performed as described in the art, e.g., by Laferrere, et al., 2007, "Incretin Levels and Effect are Markedly Enhanced 1 Month after Roux-en-Y Gastric Bypass Surgery in Obese Patients with Type 2 Diabetes, Diabetes Care 30(7): 1709-1716 (using commercially available materials obtained from Phoenix Pharmaceutical, Belmont, CA). The authors describe measuring the effect of GIP and GLP-1 on secretion of insulin by measuring the difference in insulin secretion (area under the curve, or AUC) in response to an oral glucose tolerance test and to an isoglycemic intravenous glucose test.
- AUC insulin secretion
- This assay measures the sum of GLP-l-(7-36) and its metabolite GLP-l-(9-36).
- the authors describe measurement of GIP using C-terminally directed antibody code no. R65 (RIA), that reacts 100% with a human GIP but not with 8-kDA GIP.
- GLP-1 and PYY can be directly assayed in the supernatant from venous effluents as described by, e.g., Claustre, et al. (1999, "Stimulatory effect of(3 -adrenergic agonists on ileal L cell secretion and modulation by a-adrenergic activation, J. Endocrin. 162:271-8).
- This antibody reacts 100% with GLP-1 -(7-36) amide, 84% with GLP-1 - (1-36) amide, and less than 0.1% with GLP-l-(l-37), GLP-l-(7-37), GLP-2, and glucagon.
- PYY is assayed with the A4D anti-porcine PYY antiserum at a 1 :800 000 dilution.
- PYY can also be assayed in blood using a radioimmunoassay as described by, e.g., Weickert, et al, 2006, "Soy isoflavones increase preprandial peptide YY (PYY), but have no effect on ghrelin and body weight in healthy postmenopausal women" Journal of Negative Results in BioMedicine, 5: 11. Blood is collected in ice-chilled EDTA tubes for the analysis of glucose, ghrelin, and PYY. Following centrifugation at 1600 g for 10 minutes at 4°C, aliquots were immediately frozen at -20°C until assayed. All samples from individual patients were measured in the same assay.
- Immunoreactive total human PYY is measured by a commercially available radioimmunoassay (LINCO Research, Missouri, USA), using 1251-labeled bioactive PYY as tracer and a PYY antiserum to determine the level of active PYY by the double antibody/PEG technique.
- the PYY antibody is raised in guinea pigs and recognizes both the PYY 1-36 and PYY 3-36 (active) forms of human PYY.
- SGLT-1 the intestinal sodium-dependent glucose transporter 1
- T1R3 the intestinal sodium-dependent glucose transporter 1
- Expression of SGLT-1 can be detected as described, e.g., by Margolskee, et al., for example, using quantitative PCR and Western Blotting methods known in the art.
- Measurement of glucose transport has been described in the literature, e.g., by Dyer, et al, 1997, Gut 41 :56-9 and Dyer, et al, 2003, Eur. J. Biochem 270:3377-88.
- Measurement of glucose transport in brush border membrane vesicles can be made, e.g., by initiating D-glucose uptake by the addition of 100 pi of incubation medium containing 100 mM NaSCN (or KSCN), 100 mM mannitol, 20 mM Hepes/Tris (pH 7.4), 0.1 mM MgS04, 0.02% (wt/vol) NaN3, and 0.1 mM D-[U14C]glucose to BBMV (100 ⁇ g of protein).
- the reaction is stopped after 3 sec by addition of 1 ml of ice-cold stop buffer, containing 150 mM KSCN, 20 mM Hepes/Tris (pH 7.4), 0.1 mM MgS04, 0.02% (wt/vol) NaN3, and 0.1 mM phlorizin.
- a 0.9-ml portion of the reaction mixture is removed and filtered under vacuum through a 0.22-[tm pore cellulose acetate/nitrate filter (GSTF02500; Millipore, Bedford, MA). The filter is washed five times with 1 ml of stop buffer, and the radioactivity retained on the filter is measured by liquid scintillation counting.
- EXAMPLE 1 ENTEROENDOCRINE PRODUCTION OF PYY, GLP-1 (Active) AND GLP-1 (Total) AND REDUCTION OF GLUCOSE AND INSULIN IS INDEPENDENT OF PLASMA ABSORPTION OF METFORMIN
- gastrointestinal disease (iii) gastrointestinal disease; (iv) Endocrine disorder, including diabetes; (v) Cardiovascular disease; (vi) Seizure disorder; (vii) Organ transplantation; and (viii) Chronic infection; and (e) an ability to understand and willingness to adhere to protocol requirements.
- the metformin DR formulation was a US-supplied commercially available film- coated immediate-release tablet containing 500 mg metformin hydrochloride, to which additional coatings (a seal coating and an enteric coating) were applied in order to delay release of the drug in the GI tract until the tablet reached a pH 6.5 region of the distal small intestine.
- the tablets were white, biconvex, circular-shaped coated tablets, each containing 500 mg metformin hydrochloride.
- Inactive ingredients in the commercially available tablet included povidone, magnesium stearate, hypromellose, and polyethylene glycol.
- Inactive ingredients in the additional coating systems included hypromellose, triacetin, talc, methacrylic acid copolymer (Eudragit® L30 D-55), poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3: 1 (Eudragit® FS 30 D), sodium lauryl sulfate, polysorbate 80, glyceryl monostearate, and triethyl citrate.
- metformin IR formulation was the identical US-supplied commercially available film-coated immediate-release tablet containing 500 mg metformin hydrochloride, to which only the additional seal coating is applied. No delayed-release (enteric) coating was applied. Inactive ingredients in the additional seal coating system included hypromellose, triacetin and talc.
- metformin formulations were supplied to the site as bulk tablets packaged in screw cap containers labeled with container number and lot number. All study medications were stored in cool and dry conditions as indicated on the label, and used only as directed by study personnel. Study medication was dispensed by the unblinded site pharmacist or study personnel according to the randomization scheme at the beginning of each treatment period.
- Study medication was dispensed by an unblinded site pharmacist or study personnel according a randomization scheme at Visits 2 and 4. At the end of Visits 2 and 4, subjects were discharged from the clinic with assigned study medications and with instructions for self- administration until they returned for their next study visit (Visit 3 or 5).
- Study medication was administered orally as intact tablets (swallowed whole, not chewed or crushed), and with water.
- the first dose and the last two doses of study medication for each treatment period were administered to subjects by qualified study site personnel (first dose at Visits 2 and 4 and last two doses at Visits 3 and 5).
- Subjects self-administered the assigned study medications according to instructions until they returned for their next study visit (Visit 3 or 5).
- Study site personnel contacted subjects by telephone on the second day of dosing of each treatment period to assess compliance and adverse events through non-directed questioning. If the subject was experiencing significant gastrointestinal symptoms, at the investigator's discretion, subjects were instructed not to dose escalate.
- Table 2 Schedule of Standardized Breakfast and Blood Sampling Profile at Visit 2 and Visit 4
- Table 3 Day 5 Schedule of Dosing, Standardized Breakfast and Blood Sampling Profile at Visit 3 and
- glucose, insulin, and triglycerides glucose, insulin, and triglycerides.
- Plasma metformin concentrations were measured by analytical methods. Blood samples from each visit were processed and stored at -70°C for future exploratory analysis of additional hormones.
- Hematology assessments included the following: red cell count, hemoglobin, hematocrit, white cell count, platelets, differential count, mean cell volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin concentration (or other approved routine hematology assessments).
- Urinalysis assessments included the following: H, specific gravity, glucose, blood, ketones, and protein (or other approved routine urinalysis).
- Vital sign measurements included sitting systolic and diastolic blood pressure, heart rate, and body temperature. Vital signs were measured after the subject rested for approximately 5 minutes and with the subject in a sitting position. The blood pressure measurement was repeated after at least 30 seconds and the average of the two readings recorded.
- FIG. 3 demonstrates that ingestion of Metformin DR minimized adsorption of metformin in the plasma compared to Metformin IR.
- the area under the curve (AUC) and Cmax values for Metformin DR and Metformin IR are provided in Table 6 below.
- FIG. 4A-C shows an increase in meal-enhanced gut hormones in 16 subjects after treatment of Metformin DR comparable to that of Metformin IR, although treatment with Metformin DR minimized the systemic level of metformin compared to Metformin IR (FIG. 3).
- FIGs. 5A-B show a reduction in meal-enhanced glucose and insulin after treatment with Metformin DR in 16 subjects comparable to that of Metformin IR.
- FIG. 6 shows that treatment with Metformin DR results in a similar PYY response as Metformin IR, but has a lower systemic exposure.
- FIGs. 7A-B show that the metformin PK/PD relationship was dissociable in at least one patient.
- EXAMPLE 2 A RANDOMIZED, CROSSOVER STUDY TO ASSESS STEADY- STA TE PK AND PD OF DEL A YED-RELEASE AND IMMEDIA TE RELEASE METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS
- This randomized, crossover study assessed the steady-state pharmacokinetics and pharmacodynamics (glucose, insulin, glucagon- like peptide- 1 [GLP-1], and peptide YY [PYY], of 500 mg and 1000 mg metformin delayed-release (Metformin DR), 1000 mg metformin immediate-release (Metformin IR), and 500 mg Metformin IR + 1000 mg Metformin DR in subjects with type 2 diabetes mellitus. Subjects managing their diabetes with oral anti-diabetic therapy must have been off of those medications for at least the fourteen days immediately prior to randomization.
- Each treatment period was five days long and separated by washout intervals of seven days. Each treatment period contained a standardized breakfast and lunch profile on Day 1 prior to administration of study drug (baseline assessment) and an identical profile on the morning of Day 5 (on-drug assessment).
- the metformin DR formulation was a US-supplied commercially available film- coated immediate-release tablet containing 500 mg metformin hydrochloride, to which additional coatings (a seal coating and an enteric coating) were applied in order to delay release of the drug in the GI tract until the tablet reaches a pH 6.5 region of the the distal small intestine.
- the tablets are white, biconvex, circular-shaped coated tablets, each containing 500 mg metformin hydrochloride.
- Inactive ingredients in the commercially available tablet included povidone, magnesium stearate, hypromellose, and polyethylene glycol.
- Inactive ingredients in the additional Elcelyx coating systems included hypromellose, triacetin, talc, methacrylic acid copolymer (Eudragit® L30 D-55), poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3: 1 (Eudragit® FS 30 D), sodium lauryl sulfate, polysorbate 80, glyceryl monostearate, and triethyl citrate.
- metformin IR formulation was the identical US-supplied commercially available film-coated immediate-release tablet containing 500 mg metformin hydrochloride, to which only the additional seal coating is applied. No delayed-release (enteric) coating was applied. Inactive ingredients in the additional seal coating system included hypromellose, triacetin and talc.
- metformin formulations were supplied to the site as bulk tablets packaged in screw cap containers labeled with container number and lot number. All study medications were stored in cool and dry conditions as indicated on the label, and used only as directed by study personnel. Study medication was dispensed by the unblinded site pharmacist or study personnel according to the randomization scheme at the beginning of each treatment period.
- Study medication was administered orally as intact tablets (swallowed whole) with water at the beginning of the breakfast and dinner meals. Subjects self-administered their assigned study medications on the evening of Day 1 through the morning of Day 4 according to instructions provided on Day 1 by the study site staff. The last two doses of study medication for each treatment period (evening of Day 4 and morning of Day 5) were administered to subjects by qualified study site personnel. In order to reduce gastrointestinal side effects, all treatment regimens initiated treatment at 500 mg/dose for the first 3 doses, followed by an increase to the randomized dose (500 mg/dose, 1000 mg, or 1500 mg/dose) for the remainder of the study period. Study site personnel contacted subjects by telephone on the second day of dosing of each treatment period to assess compliance and adverse events through non-directed questioning and to remind them to dose-escalate if appropriate.
- Figure 8 presents the mean plasma metformin concentrations at Day 5 by treatment and time point.
- the pre-dose concentrations for both doses of Metformin DR were approximately 2 times higher than those for Metformin IR (716 ng/mL for 1000 mg DR and 602 ng/mL for 500 ng/mL DR vs. 350 ng/dL for 1000 mg IR).
- Metformin IR 716 ng/mL for 1000 mg DR and 602 ng/mL for 500 ng/mL DR vs. 350 ng/dL for 1000 mg IR.
- Metformin DR dosing with the evening meal were slowed relative to doses administered with the breakfast meal, consistent with slowed intestinal transit during the sleeping hours.
- Metformin DR concentrations for the 500-mg dose were lower than the 1000-mg dose at all time points although the reductions were less than dose-proportional. This observation is consistent with the lack of dose-proportionality reported for Metformin IR and could be due to a saturable absorption process in the gut.
- Table 7 and Figure 9 present the relative bioavailability of metformin by treatment versus Metformin IR at Day 5.
- Metformin IR 0 to time of last concentration after study medication administration
- C max was also was statistically significantly reduced by 34.9%> with 1000 mg Metformin DR (% mean ratio of 65.1; p ⁇ 0.0001) and 47.7% with 500 mg metformin DR (% mean ratio of 52.3; p ⁇ 0.0001).
- NA not applicable
- t last quantifiable concentration following dose administration.
- Intra subject CV% was 24.2 for AUC 0 - t and 26.3 for C ⁇ .
- Figure 10 and Table 8 present the mean plasma PYY total concentration profiles at baseline and Day 5 by treatment and time point and the corresponding analysis of
- Baseline plasma PYY total concentrations were similar between treatments at most time points. Additionally, all metformin treatments statistically significantly increased PYY total exposure and peak concentrations (p ⁇ 0.01 for all), with percent ratios (Day5/Dayl) for AUCo-t and Cmax ranging from 1.26 to 1.55. Fasting plasma PYY total concentrations were also statistically significantly increased from baseline at Day 5 for each treatment (Table 9, p ⁇ 0.01 for all). These results indicate that all of the treatments studied elicited similar PYY total responses to two standardized meals.
- Figure 11 and Table 10 present the mean plasma GLP-1 active concentration profiles at baseline and Day 5 by treatment and time point and the corresponding analysis of
- Baseline plasma GLP-1 active concentrations were similar between treatments at most time points. Additionally, all metformin treatments statistically significantly increased GLP-1 active exposure and peak concentrations (p ⁇ 0.01 for all), with percent ratios (Day5/Dayl) for AUCO-t and Cmax ranging from 1.42 to 1.88. Fasting plasma GLP-1 total concentrations were also statistically significantly increased from baseline at Day 5 for each treatment (Table 11, p ⁇ 0.05 for all). These results indicate that all of the treatments studied elicited similar GLP-1 active responses to two standardized meals.
- Figure 12 and Table 12 present mean plasma glucose concentration profiles at baseline and Day 5 by treatment and timepoint and the corresponding pharmacodynamic parameters by meal, respectively.
- Baseline plasma glucose concentrations were similar between treatments at most time points. Additionally, all metformin treatments statistically significantly decreased glucose exposure and peak concentrations for both meal intervals to a similar extent (p ⁇ 0.001 for all).
- LS mean (SE) 66642 (5480) 66257 (5815) 65755 (5906) 66507 (5617) EOT geo.
- LS mean (SE) 76286 (6051) 75132 (6199) 74566 (6634) 74799 (5972) EOT geo.
- LS mean (SE) 65558 (5200) 66330 (5473) 68480 (6093) 63495 (5070) % ratio [1]
- Table 14 presents the LS mean (SE) and Figure 13 presents the individual change in fasting plasma glucose concentrations from baseline to Day 5 by treatment. Baseline fasting glucose concentrations were similar and ranged from 196 mg/dL to 200 mg/dL among the treatment groups. All treatment groups achieved statistically significant reductions (p ⁇ 0.01 for all) in fasting plasma glucose after 5 days of treatment. As shown in Figure 13, the LSM and distribution of individual responses were similar between treatment groups.
- Tables 15 and 16 present the pharmacodynamic parameters for insulin and baseline and Day 5 fasting plasma insulin concentrations, respectively. There were no statistically significant changes in insulin exposure, peak concentrations, or fasting concentrations for any of the treatments (p>0.05 for all). Maintenance of insulin concentrations despite the lower circulating glucose concentrations is indicative of an incretin effect.
- Table 17 summarizes treatment-emergent adverse events by SOC, preferred term, and most recent treatment at onset.
- Gastrointestinal 0 (0) 1 (5.0) 0(0) 0(0)
- Nervous System 5 (22.7) 1 (5.0) 1 (5.0) 0(0) Disorders
- Metformin DR or a combination of 500 mg Metformin IR and 1000 mg Metformin DR. All subjects had type 2 diabetes and received each treatment in a randomized crossover design with a one week washout between treatments.
- EXAMPLE 3 ANALYSIS OF PHARMACOKINETIC DIFFERENCES BETWEEN MORNING AND EVENING DOSING
- Example 3 To better characterize the pharmacokinetic differences between morning and evening doses, the study of Example 3 was designed to obtain 36-hour PK profiles of Metformin DR at doses of 500 and 1000 mg given at the evening and breakfast meals in healthy subjects. Subjects also received 1000 mg Metformin IR with the evening and breakfast meals and 2000 mg metformin extended-release (Metformin XR) with the evening meal during separate treatment periods. All subjects received each treatment in a randomized crossover design with a one week washout between treatments.
- Metformin XR metformin extended-release
- the metformin DR formulation was a US-supplied commercially available film- coated immediate-release tablet containing 500 mg metformin hydrochloride, to which additional coatings (a seal coating and an enteric coating) were applied in order to delay release of the drug in the GI tract until the tablet reaches a pH 6.5 region of the distal small intestine.
- the tablets are white, biconvex, circular-shaped coated tablets, each containing 500 mg metformin
- Inactive ingredients in the commercially available tablet included povidone, magnesium stearate, hypromellose, and polyethylene glycol.
- Inactive ingredients in the additional coating systems included hypromellose, triacetin, talc, methacrylic acid copolymer (Eudragit® L30 D-55), poly(methyl acrylate-co-methyl methacrylate-co-methacrylic acid) 7:3: 1 (Eudragit® FS 30 D), sodium lauryl sulfate, polysorbate 80, glyceryl monostearate, and triethyl citrate.
- the metformin IR and metformin XR formulations were commercially available formulations (Aurobindo Pharma Limited and Bristol-Myers Squibb respectively) without any modification.
- Table 18 shows the Mean (CV%) plasma pharmacokinetic parameters of metformin following oral administration of each treatment and Figure 15 compares the mean (SEM) values of C max (left panel) and AUCo-36 hi (right panel). Both doses of Metformin DR resulted in substantial reductions in exposure as well as a delay in absorption of 6-7 hours.
- Treatment A 1000 mg Metformin IR BID (2 x 500 mg metformin HC1 tablets [immediate-release])
- Treatment B 500 mg Metformin DR BID (1 x 500 mg metformin HC1 tablet [delayed-release pH 6.5 enteric-coated])
- Treatment C 1000 mg Metformin DR BID (2 x 500 mg metformin HC1 tablets [delayed-release pH 6.5 enteric-coated])
- Treatment B 500 mg Metformin DR BID (1 x 500 mg metformin HC1 tablet [delayed-release pH 6.5 enteric-coated])
- Treatment C 1000 mg Metformin DR BID (2 x 500 mg metformin HC1 tablets [delayed-release pH 6.5 enteric-coated])
- Treatment D 2000 mg Metformin XR QD (4 x 500 mg metformin HC1 tablets [extended-release])
- the pharmacokinetic results of Examples 2 and 3 indicate that delivery of metformin to the lower bowel by administering Metformin DR reduces 24 hour bioavailability by approximately 50% relative to Metformin IR and Metformin XR at the same daily dose. Greater reductions in exposure were observed when the Metformin DR dose was reduced from a total daily dose of 2000 mg to 1000 mg, without a reduction in efficacy.
- the time of Metformin DR dosing (with the morning or evening meals) meaningfully affected the timing of metformin release in the intestine (3 vs.
- Example 2 study while the systemic exposure to metformin was substantially reduced with Metformin DR (45% with 2000 mg/day and -60% with 1000 mg/day, relative to 2000 mg/day of Metformin IR), the full glucose lowering effects of Metformin IR (2000 mg/day) were maintained. Given that the full glucose lowering effect was observed at both 2000 mg and 1000 mg daily of Metformin DR, lower doses are viable, allowing for more elegant dosage forms than are currently available with existing products (Metformin IR and Metformin XR (i.e., smaller tablets, fully effective fixed dose combinations, once daily dosing). Moreover, unlike Metformin IR, Metformin DR was not associated with any nausea and vomiting at either dose.
- EXAMPLE 4 A 12-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS THE
- This study will compare the effect of delayed-release metformin (Met DR) to placebo on glycemic control as assessed by fasting plasma glucose when administered for 4 weeks in subjects with type 2 diabetes mellitus (T2DM), and will further assess the safety and tolerability of a range of doses of Met DR administered for 4 weeks in subjects with T2DM.
- T2DM type 2 diabetes mellitus
- the study will also compare the effect of Met DR to placebo on glycemic control as assessed by HbAlc and fasting plasma glucose when administered for 12 weeks in subjects with T2DM. Assess the safety and tolerability of a range of doses of Met DR when administered for 12 weeks in subjects with T2DM. It will also assess the dose-dependent effect of Met DR on HbAlc and fasting plasma glucose when administered for 4 and 12 weeks in subjects with T2DM, and compare the effects of Met DR, extended-release metformin (Met XR), and placebo administered for 4 and 12 weeks in subjects with T2DM on the following:
- Protocol LCRM105 is a Phase 2, randomized, double-blind, multicenter, placebo- controlled, six-arm study. There are 8 study visits; one screening visit (Visit 1) followed by 7 randomized treatment period visits (Visits 2 through 8). Subjects on metformin and/or dipeptidyl peptidase-4 (DPP-4) inhibitors are to discontinue use of these medications for at least 14 days and no more than 17 days prior to randomization at Visit 2.
- DPP-4 dipeptidyl peptidase-4
- each of approximately 240 subjects will be randomized to one of 6 treatment groups in the proportion of 1 : 1 : 1 : 1 : 1 : 1.
- Treatments A, B, C and D will be administered once daily (QD) in the morning (AM) and will be blinded. Treatments E and F will be administered QD in the evening (PM) and will not be blinded. Randomization is to be stratified by Visit 1 (Screening) HbAlc ( ⁇ 8% vs. >8%).
- Met XR 2000 mg QD PM arm will initiate at Met XR 1000 mg QD for 1 week, then titrate to 1500mg QD for 1 week, before increasing to 2000 mg QD for the remainder of the study
- HbAlc is to be measured at Visits 2, 6, 7 and 8. Fasting blood samples will be collected for measurement of plasma glucose, metformin pharmacokinetics (PK), insulin, PYY, and GLP-1 at Visits 2 through 8. Adverse events are to be assessed at Visits 2 through 8. Review of study medication dosing compliance is to be performed at Visits 3 through 8
- a subject's underlying diabetes is inadequately controlled during the study and if the subject is experiencing hyperglycemia that is a significant worsening from the baseline condition, resulting in a loss of glucose control, the subject is to be withdrawn from the study based on the investigator's clinical judgment, guided by appropriate criteria.
- the investigator may contact the medical monitor to discuss appropriate clinical management as well as the continued participation of subjects experiencing hyperglycemia.
- Total study duration may be between 83 to 107 days depending on the number of intervening days between study visits
- Met DR (EFB0081): 300 mg metformin HCl delayed-release tablets (with a pH 6.5 enteric coating)
- Met XR 500 mg metformin HCl extended-release tablets (Glucophage® XR) [0195] STUDY METHODS
- Randomized treatment is to be administered QD before the morning meal
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380046376.XA CN104780915A (en) | 2012-07-11 | 2013-07-11 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
AU2013290100A AU2013290100A1 (en) | 2012-07-11 | 2013-07-11 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
CA2878625A CA2878625A1 (en) | 2012-07-11 | 2013-07-11 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US14/414,091 US9572784B2 (en) | 2011-01-07 | 2013-07-11 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
JP2015521822A JP2015522080A (en) | 2012-07-11 | 2013-07-11 | Compositions for reducing cardiovascular metabolic risk comprising statins, biguanides, and additional agents |
EP13739919.2A EP2872127A1 (en) | 2012-07-11 | 2013-07-11 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
IL236647A IL236647A0 (en) | 2012-07-11 | 2015-01-11 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
HK15111491.4A HK1210825A1 (en) | 2012-07-11 | 2015-11-20 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US15/433,987 US10159658B2 (en) | 2011-01-07 | 2017-02-15 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/547,022 | 2012-07-11 | ||
US13/547,022 US8796338B2 (en) | 2011-01-07 | 2012-07-11 | Biguanide compositions and methods of treating metabolic disorders |
US13/734,966 US9211263B2 (en) | 2012-01-06 | 2013-01-05 | Compositions and methods of treating metabolic disorders |
US13/734,966 | 2013-01-05 |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/547,022 Continuation-In-Part US8796338B2 (en) | 2011-01-07 | 2012-07-11 | Biguanide compositions and methods of treating metabolic disorders |
US13/734,966 Continuation-In-Part US9211263B2 (en) | 2011-01-07 | 2013-01-05 | Compositions and methods of treating metabolic disorders |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/414,091 A-371-Of-International US9572784B2 (en) | 2011-01-07 | 2013-07-11 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US15/433,987 Continuation US10159658B2 (en) | 2011-01-07 | 2017-02-15 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014011926A1 true WO2014011926A1 (en) | 2014-01-16 |
Family
ID=48833086
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/050142 WO2014011926A1 (en) | 2011-01-07 | 2013-07-11 | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP2872127A1 (en) |
JP (2) | JP2015522080A (en) |
CN (1) | CN104780915A (en) |
AR (1) | AR091739A1 (en) |
AU (1) | AU2013290100A1 (en) |
CA (1) | CA2878625A1 (en) |
HK (1) | HK1210825A1 (en) |
IL (1) | IL236647A0 (en) |
WO (1) | WO2014011926A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9949998B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9949997B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20180185291A1 (en) | 2011-03-07 | 2018-07-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US10406172B2 (en) | 2009-02-13 | 2019-09-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
CN111818911A (en) * | 2017-12-26 | 2020-10-23 | 广东东阳光药业有限公司 | Lurasidone solid dispersion and preparation method thereof |
US11666590B2 (en) | 2013-04-18 | 2023-06-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
Citations (268)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4036948A (en) | 1975-07-24 | 1977-07-19 | Takeda Chemical Industries, Ltd. | L-ascorbic acid tablets |
US5059595A (en) | 1989-03-22 | 1991-10-22 | Bioresearch, S.P.A. | Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutically acceptable salts in controlled-release form active in the therapy of organic mental disturbances |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5135757A (en) | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
US5354556A (en) | 1984-10-30 | 1994-10-11 | Elan Corporation, Plc | Controlled release powder and process for its preparation |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5603957A (en) | 1993-04-19 | 1997-02-18 | Flamel Technologies | Microcapsules for the controlled release of acetylsalicyclic acid in the gastrointestinal environment |
US5639476A (en) | 1992-01-27 | 1997-06-17 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5674533A (en) | 1994-07-07 | 1997-10-07 | Recordati, S.A., Chemical And Pharmaceutical Company | Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5891919A (en) | 1997-09-19 | 1999-04-06 | Burlington Bio-Medical & Scientific Corp. | Denatonium capsaicinate and methods of producing the same |
US6022562A (en) | 1994-10-18 | 2000-02-08 | Flamel Technologies | Medicinal and/or nutritional microcapsules for oral administration |
WO2000028083A1 (en) | 1998-11-06 | 2000-05-18 | Smithkline Beecham Corporation | Mouse 7-transmembrane receptor gpr43 |
US6245356B1 (en) | 1993-09-09 | 2001-06-12 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems-amorphous drugs |
WO2001061359A2 (en) | 2000-02-18 | 2001-08-23 | Glaxo Group Limited | Identification of modulators of gpr41 or gpr42 activity |
US6376657B1 (en) | 1997-04-15 | 2002-04-23 | Csir | Pharmaceutical compositions having appetite suppressant activity |
WO2003057730A1 (en) | 2002-01-07 | 2003-07-17 | Euroscreen S.A. | Ligand for g-protein coupled receptor gpr43 and uses thereof |
WO2003075933A1 (en) * | 2002-03-07 | 2003-09-18 | Upsher-Smith Laboratories, Inc. | Composition for reducing blood glucose and cholesterol |
WO2004032928A1 (en) | 2002-10-10 | 2004-04-22 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia |
WO2004033431A2 (en) | 2002-10-04 | 2004-04-22 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
WO2004038405A2 (en) | 2002-10-25 | 2004-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43) |
WO2004038421A2 (en) | 2002-10-25 | 2004-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41) |
WO2004041266A1 (en) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
US20040138189A1 (en) | 2001-03-28 | 2004-07-15 | Sebti Said M. | Materials and methods for treatment of cancer and identification of anti-cancer compounds |
US6773720B1 (en) | 1999-06-14 | 2004-08-10 | Cosmo S.P.A. | Mesalazine controlled release oral pharmaceutical compositions |
WO2004072650A1 (en) | 2003-02-17 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 40 (gpr40) |
WO2004106276A1 (en) | 2003-05-30 | 2004-12-09 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
WO2005011677A1 (en) | 2003-06-13 | 2005-02-10 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases |
WO2005023766A1 (en) * | 2003-09-11 | 2005-03-17 | Biocon Limited | Salt of atorvastatin with metformin |
WO2005028488A1 (en) | 2003-09-12 | 2005-03-31 | Quatrx Pharmaceuticals Co. | Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels |
WO2005044816A1 (en) | 2003-10-31 | 2005-05-19 | Arena Pharmaceuticals, Inc. | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
WO2005051937A2 (en) | 2003-11-21 | 2005-06-09 | Arena Pharmaceuticals, Inc. | 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof |
WO2005063729A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
WO2005063725A1 (en) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
WO2005087710A1 (en) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
WO2005095338A1 (en) | 2004-03-30 | 2005-10-13 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
US20060019346A1 (en) | 2002-07-29 | 2006-01-26 | Senomyx, Inc. | Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands |
US20060024335A1 (en) | 2004-07-29 | 2006-02-02 | Roger Stier E | Oral compositions which mask the bitter taste of a bitter-tasting agent |
WO2006011615A1 (en) | 2004-07-27 | 2006-02-02 | Takeda Pharmaceutical Company Limited | Remedy for diabetes |
WO2006036688A2 (en) | 2004-09-22 | 2006-04-06 | Arena Pharmaceuticals, Inc. | Gpr43 and modulators thereof for the treatment of metabolic-related disorders |
WO2006038738A1 (en) | 2004-10-08 | 2006-04-13 | Takeda Pharmaceutical Company Limited | Receptor function regulating agent |
WO2006052566A2 (en) | 2004-11-03 | 2006-05-18 | Arena Pharmaceuticals, Inc. | Gpr41 and modulators thereof for the treatment of insulin-related disorders |
WO2006069242A2 (en) | 2004-12-23 | 2006-06-29 | Arena Pharmaceuticals, Inc. | Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related?disorders |
WO2006076231A2 (en) | 2005-01-10 | 2006-07-20 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level |
US20060172020A1 (en) | 2003-07-17 | 2006-08-03 | Djang Arthur H | Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabeties |
WO2006083612A1 (en) | 2005-01-28 | 2006-08-10 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
WO2006083781A1 (en) | 2005-01-31 | 2006-08-10 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
WO2006102653A2 (en) | 2005-03-24 | 2006-09-28 | Irm Llc | Methods and compositions for treating insulin resistance and obesity-induced diseases |
US20060222709A1 (en) * | 2005-03-18 | 2006-10-05 | Agi Therapeutics Research Ltd. | Metformin methods and formulations for treating chronic constipation |
US20060269617A1 (en) | 2005-05-26 | 2006-11-30 | Suracell, Inc. | Supplement compositions and method of use for enhancement of insulin sensitivity |
WO2006127595A1 (en) | 2005-05-23 | 2006-11-30 | Arena Pharmaceuticals, Inc. | 5-aminopyrazole carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof |
US20060275765A1 (en) | 2002-12-18 | 2006-12-07 | Givaudan Sa | G-proteins |
WO2007013689A1 (en) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
WO2007014824A1 (en) | 2005-07-28 | 2007-02-08 | Nestec S.A. | Fat taste receptors and their methods of use |
US20070037212A1 (en) | 2005-06-22 | 2007-02-15 | Senomyx, Inc. | Human T2R receptors recognizing a class of bitter molecules from coffee |
WO2007021744A1 (en) | 2005-08-10 | 2007-02-22 | Arena Pharmaceuticals, Inc. | Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist |
WO2007026874A1 (en) | 2005-09-02 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Method for screening of substance effective on disease using gpr120 and phospholipase |
WO2007049050A2 (en) | 2005-10-27 | 2007-05-03 | Heptahelix Ab | Modulators of gpr40 for the treatment of diabetes |
US20070104805A1 (en) | 2005-11-01 | 2007-05-10 | Udell Ronald G | Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives |
US7247427B1 (en) | 1999-10-11 | 2007-07-24 | Yeda Research And Development Co., Ltd. | Leptin assay |
WO2007116229A1 (en) | 2006-04-06 | 2007-10-18 | Prosidion Limited | Heterocyclic gpcr agonists |
WO2007116230A1 (en) | 2006-04-11 | 2007-10-18 | Prosidion Ltd | Azetidine derivatives as g-protein coupled receptor (gpr119 ) agonists |
WO2007116404A2 (en) | 2006-04-10 | 2007-10-18 | Bar-Ilan University | Cucurbitacin glucosides and use thereof in treating cancer |
WO2007120702A2 (en) | 2006-04-11 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto |
WO2007120689A2 (en) | 2006-04-11 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual |
WO2007123225A1 (en) | 2006-04-24 | 2007-11-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
WO2007134613A1 (en) | 2006-05-24 | 2007-11-29 | Rheoscience A/S | Modulation of gpr120 activity in adipocytes/fat tissue |
WO2007136572A2 (en) | 2006-05-15 | 2007-11-29 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
US20080003268A1 (en) | 2006-02-23 | 2008-01-03 | Conopco Inc., D/B/A Unilever | Unit serving appetite suppressant compositions with steroidal glycosides |
WO2008000063A1 (en) | 2006-06-27 | 2008-01-03 | Innovative Life Sciences Corporation | Herbal product comprising cinnamon and bitter melon for treating diabetes |
WO2008001931A2 (en) | 2006-06-27 | 2008-01-03 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
WO2008008887A2 (en) | 2006-07-13 | 2008-01-17 | Smithkline Beecham Corporation | Gpr119 agonists for treating metabolic disorders |
US20080050499A1 (en) | 2006-08-24 | 2008-02-28 | Conopco Inc, D/B/A Unilever | Process for preparing a composition comprising steroidal glycosides |
WO2008025799A1 (en) | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyridazine compounds for treating gpr119 related disorders |
WO2008030520A1 (en) | 2006-09-07 | 2008-03-13 | Amgen Inc. | Heterocyclic gpr40 modulators |
WO2008054674A2 (en) | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
WO2008054675A2 (en) | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
US20080108604A1 (en) | 2005-04-28 | 2008-05-08 | Ajinomoto Co., Inc. | Novel lactam compound |
WO2008058355A2 (en) * | 2006-11-16 | 2008-05-22 | Walter Santos Junior | Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases |
WO2008058358A2 (en) * | 2006-11-16 | 2008-05-22 | Walter Santos Junior | Descriptive report of the patent of invention of the medicament 'rosuvastatin + metformin' in combined form for cardiovascular diseases. |
WO2008063321A2 (en) | 2006-10-13 | 2008-05-29 | Janssen Pharmaceutica N.V. | Gpr81-ligand complexes and their preparation and use |
WO2008066131A1 (en) | 2006-12-01 | 2008-06-05 | Banyu Pharmaceutical Co., Ltd. | Novel phenyl-isoxazol-3-ol derivative |
WO2008066097A1 (en) | 2006-12-01 | 2008-06-05 | Astellas Pharma Inc. | Carboxylic acid derivative |
US20080187936A1 (en) | 2001-04-05 | 2008-08-07 | Senomyx, Inc. | Identification of bitter ligands that specifically activate human t2r receptors and related assays for identifying human bitter taste modulators |
WO2008097428A2 (en) | 2007-02-02 | 2008-08-14 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
US7416867B2 (en) | 2003-02-26 | 2008-08-26 | Basf Aktiengesellschaft | Enzymatic production of (meth)acrylic acid esters |
WO2008103500A1 (en) | 2007-02-22 | 2008-08-28 | Irm Llc | Thiazole derivatives as modulators of g protein-coupled receptors |
WO2008109702A1 (en) | 2007-03-08 | 2008-09-12 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2008130581A1 (en) | 2007-04-20 | 2008-10-30 | Schering Corporation | Pyrimidinone derivatives and methods of use thereof |
WO2008130584A1 (en) | 2007-04-20 | 2008-10-30 | Schering Corporation | Pyrimidinone derivatives and methods of use thereof |
WO2008130514A1 (en) | 2007-04-16 | 2008-10-30 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
WO2008130615A1 (en) | 2007-04-20 | 2008-10-30 | Schering Corporation | Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof |
WO2008137435A1 (en) | 2007-05-04 | 2008-11-13 | Bristol-Myers Squibb Company | [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
WO2008137436A1 (en) | 2007-05-04 | 2008-11-13 | Bristol-Myers Squibb Company | [6,5]-bicyclic gpr119 g protein-coupled receptor agonists |
WO2008139987A1 (en) | 2007-04-26 | 2008-11-20 | Japan Science And Technology Agency | G-protein-conjugated receptor agonist |
WO2008144423A2 (en) | 2007-05-15 | 2008-11-27 | Medical College Of Georgia Research Institute, Inc. | Compositions comprising a gpr109 ligand for treating disorders of the digestive tract and/or cancer |
WO2009012275A1 (en) | 2007-07-17 | 2009-01-22 | Bristol-Myers Squibb Company | Pyridone gpr119 g protein-coupled receptor agonists |
WO2009014910A2 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders |
US20090042813A1 (en) | 2007-08-10 | 2009-02-12 | Sergey Michailovich Melnikov | Hoodia extract oil compositions comprising medium chain triglycerides |
WO2009033078A2 (en) | 2007-09-05 | 2009-03-12 | Raif Tawakol | Compositions and methods for controlling cholesterol levels |
WO2009034388A1 (en) | 2007-09-10 | 2009-03-19 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
WO2009038974A1 (en) | 2007-09-20 | 2009-03-26 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2009038204A1 (en) | 2007-09-17 | 2009-03-26 | Pharma Frontier Co., Ltd. | Novel long-chain fatty acid derivative compound and g-protein-coupled receptor agonist containing the compound as active ingredient |
WO2009048527A1 (en) | 2007-10-10 | 2009-04-16 | Amgen Inc. | Substituted biphenyl gpr40 modulators |
WO2009050523A1 (en) | 2007-10-18 | 2009-04-23 | Prosidion Limited | Azetidinyl g-protein coupled receptor agonists |
WO2009050522A1 (en) | 2007-10-18 | 2009-04-23 | Prosidion Limited | Azetidinyl g-protein coupled receptor agonists |
WO2009054423A1 (en) | 2007-10-24 | 2009-04-30 | Astellas Pharma Inc. | Oxadiazolidinedione compound |
WO2009054390A1 (en) | 2007-10-23 | 2009-04-30 | Astellas Pharma Inc. | Thiazolidinedione compound |
WO2009055331A2 (en) | 2007-10-22 | 2009-04-30 | Schering Corporation | Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119 |
WO2009058237A1 (en) | 2007-10-29 | 2009-05-07 | Merck & Co., Inc. | Antidiabetic tricyclic compounds |
WO2009105715A1 (en) | 2008-02-22 | 2009-08-27 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2009105717A1 (en) | 2008-02-22 | 2009-08-27 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2009105722A1 (en) | 2008-02-22 | 2009-08-27 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2009106561A1 (en) | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Pyrazine compounds for treating gpr119 related disorders |
WO2009106565A1 (en) | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Agonists of gpr119 |
WO2009117421A2 (en) | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
WO2009123992A1 (en) | 2008-03-31 | 2009-10-08 | Metabolex, Inc. | Oxymethylene aryl compounds and uses thereof |
WO2009125804A1 (en) | 2008-04-09 | 2009-10-15 | 武田薬品工業株式会社 | Screening method |
WO2009126245A1 (en) | 2008-04-07 | 2009-10-15 | Arena Pharmaceuticals, Inc. | Methods of using a g protein-coupled receptor to identify peptide yy (pyy) secretagogues and compounds useful in the treatment of conditions modulated by pyy |
WO2009126535A1 (en) | 2008-04-07 | 2009-10-15 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2009143049A1 (en) | 2008-05-19 | 2009-11-26 | Schering Corporation | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
WO2009141238A1 (en) | 2008-05-19 | 2009-11-26 | F. Hoffmann-La Roche Ag | Gpr119 receptor agonists |
WO2009147990A1 (en) | 2008-06-02 | 2009-12-10 | 萬有製薬株式会社 | Novel isoxazole derivative |
WO2009150144A1 (en) | 2008-06-10 | 2009-12-17 | Inovacia Ab | New gpr119modulators |
WO2009151542A2 (en) | 2008-05-27 | 2009-12-17 | Duke University | Nicotinic acid receptor ligands |
WO2010001166A1 (en) | 2008-07-01 | 2010-01-07 | Prosidion Limited | Thiazole derivatives as gpr 119 modulators |
WO2010004347A1 (en) | 2008-07-10 | 2010-01-14 | Prosidion Limited | Heterocyclic gpcr agonists |
WO2010004348A1 (en) | 2008-07-10 | 2010-01-14 | Prosidion Limited | Heterocyclic gpcr agonists |
WO2010006191A1 (en) | 2008-07-11 | 2010-01-14 | Irm Llc | 4-phenoxymethylpiperidines as modulators of gpr119 activity |
WO2010009195A1 (en) | 2008-07-16 | 2010-01-21 | Schering Corporation | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
WO2010008739A2 (en) | 2008-06-20 | 2010-01-21 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
WO2010009183A1 (en) | 2008-07-16 | 2010-01-21 | Bristol-Myers Squibb Company | Pyridone and pyridazone analogues as gpr119 modulators |
WO2010013849A1 (en) | 2008-08-01 | 2010-02-04 | 日本ケミファ株式会社 | Gpr119 agonist |
WO2010012650A1 (en) | 2008-07-28 | 2010-02-04 | Syddansk Universitet | Compounds for the treatment of metabolic diseases |
US20100055209A1 (en) | 2006-07-10 | 2010-03-04 | Chen Xie | Standardized Extract And Its Use In The Manufacture Of A Medicament |
US20100056621A1 (en) | 2004-04-20 | 2010-03-04 | Deutsches Institut Fur Ernahrungsforschung | Agonists of a bitter taste receptor and uses thereof |
WO2010030360A1 (en) | 2008-09-11 | 2010-03-18 | Arena Pharmaceuticals, Inc. | 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS |
WO2010029089A2 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
CN101695575A (en) * | 2008-05-29 | 2010-04-21 | 北京奥萨医药研究中心有限公司 | Pharmaceutical composition containing statin-type lipid-lowering medicaments, phenformin-type hypoglycemic medicaments and nicotinic acid |
WO2010045258A2 (en) | 2008-10-15 | 2010-04-22 | Amgen Inc. | Spirocyclic gpr40 modulators |
WO2010048207A2 (en) | 2008-10-21 | 2010-04-29 | Metabolex, Inc. | Aryl gpr120 receptor agonists and uses thereof |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
US20100130498A1 (en) | 2007-03-29 | 2010-05-27 | Deutshes Institut Fur Ernahrungsforschung Potsdam- Rehbrucke | Agonists of bitter taste receptors and uses thereof |
WO2010060198A1 (en) | 2008-11-26 | 2010-06-03 | West Central Envirotech Inc. | Composition and method for controlling insects |
WO2010074271A1 (en) | 2008-12-26 | 2010-07-01 | 武田薬品工業株式会社 | Therapeutic agent for diabetes |
WO2010076879A1 (en) | 2009-01-03 | 2010-07-08 | 静岡県公立大学法人 | Sulfated c-glycoside, method for isolating same and method for synthesizing same |
WO2010080537A1 (en) | 2008-12-18 | 2010-07-15 | Metabolex, Inc. | Gpr120 receptor agonists and uses thereof |
US20100184796A1 (en) | 2007-03-29 | 2010-07-22 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Agonists of bitter taste receptors and uses thereof |
WO2010085522A1 (en) | 2009-01-23 | 2010-07-29 | Schering Corporation | Pentafluorosulpholane-containing antidiabetic compounds |
WO2010085528A1 (en) | 2009-01-23 | 2010-07-29 | Schering Corporation | Bridged and fused antidiabetic compounds |
WO2010085525A1 (en) | 2009-01-23 | 2010-07-29 | Schering Corporation | Bridged and fused heterocyclic antidiabetic compounds |
WO2010084944A1 (en) | 2009-01-22 | 2010-07-29 | 田辺三菱製薬株式会社 | NOVEL PYRROLO[2,3-d]PYRIMIDINE COMPOUND |
WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
WO2010091176A1 (en) | 2009-02-05 | 2010-08-12 | Schering Corporation | Phthalazine-containing antidiabetic compounds |
WO2010095663A1 (en) | 2009-02-18 | 2010-08-26 | 武田薬品工業株式会社 | Fused heterocyclic ring compound |
WO2010103333A1 (en) | 2009-03-12 | 2010-09-16 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
WO2010103334A1 (en) | 2009-03-12 | 2010-09-16 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
WO2010103335A1 (en) | 2009-03-12 | 2010-09-16 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
WO2010106457A2 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
US7807204B2 (en) | 2006-08-17 | 2010-10-05 | Phytopharm Plc | Processes for production of Hoodia plant extracts containing steroidal glycosides |
US7811788B2 (en) | 2006-09-05 | 2010-10-12 | Senomyx Inc. | Nucleic acid encoding a haplotype of human T2R receptor hT2R50 |
WO2010123017A1 (en) | 2009-04-22 | 2010-10-28 | アステラス製薬株式会社 | Tetrazole compound |
WO2010123016A1 (en) | 2009-04-22 | 2010-10-28 | アステラス製薬株式会社 | Carboxylic acid compound |
WO2010123018A1 (en) | 2009-04-24 | 2010-10-28 | 日本ケミファ株式会社 | Diazaspiroalkane derivative |
US7829299B2 (en) | 2004-11-18 | 2010-11-09 | Deutsches Institut fur Ernahrungforschung Potsdam-Rehbrucke Stiftung des Offentlichen Rechts | Agonists of bitter taste receptors and uses thereof |
WO2010128425A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
WO2010128414A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
WO2010140092A1 (en) | 2009-06-05 | 2010-12-09 | Pfizer Inc. | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
WO2010143733A1 (en) | 2009-06-09 | 2010-12-16 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
US20100316736A1 (en) | 2007-10-24 | 2010-12-16 | Desert Labs Agriculture Cooperative Association Ltd. | Appetite suppressant |
US20100330205A1 (en) | 2008-01-29 | 2010-12-30 | Nakamori Pharmaceutical Co., Ltd. | Pharmaceutical composition |
WO2011005929A1 (en) | 2009-07-09 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Piperidine derivative and its use for the treatment of diabets and obesity |
WO2011008663A1 (en) | 2009-07-15 | 2011-01-20 | Eli Lilly And Company | Gpr119 agonists |
WO2011014520A2 (en) | 2009-07-29 | 2011-02-03 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2011012298A1 (en) | 2009-07-28 | 2011-02-03 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Agonists and antagonists of human bitter taste receptor tas2r49 and uses thereof |
WO2011025006A1 (en) | 2009-08-31 | 2011-03-03 | 日本ケミファ株式会社 | Gpr119 agonist |
WO2011028689A1 (en) | 2009-09-01 | 2011-03-10 | Catabasis Pharmaceuticals, Inc. | Fatty acid niacin conjugates and their uses |
WO2011030139A1 (en) | 2009-09-11 | 2011-03-17 | Astrazeneca Ab | 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators |
WO2011036576A1 (en) | 2009-09-23 | 2011-03-31 | Pfizer Inc. | Gpr 119 modulators |
WO2011044139A1 (en) | 2009-10-05 | 2011-04-14 | Catabasis Pharmaceuticals, Inc. | Fatty acid acifran derivatives and their uses |
WO2011044136A1 (en) | 2009-10-05 | 2011-04-14 | Catabasis Pharmaceuticals, Inc. | Fatty acid acipimox derivatives and their uses |
WO2011044073A1 (en) | 2009-10-06 | 2011-04-14 | Bristol-Myers Squibb Company | Pyrrolidine gpr40 modulators |
US20110086138A1 (en) | 2008-05-23 | 2011-04-14 | Zhonghua Jia | Bitter Alkaloid Containing Consumables Comprising Bitter Blockers |
WO2011044001A1 (en) | 2009-10-09 | 2011-04-14 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2011052756A1 (en) | 2009-10-30 | 2011-05-05 | 持田製薬株式会社 | Novel 3-hydroxy-5-arylisoxazole derivative |
WO2011051966A2 (en) * | 2009-10-12 | 2011-05-05 | Ipca Laboratories Limited | Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease |
WO2011053688A1 (en) | 2009-10-29 | 2011-05-05 | Schering Corporation | Bridged bicyclic piperidine derivatives and methods of use thereof |
WO2011057110A1 (en) | 2009-11-06 | 2011-05-12 | Ruprecht-Karls-Universitat-Heidelberg | Gpr109a agonists for the treatment of cerebral ischemia |
WO2011055770A1 (en) | 2009-11-06 | 2011-05-12 | 武田薬品工業株式会社 | Fused heterocyclic compound |
US20110119499A1 (en) | 2006-01-11 | 2011-05-19 | Canon Kabushiki Kaisha | Information processing apparatus, control method for the same, program and storage medium |
WO2011061679A1 (en) | 2009-11-23 | 2011-05-26 | Pfizer Inc. | Imidazo-pyrazoles as gpr119 inhibitors |
US20110124609A1 (en) | 2009-10-21 | 2011-05-26 | Wisconsin Alumni Research Foundation | Method of Preventing Type I Diabetes |
WO2011066137A1 (en) | 2009-11-24 | 2011-06-03 | Schering Corporation | Substituted biaryl derivatives and methods of use thereof |
WO2011068814A1 (en) | 2009-12-04 | 2011-06-09 | Colgate-Palmolive Company | Oral compositions containing extracts of garcinia mangostana l. and related methods |
WO2011069958A2 (en) | 2009-12-07 | 2011-06-16 | Nestec S.A. | Low caloric fat replacers |
US20110143376A1 (en) | 2008-08-29 | 2011-06-16 | Givaudan Sa | Methods to Identify Modulators |
WO2011072132A1 (en) | 2009-12-09 | 2011-06-16 | The Regents Of The University Of California | Methods of treating inflammatory conditions |
US20110152361A1 (en) | 2008-08-29 | 2011-06-23 | Suntory Holdings Limited | Novel epigallocatechin gallate tetramer and vascular endothelial function improving agent containing the same |
WO2011073376A1 (en) | 2009-12-18 | 2011-06-23 | Euroscreen S.A. | Pyrrolidine or thiazolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disordersas as agonists of g- protein coupled receptor 43 (gpr43) |
WO2011078371A1 (en) | 2009-12-25 | 2011-06-30 | 持田製薬株式会社 | Novel 3-hydroxy-5-arylisothiazole derivative |
WO2011078306A1 (en) | 2009-12-24 | 2011-06-30 | 日本ケミファ株式会社 | Gpr119 agonist |
WO2011085979A1 (en) | 2010-01-14 | 2011-07-21 | Intermed Discovery Gmbh | Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions |
WO2011092284A1 (en) | 2010-01-29 | 2011-08-04 | Euroscreen S.A. | Novel amino acid derivatives and their use as gpr43 receptor modulators |
WO2011093501A1 (en) | 2010-02-01 | 2011-08-04 | 日本ケミファ株式会社 | Gpr119 agonist |
US20110217394A1 (en) | 2000-12-05 | 2011-09-08 | Brett Justin West | Iridoid Based Formulations |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2011127106A1 (en) | 2010-04-08 | 2011-10-13 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators |
WO2011128394A1 (en) | 2010-04-14 | 2011-10-20 | Prosidion Limited | 3-substituted 5-(pyrrolidine-1-carbonyl) pyrrolidine and its derivatives for use in the treatment of metabolic disorders |
WO2011128395A1 (en) | 2010-04-14 | 2011-10-20 | Prosidion Limited | N- substituted 3-amino 4 - ( pyrrolidine - 1 - carbonyl) pyrrolidine and its derivatives for use in the treatment of metabolic disorders |
WO2011140160A1 (en) | 2010-05-06 | 2011-11-10 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds as gpr119 modulators |
WO2011140161A1 (en) | 2010-05-06 | 2011-11-10 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
WO2011138427A2 (en) | 2010-05-07 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Pyridazinones as gpr119 agonists |
WO2011145718A1 (en) | 2010-05-21 | 2011-11-24 | 田辺三菱製薬株式会社 | Novel pyrrolo[2,3-d]pyrimidine compound |
WO2011146335A1 (en) | 2010-05-17 | 2011-11-24 | Array Biopharma Inc. | Piperidinyl-substituted lactams as gpr119 modulators |
WO2011147951A1 (en) | 2010-05-28 | 2011-12-01 | Prosidion Limited | Cycloamino derivatives as gpr119 antagonists |
US20110293753A1 (en) | 2010-05-28 | 2011-12-01 | Louis Bellafiore | Tocotrienol Compositions |
WO2011148922A1 (en) | 2010-05-24 | 2011-12-01 | 田辺三菱製薬株式会社 | Novel quinazoline compound |
WO2011151436A2 (en) | 2010-06-04 | 2011-12-08 | Euroscreen S.A. | Novel compounds, method for use them and pharmaceutical composition containing them |
WO2011159657A1 (en) | 2010-06-18 | 2011-12-22 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and methods of use thereof |
WO2011157692A1 (en) | 2010-06-14 | 2011-12-22 | Katholieke Universiteit Leuven | Method for hydrogenation of iso-alpha-acids and tetrahydro-iso-alpha-acids to hexahydro-iso-alpha-acids |
WO2011159297A1 (en) | 2010-06-16 | 2011-12-22 | Metabolex, Inc. | Gpr120 receptor agonists and uses thereof |
US20110311991A1 (en) | 2008-06-13 | 2011-12-22 | Givaudan Sa | Methods of Identifying Modulators of the Bitter Taste Receptor TAS2R44 |
WO2011163183A2 (en) | 2010-06-21 | 2011-12-29 | Abbott Laboratories | Methods for delaying progression of diabetes using salacia oblonga extract |
WO2011161030A1 (en) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators |
WO2012004269A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals |
WO2012006955A1 (en) | 2010-07-14 | 2012-01-19 | Zhejiang Beta Pharma Inc. | Compounds for treatment of metabolic disorders |
WO2012010413A1 (en) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament |
WO2012011125A1 (en) | 2010-07-23 | 2012-01-26 | Connexios Life Sciences Pvt. Ltd. | Agonists of gpr40 |
WO2012011707A2 (en) | 2010-07-23 | 2012-01-26 | Hyundai Pharm Co., Ltd. | Substituted pyridinone derivatives and methods for manufacturing the same |
WO2012025811A1 (en) | 2010-08-23 | 2012-03-01 | Lupin Limited | Indolylpyrimidines as modulators of gpr119 |
WO2012037393A1 (en) | 2010-09-17 | 2012-03-22 | Array Biopharma Inc. | Piperidinyl-substituted lactams as gpr119 modulators |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012041158A1 (en) | 2010-09-29 | 2012-04-05 | 上海恒瑞医药有限公司 | Tricyclic compound, preparation method and pharmaceutical use thereof |
WO2012046869A1 (en) | 2010-10-08 | 2012-04-12 | 持田製薬株式会社 | Cyclic amide derivative |
WO2012046792A1 (en) | 2010-10-08 | 2012-04-12 | 日本ケミファ株式会社 | Gpr119 agonist |
WO2012046249A1 (en) | 2010-10-08 | 2012-04-12 | Cadila Healthcare Limited | Novel gpr 119 agonists |
WO2012058649A1 (en) | 2010-10-30 | 2012-05-03 | Kindex Therapeutics, Llc | Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(-3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods |
WO2012069948A1 (en) | 2010-11-23 | 2012-05-31 | Pfizer Inc. | 4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as gpr 119 modulators |
WO2012069917A1 (en) | 2010-11-26 | 2012-05-31 | Lupin Limited | Bicyclic gpr119 modulators |
WO2012072691A1 (en) | 2010-12-01 | 2012-06-07 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
WO2012077655A1 (en) | 2010-12-07 | 2012-06-14 | 塩野義製薬株式会社 | Spiro derivative having gpr119 agonist activity |
WO2012080476A1 (en) | 2010-12-17 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Fused dihydropyrans as gpr119 modulators for the treatment of diabetes, obesity and related diseases |
WO2012093809A2 (en) | 2011-01-03 | 2012-07-12 | Hanmi Pharm Co., Ltd. | New bicyclic compound for modulating g protein-coupled receptors |
WO2012098217A1 (en) | 2011-01-21 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Fused dihydrofurans as gpr119 modulators for the treatment of diabetes, obesity and related disorders |
WO2012103806A1 (en) | 2011-01-31 | 2012-08-09 | Centaurus Biopharma Co., Ltd. | Bicyclic heteroaryl compounds as gpr119 receptor agonists |
WO2012111995A1 (en) | 2011-02-17 | 2012-08-23 | Lg Life Sciences Ltd. | Oxime derivatives as gpr119 agonists |
WO2012123449A1 (en) | 2011-03-14 | 2012-09-20 | Boehringer Ingelheim International Gmbh | N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012136221A1 (en) | 2011-04-08 | 2012-10-11 | Syddansk Universitet | Ortho-fluoro substituted compounds for the treatment of metabolic diseases |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012147516A1 (en) | 2011-04-28 | 2012-11-01 | 持田製薬株式会社 | Cyclic amide derivative |
WO2012147518A1 (en) | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | Novel 3-hydroxyisothiazole 1-oxide derivative |
WO2012154009A2 (en) | 2011-05-12 | 2012-11-15 | 한국화학연구원 | Thienopyrimidine derivatives, pharmaceutically acceptable salts thereof, method for preparing thienopyrimidine derivatives, and pharmaceutical composition containing thienopyrimidine derivatives as active ingredients for preventing or treating diabetes-related diseases |
WO2012168315A1 (en) | 2011-06-09 | 2012-12-13 | Boehringer Ingelheim International Gmbh | Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012173174A1 (en) | 2011-06-17 | 2012-12-20 | 大正製薬株式会社 | Azaspiroalkane compound |
WO2013011402A1 (en) | 2011-07-15 | 2013-01-24 | Pfizer Inc. | Gpr 119 modulators |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003261298A1 (en) * | 2002-08-02 | 2004-02-23 | Penwest Pharmaceuticals Company | Sustained release formulations of metformin |
CN1413582A (en) * | 2002-11-29 | 2003-04-30 | 贵州圣济堂制药有限公司 | Dimethyldiguanide hydrochloride enteric solubility tablet and its preparation method |
CN101190179B (en) * | 2006-11-20 | 2010-05-12 | 北京利龄恒泰药业有限公司 | Enteric medicinal composition for treating diabetes and preparation method thereof |
JP4592818B2 (en) * | 2007-01-29 | 2010-12-08 | ハナル バイオファーマ カンパニー リミテッド | N, N-dimethylimidodicarbonimidic acid diamide acetate, process for producing the same, and pharmaceutical composition containing the same |
CN101785763B (en) * | 2010-02-04 | 2011-11-23 | 贵州天安药业股份有限公司 | Metformin hydrochloride enteric-coated sustained release tablet and preparation method thereof |
CN101978956B (en) * | 2010-10-13 | 2012-03-28 | 北京京丰制药有限公司 | Metformin hydrochloride enteric-coated tablets and preparation method thereof |
CN102357088A (en) * | 2011-10-26 | 2012-02-22 | 河北山姆士药业有限公司 | Metformin hydrochloride enteric-coated tablet |
-
2013
- 2013-07-11 AR ARP130102472 patent/AR091739A1/en unknown
- 2013-07-11 JP JP2015521822A patent/JP2015522080A/en active Pending
- 2013-07-11 WO PCT/US2013/050142 patent/WO2014011926A1/en active Application Filing
- 2013-07-11 EP EP13739919.2A patent/EP2872127A1/en not_active Withdrawn
- 2013-07-11 CN CN201380046376.XA patent/CN104780915A/en active Pending
- 2013-07-11 CA CA2878625A patent/CA2878625A1/en not_active Abandoned
- 2013-07-11 AU AU2013290100A patent/AU2013290100A1/en not_active Abandoned
-
2015
- 2015-01-11 IL IL236647A patent/IL236647A0/en unknown
- 2015-11-20 HK HK15111491.4A patent/HK1210825A1/en unknown
-
2018
- 2018-02-01 JP JP2018016141A patent/JP2018087214A/en active Pending
Patent Citations (274)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4036948A (en) | 1975-07-24 | 1977-07-19 | Takeda Chemical Industries, Ltd. | L-ascorbic acid tablets |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US5354556A (en) | 1984-10-30 | 1994-10-11 | Elan Corporation, Plc | Controlled release powder and process for its preparation |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
US5135757A (en) | 1988-09-19 | 1992-08-04 | Edward Mendell Co., Inc. | Compressible sustained release solid dosage forms |
US5059595A (en) | 1989-03-22 | 1991-10-22 | Bioresearch, S.P.A. | Pharmaceutical compositions containing 5-methyltetrahydrofolic acid, 5-formyltetrahydrofolic acid and their pharmaceutically acceptable salts in controlled-release form active in the therapy of organic mental disturbances |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5639476A (en) | 1992-01-27 | 1997-06-17 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
US5603957A (en) | 1993-04-19 | 1997-02-18 | Flamel Technologies | Microcapsules for the controlled release of acetylsalicyclic acid in the gastrointestinal environment |
US5846566A (en) | 1993-04-19 | 1998-12-08 | Flamel Technologies | Microcapsules for the controlled release of acetylsalicylic acid in the gastrointestinal environment |
US6245356B1 (en) | 1993-09-09 | 2001-06-12 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems-amorphous drugs |
US5674533A (en) | 1994-07-07 | 1997-10-07 | Recordati, S.A., Chemical And Pharmaceutical Company | Pharmaceutical composition for the controlled release of moguisteine in a liquid suspension |
US6022562A (en) | 1994-10-18 | 2000-02-08 | Flamel Technologies | Medicinal and/or nutritional microcapsules for oral administration |
US6376657B1 (en) | 1997-04-15 | 2002-04-23 | Csir | Pharmaceutical compositions having appetite suppressant activity |
US5891919A (en) | 1997-09-19 | 1999-04-06 | Burlington Bio-Medical & Scientific Corp. | Denatonium capsaicinate and methods of producing the same |
WO2000028083A1 (en) | 1998-11-06 | 2000-05-18 | Smithkline Beecham Corporation | Mouse 7-transmembrane receptor gpr43 |
US6773720B1 (en) | 1999-06-14 | 2004-08-10 | Cosmo S.P.A. | Mesalazine controlled release oral pharmaceutical compositions |
US7247427B1 (en) | 1999-10-11 | 2007-07-24 | Yeda Research And Development Co., Ltd. | Leptin assay |
WO2001061359A2 (en) | 2000-02-18 | 2001-08-23 | Glaxo Group Limited | Identification of modulators of gpr41 or gpr42 activity |
US20110217394A1 (en) | 2000-12-05 | 2011-09-08 | Brett Justin West | Iridoid Based Formulations |
US20040138189A1 (en) | 2001-03-28 | 2004-07-15 | Sebti Said M. | Materials and methods for treatment of cancer and identification of anti-cancer compounds |
US20080187936A1 (en) | 2001-04-05 | 2008-08-07 | Senomyx, Inc. | Identification of bitter ligands that specifically activate human t2r receptors and related assays for identifying human bitter taste modulators |
WO2003057730A1 (en) | 2002-01-07 | 2003-07-17 | Euroscreen S.A. | Ligand for g-protein coupled receptor gpr43 and uses thereof |
WO2003075933A1 (en) * | 2002-03-07 | 2003-09-18 | Upsher-Smith Laboratories, Inc. | Composition for reducing blood glucose and cholesterol |
US20060019346A1 (en) | 2002-07-29 | 2006-01-26 | Senomyx, Inc. | Identification of a novel bitter taste receptor T2R76 that specifically responds to brucine and prop bitter ligands |
WO2004033431A2 (en) | 2002-10-04 | 2004-04-22 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
WO2004032928A1 (en) | 2002-10-10 | 2004-04-22 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia |
WO2004038421A2 (en) | 2002-10-25 | 2004-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41) |
WO2004038405A2 (en) | 2002-10-25 | 2004-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43) |
WO2004041266A1 (en) | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
US20060275765A1 (en) | 2002-12-18 | 2006-12-07 | Givaudan Sa | G-proteins |
WO2004072650A1 (en) | 2003-02-17 | 2004-08-26 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 40 (gpr40) |
US7416867B2 (en) | 2003-02-26 | 2008-08-26 | Basf Aktiengesellschaft | Enzymatic production of (meth)acrylic acid esters |
WO2004106276A1 (en) | 2003-05-30 | 2004-12-09 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
WO2005011677A1 (en) | 2003-06-13 | 2005-02-10 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases |
US20060172020A1 (en) | 2003-07-17 | 2006-08-03 | Djang Arthur H | Dietary supplement for promoting control of blood-sugar levels and associated pathology in type 2 diabeties |
WO2005023766A1 (en) * | 2003-09-11 | 2005-03-17 | Biocon Limited | Salt of atorvastatin with metformin |
WO2005028488A1 (en) | 2003-09-12 | 2005-03-31 | Quatrx Pharmaceuticals Co. | Heteroaryl phosphinyl and thiophosphinyl compounds for regulation of glucose, triglycerides, and ldl/hdl levels |
WO2005044816A1 (en) | 2003-10-31 | 2005-05-19 | Arena Pharmaceuticals, Inc. | Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
WO2005051890A1 (en) | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
WO2005051937A2 (en) | 2003-11-21 | 2005-06-09 | Arena Pharmaceuticals, Inc. | 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof |
WO2005063729A1 (en) | 2003-12-25 | 2005-07-14 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl)propanoic acid derivatives |
WO2005063725A1 (en) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | Phenylpropanoic acid derivatives |
WO2005087710A1 (en) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
WO2005095338A1 (en) | 2004-03-30 | 2005-10-13 | Takeda Pharmaceutical Company Limited | Alkoxyphenylpropanoic acid derivatives |
US20100056621A1 (en) | 2004-04-20 | 2010-03-04 | Deutsches Institut Fur Ernahrungsforschung | Agonists of a bitter taste receptor and uses thereof |
WO2006011615A1 (en) | 2004-07-27 | 2006-02-02 | Takeda Pharmaceutical Company Limited | Remedy for diabetes |
US20060024335A1 (en) | 2004-07-29 | 2006-02-02 | Roger Stier E | Oral compositions which mask the bitter taste of a bitter-tasting agent |
WO2006036688A2 (en) | 2004-09-22 | 2006-04-06 | Arena Pharmaceuticals, Inc. | Gpr43 and modulators thereof for the treatment of metabolic-related disorders |
WO2006038738A1 (en) | 2004-10-08 | 2006-04-13 | Takeda Pharmaceutical Company Limited | Receptor function regulating agent |
WO2006052566A2 (en) | 2004-11-03 | 2006-05-18 | Arena Pharmaceuticals, Inc. | Gpr41 and modulators thereof for the treatment of insulin-related disorders |
US7829299B2 (en) | 2004-11-18 | 2010-11-09 | Deutsches Institut fur Ernahrungforschung Potsdam-Rehbrucke Stiftung des Offentlichen Rechts | Agonists of bitter taste receptors and uses thereof |
WO2006069242A2 (en) | 2004-12-23 | 2006-06-29 | Arena Pharmaceuticals, Inc. | Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related?disorders |
WO2006076231A2 (en) | 2005-01-10 | 2006-07-20 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level |
WO2006083612A1 (en) | 2005-01-28 | 2006-08-10 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
WO2006083781A1 (en) | 2005-01-31 | 2006-08-10 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
US20060222709A1 (en) * | 2005-03-18 | 2006-10-05 | Agi Therapeutics Research Ltd. | Metformin methods and formulations for treating chronic constipation |
WO2006102653A2 (en) | 2005-03-24 | 2006-09-28 | Irm Llc | Methods and compositions for treating insulin resistance and obesity-induced diseases |
US20080108604A1 (en) | 2005-04-28 | 2008-05-08 | Ajinomoto Co., Inc. | Novel lactam compound |
WO2006127595A1 (en) | 2005-05-23 | 2006-11-30 | Arena Pharmaceuticals, Inc. | 5-aminopyrazole carboxylic acid derivatives and methods of treatment of metabolic-related disorders thereof |
US20060269617A1 (en) | 2005-05-26 | 2006-11-30 | Suracell, Inc. | Supplement compositions and method of use for enhancement of insulin sensitivity |
US20070037212A1 (en) | 2005-06-22 | 2007-02-15 | Senomyx, Inc. | Human T2R receptors recognizing a class of bitter molecules from coffee |
WO2007014824A1 (en) | 2005-07-28 | 2007-02-08 | Nestec S.A. | Fat taste receptors and their methods of use |
WO2007013689A1 (en) | 2005-07-29 | 2007-02-01 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
WO2007021744A1 (en) | 2005-08-10 | 2007-02-22 | Arena Pharmaceuticals, Inc. | Methods for determining probability of an adverse or favorable reaction to a niacin receptor agonist |
WO2007026874A1 (en) | 2005-09-02 | 2007-03-08 | Eisai R & D Management Co., Ltd. | Method for screening of substance effective on disease using gpr120 and phospholipase |
WO2007049050A2 (en) | 2005-10-27 | 2007-05-03 | Heptahelix Ab | Modulators of gpr40 for the treatment of diabetes |
US20070104805A1 (en) | 2005-11-01 | 2007-05-10 | Udell Ronald G | Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives |
US20110119499A1 (en) | 2006-01-11 | 2011-05-19 | Canon Kabushiki Kaisha | Information processing apparatus, control method for the same, program and storage medium |
US20080003268A1 (en) | 2006-02-23 | 2008-01-03 | Conopco Inc., D/B/A Unilever | Unit serving appetite suppressant compositions with steroidal glycosides |
WO2007116229A1 (en) | 2006-04-06 | 2007-10-18 | Prosidion Limited | Heterocyclic gpcr agonists |
WO2007116404A2 (en) | 2006-04-10 | 2007-10-18 | Bar-Ilan University | Cucurbitacin glucosides and use thereof in treating cancer |
WO2007120689A2 (en) | 2006-04-11 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Methods of using gpr119 receptor to identify compounds useful for increasing bone mass in an individual |
WO2007120702A2 (en) | 2006-04-11 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto |
WO2007116230A1 (en) | 2006-04-11 | 2007-10-18 | Prosidion Ltd | Azetidine derivatives as g-protein coupled receptor (gpr119 ) agonists |
WO2007123225A1 (en) | 2006-04-24 | 2007-11-01 | Astellas Pharma Inc | Oxadiazolidinedione compound |
WO2007136572A2 (en) | 2006-05-15 | 2007-11-29 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
WO2007136573A2 (en) | 2006-05-15 | 2007-11-29 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
WO2007134613A1 (en) | 2006-05-24 | 2007-11-29 | Rheoscience A/S | Modulation of gpr120 activity in adipocytes/fat tissue |
WO2008000063A1 (en) | 2006-06-27 | 2008-01-03 | Innovative Life Sciences Corporation | Herbal product comprising cinnamon and bitter melon for treating diabetes |
WO2008001931A2 (en) | 2006-06-27 | 2008-01-03 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
US20100055209A1 (en) | 2006-07-10 | 2010-03-04 | Chen Xie | Standardized Extract And Its Use In The Manufacture Of A Medicament |
WO2008008895A1 (en) | 2006-07-13 | 2008-01-17 | Smithkline Beecham Corporation | Gpr119 agonists for the treatment of diabetes and related disorders |
WO2008008887A2 (en) | 2006-07-13 | 2008-01-17 | Smithkline Beecham Corporation | Gpr119 agonists for treating metabolic disorders |
US7807204B2 (en) | 2006-08-17 | 2010-10-05 | Phytopharm Plc | Processes for production of Hoodia plant extracts containing steroidal glycosides |
US20080050499A1 (en) | 2006-08-24 | 2008-02-28 | Conopco Inc, D/B/A Unilever | Process for preparing a composition comprising steroidal glycosides |
WO2008025799A1 (en) | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyridazine compounds for treating gpr119 related disorders |
WO2008025800A1 (en) | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyrimidine compounds for treating gpr119 related disorders |
WO2008025798A1 (en) | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyridine compounds for treating gpr119 related disorders |
US7811788B2 (en) | 2006-09-05 | 2010-10-12 | Senomyx Inc. | Nucleic acid encoding a haplotype of human T2R receptor hT2R50 |
WO2008030520A1 (en) | 2006-09-07 | 2008-03-13 | Amgen Inc. | Heterocyclic gpr40 modulators |
WO2008063321A2 (en) | 2006-10-13 | 2008-05-29 | Janssen Pharmaceutica N.V. | Gpr81-ligand complexes and their preparation and use |
WO2008054675A2 (en) | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
WO2008054674A2 (en) | 2006-10-31 | 2008-05-08 | Merck & Co., Inc. | Antidiabetic bicyclic compounds |
WO2008058358A2 (en) * | 2006-11-16 | 2008-05-22 | Walter Santos Junior | Descriptive report of the patent of invention of the medicament 'rosuvastatin + metformin' in combined form for cardiovascular diseases. |
WO2008058355A2 (en) * | 2006-11-16 | 2008-05-22 | Walter Santos Junior | Descriptive report of patent of invention of the medicament 'atorvastatin + metformin' in combined form for cardiovascular diseases |
WO2008066097A1 (en) | 2006-12-01 | 2008-06-05 | Astellas Pharma Inc. | Carboxylic acid derivative |
WO2008066131A1 (en) | 2006-12-01 | 2008-06-05 | Banyu Pharmaceutical Co., Ltd. | Novel phenyl-isoxazol-3-ol derivative |
WO2008097428A2 (en) | 2007-02-02 | 2008-08-14 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2008103500A1 (en) | 2007-02-22 | 2008-08-28 | Irm Llc | Thiazole derivatives as modulators of g protein-coupled receptors |
WO2008109702A1 (en) | 2007-03-08 | 2008-09-12 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
US20100184796A1 (en) | 2007-03-29 | 2010-07-22 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Agonists of bitter taste receptors and uses thereof |
US20100130498A1 (en) | 2007-03-29 | 2010-05-27 | Deutshes Institut Fur Ernahrungsforschung Potsdam- Rehbrucke | Agonists of bitter taste receptors and uses thereof |
WO2008130514A1 (en) | 2007-04-16 | 2008-10-30 | Amgen Inc. | Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators |
WO2008130615A1 (en) | 2007-04-20 | 2008-10-30 | Schering Corporation | Tetrahydropyrido[4,3-d]pyrimidinone derivatives and methods of use thereof |
WO2008130581A1 (en) | 2007-04-20 | 2008-10-30 | Schering Corporation | Pyrimidinone derivatives and methods of use thereof |
WO2008130584A1 (en) | 2007-04-20 | 2008-10-30 | Schering Corporation | Pyrimidinone derivatives and methods of use thereof |
WO2008139987A1 (en) | 2007-04-26 | 2008-11-20 | Japan Science And Technology Agency | G-protein-conjugated receptor agonist |
WO2008137435A1 (en) | 2007-05-04 | 2008-11-13 | Bristol-Myers Squibb Company | [6,6] and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists |
WO2008137436A1 (en) | 2007-05-04 | 2008-11-13 | Bristol-Myers Squibb Company | [6,5]-bicyclic gpr119 g protein-coupled receptor agonists |
WO2008144423A2 (en) | 2007-05-15 | 2008-11-27 | Medical College Of Georgia Research Institute, Inc. | Compositions comprising a gpr109 ligand for treating disorders of the digestive tract and/or cancer |
WO2009012275A1 (en) | 2007-07-17 | 2009-01-22 | Bristol-Myers Squibb Company | Pyridone gpr119 g protein-coupled receptor agonists |
WO2009012277A1 (en) | 2007-07-17 | 2009-01-22 | Bristol-Myers Squibb Company | Method for modulating gpr119 g protein-coupled receptor and selected compounds |
WO2009014910A2 (en) | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders |
US20090042813A1 (en) | 2007-08-10 | 2009-02-12 | Sergey Michailovich Melnikov | Hoodia extract oil compositions comprising medium chain triglycerides |
WO2009033078A2 (en) | 2007-09-05 | 2009-03-12 | Raif Tawakol | Compositions and methods for controlling cholesterol levels |
WO2009034388A1 (en) | 2007-09-10 | 2009-03-19 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
WO2009038204A1 (en) | 2007-09-17 | 2009-03-26 | Pharma Frontier Co., Ltd. | Novel long-chain fatty acid derivative compound and g-protein-coupled receptor agonist containing the compound as active ingredient |
WO2009038974A1 (en) | 2007-09-20 | 2009-03-26 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2009048527A1 (en) | 2007-10-10 | 2009-04-16 | Amgen Inc. | Substituted biphenyl gpr40 modulators |
WO2009050522A1 (en) | 2007-10-18 | 2009-04-23 | Prosidion Limited | Azetidinyl g-protein coupled receptor agonists |
WO2009050523A1 (en) | 2007-10-18 | 2009-04-23 | Prosidion Limited | Azetidinyl g-protein coupled receptor agonists |
WO2009055331A2 (en) | 2007-10-22 | 2009-04-30 | Schering Corporation | Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119 |
WO2009054390A1 (en) | 2007-10-23 | 2009-04-30 | Astellas Pharma Inc. | Thiazolidinedione compound |
WO2009054423A1 (en) | 2007-10-24 | 2009-04-30 | Astellas Pharma Inc. | Oxadiazolidinedione compound |
US20100316736A1 (en) | 2007-10-24 | 2010-12-16 | Desert Labs Agriculture Cooperative Association Ltd. | Appetite suppressant |
WO2009058237A1 (en) | 2007-10-29 | 2009-05-07 | Merck & Co., Inc. | Antidiabetic tricyclic compounds |
US20100330205A1 (en) | 2008-01-29 | 2010-12-30 | Nakamori Pharmaceutical Co., Ltd. | Pharmaceutical composition |
WO2009105722A1 (en) | 2008-02-22 | 2009-08-27 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2009105717A1 (en) | 2008-02-22 | 2009-08-27 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2009105715A1 (en) | 2008-02-22 | 2009-08-27 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2009106565A1 (en) | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Agonists of gpr119 |
WO2009106561A1 (en) | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Pyrazine compounds for treating gpr119 related disorders |
WO2009117421A2 (en) | 2008-03-17 | 2009-09-24 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
WO2009123992A1 (en) | 2008-03-31 | 2009-10-08 | Metabolex, Inc. | Oxymethylene aryl compounds and uses thereof |
WO2009126245A1 (en) | 2008-04-07 | 2009-10-15 | Arena Pharmaceuticals, Inc. | Methods of using a g protein-coupled receptor to identify peptide yy (pyy) secretagogues and compounds useful in the treatment of conditions modulated by pyy |
WO2009126535A1 (en) | 2008-04-07 | 2009-10-15 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2009125804A1 (en) | 2008-04-09 | 2009-10-15 | 武田薬品工業株式会社 | Screening method |
WO2009141238A1 (en) | 2008-05-19 | 2009-11-26 | F. Hoffmann-La Roche Ag | Gpr119 receptor agonists |
WO2009143049A1 (en) | 2008-05-19 | 2009-11-26 | Schering Corporation | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
US20110086138A1 (en) | 2008-05-23 | 2011-04-14 | Zhonghua Jia | Bitter Alkaloid Containing Consumables Comprising Bitter Blockers |
WO2009151542A2 (en) | 2008-05-27 | 2009-12-17 | Duke University | Nicotinic acid receptor ligands |
CN101695575A (en) * | 2008-05-29 | 2010-04-21 | 北京奥萨医药研究中心有限公司 | Pharmaceutical composition containing statin-type lipid-lowering medicaments, phenformin-type hypoglycemic medicaments and nicotinic acid |
WO2009147990A1 (en) | 2008-06-02 | 2009-12-10 | 萬有製薬株式会社 | Novel isoxazole derivative |
WO2009150144A1 (en) | 2008-06-10 | 2009-12-17 | Inovacia Ab | New gpr119modulators |
US20110311991A1 (en) | 2008-06-13 | 2011-12-22 | Givaudan Sa | Methods of Identifying Modulators of the Bitter Taste Receptor TAS2R44 |
WO2010008739A2 (en) | 2008-06-20 | 2010-01-21 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
WO2010001166A1 (en) | 2008-07-01 | 2010-01-07 | Prosidion Limited | Thiazole derivatives as gpr 119 modulators |
WO2010004347A1 (en) | 2008-07-10 | 2010-01-14 | Prosidion Limited | Heterocyclic gpcr agonists |
WO2010004348A1 (en) | 2008-07-10 | 2010-01-14 | Prosidion Limited | Heterocyclic gpcr agonists |
WO2010006191A1 (en) | 2008-07-11 | 2010-01-14 | Irm Llc | 4-phenoxymethylpiperidines as modulators of gpr119 activity |
WO2010009183A1 (en) | 2008-07-16 | 2010-01-21 | Bristol-Myers Squibb Company | Pyridone and pyridazone analogues as gpr119 modulators |
WO2010009195A1 (en) | 2008-07-16 | 2010-01-21 | Schering Corporation | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
WO2010012650A1 (en) | 2008-07-28 | 2010-02-04 | Syddansk Universitet | Compounds for the treatment of metabolic diseases |
WO2010013849A1 (en) | 2008-08-01 | 2010-02-04 | 日本ケミファ株式会社 | Gpr119 agonist |
US20110143376A1 (en) | 2008-08-29 | 2011-06-16 | Givaudan Sa | Methods to Identify Modulators |
US20110152361A1 (en) | 2008-08-29 | 2011-06-23 | Suntory Holdings Limited | Novel epigallocatechin gallate tetramer and vascular endothelial function improving agent containing the same |
WO2010029089A2 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
WO2010030360A1 (en) | 2008-09-11 | 2010-03-18 | Arena Pharmaceuticals, Inc. | 3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS |
WO2010045258A2 (en) | 2008-10-15 | 2010-04-22 | Amgen Inc. | Spirocyclic gpr40 modulators |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
WO2010048207A2 (en) | 2008-10-21 | 2010-04-29 | Metabolex, Inc. | Aryl gpr120 receptor agonists and uses thereof |
WO2010060198A1 (en) | 2008-11-26 | 2010-06-03 | West Central Envirotech Inc. | Composition and method for controlling insects |
WO2010080537A1 (en) | 2008-12-18 | 2010-07-15 | Metabolex, Inc. | Gpr120 receptor agonists and uses thereof |
WO2010074271A1 (en) | 2008-12-26 | 2010-07-01 | 武田薬品工業株式会社 | Therapeutic agent for diabetes |
WO2010076879A1 (en) | 2009-01-03 | 2010-07-08 | 静岡県公立大学法人 | Sulfated c-glycoside, method for isolating same and method for synthesizing same |
WO2010084944A1 (en) | 2009-01-22 | 2010-07-29 | 田辺三菱製薬株式会社 | NOVEL PYRROLO[2,3-d]PYRIMIDINE COMPOUND |
WO2010085525A1 (en) | 2009-01-23 | 2010-07-29 | Schering Corporation | Bridged and fused heterocyclic antidiabetic compounds |
WO2010085528A1 (en) | 2009-01-23 | 2010-07-29 | Schering Corporation | Bridged and fused antidiabetic compounds |
WO2010085522A1 (en) | 2009-01-23 | 2010-07-29 | Schering Corporation | Pentafluorosulpholane-containing antidiabetic compounds |
WO2010088518A2 (en) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
WO2010091176A1 (en) | 2009-02-05 | 2010-08-12 | Schering Corporation | Phthalazine-containing antidiabetic compounds |
WO2010095663A1 (en) | 2009-02-18 | 2010-08-26 | 武田薬品工業株式会社 | Fused heterocyclic ring compound |
WO2010103333A1 (en) | 2009-03-12 | 2010-09-16 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
WO2010103334A1 (en) | 2009-03-12 | 2010-09-16 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
WO2010103335A1 (en) | 2009-03-12 | 2010-09-16 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
WO2010106457A2 (en) | 2009-03-20 | 2010-09-23 | Pfizer Inc. | 3-oxa-7-azabicyclo[3.3.1]nonanes |
WO2010123017A1 (en) | 2009-04-22 | 2010-10-28 | アステラス製薬株式会社 | Tetrazole compound |
WO2010123016A1 (en) | 2009-04-22 | 2010-10-28 | アステラス製薬株式会社 | Carboxylic acid compound |
WO2010123018A1 (en) | 2009-04-24 | 2010-10-28 | 日本ケミファ株式会社 | Diazaspiroalkane derivative |
WO2010128414A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
WO2010128425A1 (en) | 2009-05-08 | 2010-11-11 | Pfizer Inc. | Gpr 119 modulators |
WO2010140092A1 (en) | 2009-06-05 | 2010-12-09 | Pfizer Inc. | L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators |
WO2010143733A1 (en) | 2009-06-09 | 2010-12-16 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
WO2011005929A1 (en) | 2009-07-09 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Piperidine derivative and its use for the treatment of diabets and obesity |
WO2011008663A1 (en) | 2009-07-15 | 2011-01-20 | Eli Lilly And Company | Gpr119 agonists |
WO2011012298A1 (en) | 2009-07-28 | 2011-02-03 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Agonists and antagonists of human bitter taste receptor tas2r49 and uses thereof |
WO2011014520A2 (en) | 2009-07-29 | 2011-02-03 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2011025006A1 (en) | 2009-08-31 | 2011-03-03 | 日本ケミファ株式会社 | Gpr119 agonist |
WO2011028689A1 (en) | 2009-09-01 | 2011-03-10 | Catabasis Pharmaceuticals, Inc. | Fatty acid niacin conjugates and their uses |
WO2011030139A1 (en) | 2009-09-11 | 2011-03-17 | Astrazeneca Ab | 4- (pyrimidin-2-yl) -piperazine and 4- (pyrimidin-2-yl) -piperidine derivatives as gpr119 modulators |
WO2011036576A1 (en) | 2009-09-23 | 2011-03-31 | Pfizer Inc. | Gpr 119 modulators |
WO2011044136A1 (en) | 2009-10-05 | 2011-04-14 | Catabasis Pharmaceuticals, Inc. | Fatty acid acipimox derivatives and their uses |
WO2011044139A1 (en) | 2009-10-05 | 2011-04-14 | Catabasis Pharmaceuticals, Inc. | Fatty acid acifran derivatives and their uses |
WO2011044073A1 (en) | 2009-10-06 | 2011-04-14 | Bristol-Myers Squibb Company | Pyrrolidine gpr40 modulators |
WO2011044001A1 (en) | 2009-10-09 | 2011-04-14 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
WO2011051966A2 (en) * | 2009-10-12 | 2011-05-05 | Ipca Laboratories Limited | Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease |
US20110124609A1 (en) | 2009-10-21 | 2011-05-26 | Wisconsin Alumni Research Foundation | Method of Preventing Type I Diabetes |
WO2011053688A1 (en) | 2009-10-29 | 2011-05-05 | Schering Corporation | Bridged bicyclic piperidine derivatives and methods of use thereof |
WO2011052756A1 (en) | 2009-10-30 | 2011-05-05 | 持田製薬株式会社 | Novel 3-hydroxy-5-arylisoxazole derivative |
WO2011055770A1 (en) | 2009-11-06 | 2011-05-12 | 武田薬品工業株式会社 | Fused heterocyclic compound |
WO2011057110A1 (en) | 2009-11-06 | 2011-05-12 | Ruprecht-Karls-Universitat-Heidelberg | Gpr109a agonists for the treatment of cerebral ischemia |
WO2011061679A1 (en) | 2009-11-23 | 2011-05-26 | Pfizer Inc. | Imidazo-pyrazoles as gpr119 inhibitors |
WO2011066137A1 (en) | 2009-11-24 | 2011-06-03 | Schering Corporation | Substituted biaryl derivatives and methods of use thereof |
WO2011068814A1 (en) | 2009-12-04 | 2011-06-09 | Colgate-Palmolive Company | Oral compositions containing extracts of garcinia mangostana l. and related methods |
WO2011069958A2 (en) | 2009-12-07 | 2011-06-16 | Nestec S.A. | Low caloric fat replacers |
WO2011072132A1 (en) | 2009-12-09 | 2011-06-16 | The Regents Of The University Of California | Methods of treating inflammatory conditions |
WO2011073376A1 (en) | 2009-12-18 | 2011-06-23 | Euroscreen S.A. | Pyrrolidine or thiazolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disordersas as agonists of g- protein coupled receptor 43 (gpr43) |
WO2011078306A1 (en) | 2009-12-24 | 2011-06-30 | 日本ケミファ株式会社 | Gpr119 agonist |
WO2011078371A1 (en) | 2009-12-25 | 2011-06-30 | 持田製薬株式会社 | Novel 3-hydroxy-5-arylisothiazole derivative |
WO2011085979A1 (en) | 2010-01-14 | 2011-07-21 | Intermed Discovery Gmbh | Use of tricyclic sesquiterpene lactones in the treatment of obesity and related diseases and non-therapeutic treatable conditions |
WO2011092284A1 (en) | 2010-01-29 | 2011-08-04 | Euroscreen S.A. | Novel amino acid derivatives and their use as gpr43 receptor modulators |
WO2011093501A1 (en) | 2010-02-01 | 2011-08-04 | 日本ケミファ株式会社 | Gpr119 agonist |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2011127106A1 (en) | 2010-04-08 | 2011-10-13 | Bristol-Myers Squibb Company | Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators |
WO2011128394A1 (en) | 2010-04-14 | 2011-10-20 | Prosidion Limited | 3-substituted 5-(pyrrolidine-1-carbonyl) pyrrolidine and its derivatives for use in the treatment of metabolic disorders |
WO2011128395A1 (en) | 2010-04-14 | 2011-10-20 | Prosidion Limited | N- substituted 3-amino 4 - ( pyrrolidine - 1 - carbonyl) pyrrolidine and its derivatives for use in the treatment of metabolic disorders |
WO2011140160A1 (en) | 2010-05-06 | 2011-11-10 | Bristol-Myers Squibb Company | Bicyclic heteroaryl compounds as gpr119 modulators |
WO2011140161A1 (en) | 2010-05-06 | 2011-11-10 | Bristol-Myers Squibb Company | Benzofuranyl analogues as gpr119 modulators |
WO2011138427A2 (en) | 2010-05-07 | 2011-11-10 | Boehringer Ingelheim International Gmbh | Pyridazinones as gpr119 agonists |
WO2011146335A1 (en) | 2010-05-17 | 2011-11-24 | Array Biopharma Inc. | Piperidinyl-substituted lactams as gpr119 modulators |
WO2011145718A1 (en) | 2010-05-21 | 2011-11-24 | 田辺三菱製薬株式会社 | Novel pyrrolo[2,3-d]pyrimidine compound |
WO2011148922A1 (en) | 2010-05-24 | 2011-12-01 | 田辺三菱製薬株式会社 | Novel quinazoline compound |
US20110293753A1 (en) | 2010-05-28 | 2011-12-01 | Louis Bellafiore | Tocotrienol Compositions |
WO2011147951A1 (en) | 2010-05-28 | 2011-12-01 | Prosidion Limited | Cycloamino derivatives as gpr119 antagonists |
WO2011151436A2 (en) | 2010-06-04 | 2011-12-08 | Euroscreen S.A. | Novel compounds, method for use them and pharmaceutical composition containing them |
WO2011157692A1 (en) | 2010-06-14 | 2011-12-22 | Katholieke Universiteit Leuven | Method for hydrogenation of iso-alpha-acids and tetrahydro-iso-alpha-acids to hexahydro-iso-alpha-acids |
WO2011159297A1 (en) | 2010-06-16 | 2011-12-22 | Metabolex, Inc. | Gpr120 receptor agonists and uses thereof |
WO2011159657A1 (en) | 2010-06-18 | 2011-12-22 | Merck Sharp & Dohme Corp. | Bicyclic heterocycle derivatives and methods of use thereof |
WO2011163183A2 (en) | 2010-06-21 | 2011-12-29 | Abbott Laboratories | Methods for delaying progression of diabetes using salacia oblonga extract |
WO2011161030A1 (en) | 2010-06-21 | 2011-12-29 | Sanofi | Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators |
WO2012004269A1 (en) | 2010-07-05 | 2012-01-12 | Sanofi | (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals |
WO2012010413A1 (en) | 2010-07-05 | 2012-01-26 | Sanofi | Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament |
WO2012006955A1 (en) | 2010-07-14 | 2012-01-19 | Zhejiang Beta Pharma Inc. | Compounds for treatment of metabolic disorders |
WO2012011125A1 (en) | 2010-07-23 | 2012-01-26 | Connexios Life Sciences Pvt. Ltd. | Agonists of gpr40 |
WO2012011707A2 (en) | 2010-07-23 | 2012-01-26 | Hyundai Pharm Co., Ltd. | Substituted pyridinone derivatives and methods for manufacturing the same |
WO2012025811A1 (en) | 2010-08-23 | 2012-03-01 | Lupin Limited | Indolylpyrimidines as modulators of gpr119 |
WO2012037393A1 (en) | 2010-09-17 | 2012-03-22 | Array Biopharma Inc. | Piperidinyl-substituted lactams as gpr119 modulators |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012041158A1 (en) | 2010-09-29 | 2012-04-05 | 上海恒瑞医药有限公司 | Tricyclic compound, preparation method and pharmaceutical use thereof |
WO2012046869A1 (en) | 2010-10-08 | 2012-04-12 | 持田製薬株式会社 | Cyclic amide derivative |
WO2012046792A1 (en) | 2010-10-08 | 2012-04-12 | 日本ケミファ株式会社 | Gpr119 agonist |
WO2012046249A1 (en) | 2010-10-08 | 2012-04-12 | Cadila Healthcare Limited | Novel gpr 119 agonists |
WO2012058649A1 (en) | 2010-10-30 | 2012-05-03 | Kindex Therapeutics, Llc | Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(-3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods |
WO2012069948A1 (en) | 2010-11-23 | 2012-05-31 | Pfizer Inc. | 4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as gpr 119 modulators |
WO2012069917A1 (en) | 2010-11-26 | 2012-05-31 | Lupin Limited | Bicyclic gpr119 modulators |
WO2012072691A1 (en) | 2010-12-01 | 2012-06-07 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
WO2012077655A1 (en) | 2010-12-07 | 2012-06-14 | 塩野義製薬株式会社 | Spiro derivative having gpr119 agonist activity |
WO2012080476A1 (en) | 2010-12-17 | 2012-06-21 | Boehringer Ingelheim International Gmbh | Fused dihydropyrans as gpr119 modulators for the treatment of diabetes, obesity and related diseases |
WO2012093809A2 (en) | 2011-01-03 | 2012-07-12 | Hanmi Pharm Co., Ltd. | New bicyclic compound for modulating g protein-coupled receptors |
WO2012098217A1 (en) | 2011-01-21 | 2012-07-26 | Boehringer Ingelheim International Gmbh | Fused dihydrofurans as gpr119 modulators for the treatment of diabetes, obesity and related disorders |
WO2012103806A1 (en) | 2011-01-31 | 2012-08-09 | Centaurus Biopharma Co., Ltd. | Bicyclic heteroaryl compounds as gpr119 receptor agonists |
WO2012111995A1 (en) | 2011-02-17 | 2012-08-23 | Lg Life Sciences Ltd. | Oxime derivatives as gpr119 agonists |
WO2012123449A1 (en) | 2011-03-14 | 2012-09-20 | Boehringer Ingelheim International Gmbh | N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012136221A1 (en) | 2011-04-08 | 2012-10-11 | Syddansk Universitet | Ortho-fluoro substituted compounds for the treatment of metabolic diseases |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012147518A1 (en) | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | Novel 3-hydroxyisothiazole 1-oxide derivative |
WO2012147516A1 (en) | 2011-04-28 | 2012-11-01 | 持田製薬株式会社 | Cyclic amide derivative |
WO2012154009A2 (en) | 2011-05-12 | 2012-11-15 | 한국화학연구원 | Thienopyrimidine derivatives, pharmaceutically acceptable salts thereof, method for preparing thienopyrimidine derivatives, and pharmaceutical composition containing thienopyrimidine derivatives as active ingredients for preventing or treating diabetes-related diseases |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012168315A1 (en) | 2011-06-09 | 2012-12-13 | Boehringer Ingelheim International Gmbh | Substituted piperidines as gpr119 modulators for the treatment of metabolic disorders |
WO2012173174A1 (en) | 2011-06-17 | 2012-12-20 | 大正製薬株式会社 | Azaspiroalkane compound |
WO2013011402A1 (en) | 2011-07-15 | 2013-01-24 | Pfizer Inc. | Gpr 119 modulators |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
Non-Patent Citations (33)
Title |
---|
"Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed", 1999, LIPPINCOTT WILLIAMS & WILKINS |
"Remington: The Science and Practice of Pharmacy , Nineteeth Ed", 1995, MACK PUBLISHING COMPANY |
BAILEY; TURNER: "Metformin", N ENGI J MED., vol. 334, no. 9, 29 February 1996 (1996-02-29), XP009063754, DOI: doi:10.1056/NEJM199602293340906 |
BRUNZELL: "Lipoprotein Management in Patients with Cardiometabolic Risk", DIABETES CARE, vol. 31, 2008, pages 811 - 822 |
CARELLI ET AL., INT. J. PHARMACEUTICS, vol. 179, 1999, pages 73 - 83 |
CAREY; SUNDBERG: "ADVANCED ORGANIC CHEMISTRY 4th Ed.,", vol. A , B, 2000 |
CLAUSTRE ET AL.: "Stimulatory effect of(3-adrenergic agonists on ileal L cell secretion and modulation by a-adrenergic activation", J. ENDOCRIN., vol. 162, 1999, pages 271 - 8 |
DYER ET AL., EUR. J. BIOCHEM, vol. 270, 2003, pages 3377 - 88 |
DYER ET AL., GUT, vol. 41, 1997, pages 56 - 9 |
ECKEL: "Preventing Cardiovascular Disease and Diabetes", DIABETES CARE, vol. 29, 2006, pages 1697 - 1699 |
EXPERT OPIN. DRUG DELIV., vol. 2, no. 3, 2005, pages 587 - 89 |
GRAHAM ET AL., J. LIPID RES., vol. 48, 2007, pages 763 - 7 |
GREEN; WUTS: "PROTECTIVE GROUPS IN ORGANIC SYNTHESIS 3rd Ed.", 1999, WILEY |
HOOVER, JOHN E.: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO |
INOUYE ET AL., DRUG DESIGN AND DELIVERY, vol. 1, 1987, pages 297 - 305 |
JAMES SWARBRICK; JAMES BOYLAN: "The Encyclopedia of Pharmaceutical Technology", 1999, INFORMA HEALTH CARE, pages: 287 - 308 |
LAFERRERE ET AL.: "Incretin Levels and Effect are Markedly Enhanced 1 Month after Roux-en-Y Gastric Bypass Surgery in Obese Patients with Type 2 Diabetes", DIABETES CARE, vol. 30, no. 7, 2007, pages 1709 - 1716 |
LIBERMAN, H.A. AND LACHMAN, L.,: "Pharmaceutical Dosage Forms", 1980, MARCEL DECKER |
LINDHOLM ET AL., MOL. THER., vol. 20, 2012, pages 376 - 81 |
M. BODANZSKY: "Principles of Peptide Synthesis", 1984, SPRINGER-VERLAG |
MARCH: "ADVANCED ORGANIC CHEMISTRY 4th Ed.,", 1992, WILEY |
MARGOLSKEE ET AL.: "T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter I", PROC NATL ACAD SCI USA, vol. 104, 2007, pages 15075 - 15080, XP055126596, DOI: doi:10.1073/pnas.0706678104 |
NISSEN ET AL.: "Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes", JAMA, vol. 299, no. 13, 2008, pages 1561 - 73 |
OFFERMANNS S; COLLETTI SL; LOVENBERG TW; SEMPLE G; WISE A; IJZERMAN AP: "International Union of Basic and Clinical Pharmacology", LXXXII: NOMENCLATURE AND CLASSIFICATION OF HYDROXY-CARBOXYLIC ACID RECEPTORS (GPR81, GPRI09A, AND GPRI 09B) PHARMACOL REV, vol. 63, no. 2, 31 March 2011 (2011-03-31), pages 269 - 90 |
PLAISANCIE ET AL.: "Regulation of glucagon-like peptide-1-(7-36) amide secretion by intestinal neurotransmitters and hormones in the isolated vascularly perfused rat colon", ENDOCRINOLOGY, vol. 135, 1994, pages 2398 - 2403, XP002003516, DOI: doi:10.1210/endo.135.6.7988423 |
PLAISANCIE ET AL.: "Release of peptide YY by neurotransmitters and gut hormones in the isolated, vascularly perfused rat colon", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 30, 1995, pages 568 - 574 |
SHAN ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 375, 2008, pages 69 - 73 |
SHAN, BIOCHEM. BIOPHYS. RES. COMMUN., vol. 375, 2008, pages 69 - 73 |
STEWART; YOUNG: "Solid Phase Peptide Synthesis 2nd Ed.,", 1984, PIERCE CHEMICAL CO. |
STODDART LA; SMITH NJ; MILLIGAN G: "International Union of Pharmacology", LXXI. FREE FATTY ACID RECEPTORS FFAI, -2, AND -3: PHARMACOLOGY AND PATHOPHYSIOLOGICAL FUNCTIONS PHARMACOL REV, vol. 60, no. 4, December 2008 (2008-12-01), pages 405 - 417 |
TOFT-NIELSEN ET AL.: "Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients", J. CLIN. END. MET., vol. 86, no. 8, 2001, pages 3717 - 3723 |
TUCKER ET AL.: "Metformin kinetics in healthy subjects and in patients with diabetes mellitus", BR. J. CLIN. PHARMACOL., vol. 12, no. 2, 1981, pages 235 - 246, XP000913557 |
WEICKERT ET AL.: "Cereal fiber improves whole-body insulin sensitivity in overweight and obese women", DIABETES CARE, vol. 29, 2006, pages 775 - 780 |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10406172B2 (en) | 2009-02-13 | 2019-09-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11564886B2 (en) | 2011-03-07 | 2023-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US20180185291A1 (en) | 2011-03-07 | 2018-07-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US10596120B2 (en) | 2011-03-07 | 2020-03-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions |
US10258637B2 (en) | 2013-04-05 | 2019-04-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9949998B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11090323B2 (en) | 2013-04-05 | 2021-08-17 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US9949997B2 (en) | 2013-04-05 | 2018-04-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11833166B2 (en) | 2013-04-05 | 2023-12-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11918596B2 (en) | 2013-04-05 | 2024-03-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11666590B2 (en) | 2013-04-18 | 2023-06-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
CN111818911A (en) * | 2017-12-26 | 2020-10-23 | 广东东阳光药业有限公司 | Lurasidone solid dispersion and preparation method thereof |
CN111818911B (en) * | 2017-12-26 | 2022-11-18 | 广东东阳光药业有限公司 | Lurasidone solid dispersion and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2015522080A (en) | 2015-08-03 |
AU2013290100A1 (en) | 2015-01-29 |
AR091739A1 (en) | 2015-02-25 |
EP2872127A1 (en) | 2015-05-20 |
IL236647A0 (en) | 2015-02-26 |
CN104780915A (en) | 2015-07-15 |
JP2018087214A (en) | 2018-06-07 |
HK1210825A1 (en) | 2016-05-06 |
CA2878625A1 (en) | 2014-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10159658B2 (en) | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk | |
JP7403259B2 (en) | Compositions and methods for treating metabolic disorders | |
US10603291B2 (en) | Compositions and methods for treating metabolic disorders | |
US10201511B2 (en) | Compositions and methods for treating metabolic disorders | |
CA2896864C (en) | Delayed-release composition comprising biguanide | |
EP2872127A1 (en) | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk | |
US20230285330A9 (en) | Compositions and methods for treating metabolic disorders | |
BR112015016111B1 (en) | DELAYED RELEASE PHARMACEUTICAL COMPOSITION FOR DELIVERY OF A BIGUANIDE COMPOUND AND USE OF A BIGUANIDE COMPOUND OR SALT THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13739919 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2878625 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015521822 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14414091 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 236647 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2013290100 Country of ref document: AU Date of ref document: 20130711 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013739919 Country of ref document: EP |